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Chapter 1
General introduction
Adapted from:
MATTIJSSEN, S. • WELTING, T. • PRUIJN, G. (2010): 
'RNase MRP and disease'
WILEY INTERDISCIPLINARY REVIEWS - RNA; 1, 102-116.

General introduction
The majority of genetically inherited diseases is caused by mutations in protein encoding genes. 
However, in some examples the disease can be attributed to mutations in genes that are tran­
scribed into non-coding RNAs (ncRNA). The first ncRNA that was found to be mutated in a di­
sease, was a mitochondrial tRNA (mt-tRNA) in 1990. Mutations in mitochondrial encoded 
tRNAs are the cause of many clinically heterogeneous disorders, mainly neuromuscular. 
Amongst these are mitochondrial encephalopathy, lactacidosis, and stroke-like episode (MELAS) 
syndrome, myoclonic epilepsy with ragged-red fibers (MERRF) and Leigh Syndrome. In addition, 
a number of aminoglycosidase-induced deafness associated mutations in the mitochondrial 
12S and 16S ribosomal RNA (mt-rRNA) genes have been identified.
To date, only 2 nuclear encoded ncRNAs have been described in which mutations are involved in 
the generation of human disease. These are the TERC and RMRP genes. Mutations in TERC, the 
gene coding for the RNA component of the telomerase complex, cause the disease dyskeratosis 
congenita (DC). DC, also known as Zinsser-Cole-Engman syndrome, is a rare syndrome that is 
characterized by leukoplakia, abnormal skin pigmentation, nail dystrophy, bone marrow failure 
and predisposition to cancer. The first nuclear encoded human disease-associated ncRNA gene 
identified was RMRP, which codes for the RNA component of the RNase MRP complex. The com­
plex consists of a catalytic RNA and several protein components. RNase MRP is a ubiquitously 
expressed eukaryotic endoribonuclease that cleaves various RNAs, including ribosomal, mes­
senger and mitochondrial RNAs, in a highly specific fashion. Mutations in the RMRP gene are 
the cause of cartilage-hair hypoplasia (CHH), a highly pleiotropic disease. CHH patients are 
characterized by a short stature, hypoplastic hair and short limbs. In addition, they show a pre­
disposition to lymphomas and other cancers and suffer from defective T-cell immunity. Since 
the identification of the first CHH-associated mutations in 2001, many distinct mutations have 
been found in different patients. These mutations either affect the structure of the RNase MRP 
RNA or are located in the promoter region and reduce the expression levels.
RNase MRP is not only associated with CHH, in several autoimmune diseases autoantibodies 
targeting RNase MRP have been found. These so-called anti-Th/To autoantibodies, which most 
frequently can be detected in the sera of scleroderma patients, are directed to several protein 
components of the RNase MRP and the evolutionarily related RNase P complex. It is not yet 
known whether the anti-Th/To immune response is an epiphenomenon or whether these auto­
antibodies play a role in the pathophysiology of the diseases.
In this chapter the current knowledge about disease-associated mutations in ncRNA is sum­
marized with an emphasis on RNase MRP and CHH.
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Mitochondrial ncRNA mutations
Mitochondria and oxidative phosphorylation
Figure 1 shows a schematic structure of a mitochondrion. 
Mitochondria are double-membrane enclosed organelles 
that exist in 100-10,000 copies per cell, depending on 
the cell type. They are the energy suppliers of the eu­
karyotic cell and can be found in all nucleated mam­
malian cells. Tissues that use a lot of energy, e.g. muscle 
and brain, are especially rich in mitochondria. Through 
oxidative phosphorylation (OXPHOS) in the mitochon- 
dra most of the cellular adenosine triphosphate (ATP) 
is produced. ATP is the primary molecule that is res­
ponsible for the energy storage and transfer in the cell. 
The OXPHOS machinery consists of 5 large protein 
complexes, termed NADH: ubiquinone oxidoreductase 
(complex I), succinate-dehydrogenase-ubiquinone oxi- 
do-reductase (complex II), ubiquinol: cytochrome c 
oxidoreductase (complex III), cytochrome c oxidase 
(complex IV), and F0F1-ATP synthase (complex V). These 
complexes are located in the inner membrane of the 
mitochondrion. The first four complexes, together with 
cytochrome c and coenzyme Q10, form the electron trans­
port chain; protons are pumped from the mitochondrial 
matrix into the intermembrane space. Through complex 
V, the protons flow back into the matrix down their con­
centration gradient, this energy is used to generate ATP 
from ADP and inorganic phosphate. In addition, mito­
chondria are important for other cellular processes, a.o. 
apoptosis and maintaining calcium homeostasis (1, 2).
Mitochondrial genetics
Mitochondria contain their own mitochondrial DNA 
(mtDNA), which is a circular double-stranded DNA mo­
lecule. Human mtDNA consists of 16,569 base pairs 
(bp) and encodes for 13 proteins, 22 tRNAs and 2 rRNA 
molecules (3, 4). The mitochondrial encoded proteins, 
together with ~70 nuclear encoded proteins, constitute 
four complexes of the OXPHOS system (complex I, III, IV 
and V), complex II constists entirely of nuclear encoded 
proteins.
Every mitochondrion contains 1-15 copies of mtDNA
intermembrane space
free ribosomes
Figure 1: Schematic representation of a mitochondrion
mtDNA = mitochondrial DNA.
(5, 6). The situation that all mitochondria within an in­
dividual carry identical mtDNA is called homoplasmy. 
In contrast, when two or more of mtDNA genotypes co­
exist in an individual the term heteroplasmy is applied. 
mtDNA is only inherited from the maternal lineage; 
after fertilization, the sperm mtDNA is degraded (7, 8).
Mitochondrial disorders
Mitochondrial disorders can arise from mutations in the 
mtDNA as well as in the nuclear genome, since most 
proteins that function in the mitochondria are encoded 
by the nuclear DNA. Pathogenic mtDNA mutations re­
sult in clinical disease in 1 in 10,000 individuals (esti­
mate from North East of England) (9). The carrier rate 
for pathogenic mtDNA mutations is 1 in 200 live births
(10).
The onset of mitochondrial disorders can occur at any 
age. Symptoms include muscle weakness, loss of motor 
control, dementia, exercise intolerance, failure to thrive, 
visual/hearing impairment, seizures, stroke-like episodes, 
diabetes, cardiomyopathy, liver disease, gastro-intestinal 
abnormalities, respiratory complications and lactic aci­
dosis (11). Mitochondrial encephalopathy, lactacidosis, 
and stroke-like episode (MELAS; MIM #540000) syn­
drome is a mitochondrial disease which is associated 
with mt-tRNA mutations (12). The primary features are 
stroke-like episodes before the age of 40 years, seizures, 
dementia, lactic acidosis and ragged-red-fibers (RRFs)
10
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in muscle biopsies. Another mt-tRNA mutation-associ­
ated disease is myoclonic epilepsy with ragged-red fibers 
(MERRF; #MIM 545000) (13). Patients are characteri­
zed by myoclonus (involuntary twitching of muscles), 
weakness, generalized epilepsy, ataxia (difficulty coor­
dinating movements) and dementia. Other common 
symptoms include hearing loss and RRFs in muscle bi­
opsies. RRFs are muscle fibers with an accumulation of 
abnormal mitochondria which can be visualized with 
a Gomori trichrome stain (14).
The phenotypic variability of a given mtDNA mutation 
can be high, either between family members or tissues 
from the same individual. This can be explained by the 
proportion of heteroplasmy, which can vary between 
family members and tissues within one individual. 
There is substantial variability in the level of affected 
mtDNA that a woman transmits to her children (15). 
The heteroplasmy of pathogenic mtDNA mutations has 
to reach a certain threshold level before it results in cli­
nical disease (16). This phenotypic threshold is lower 
for tissues that are strongly dependent on oxidative 
phosphorylation such as the brain and muscles. In ge­
neral, the level of mutated mtDNA correlates with the 
severity of the disease (17). There is currently no effec­
tive treatment available for mitochondrial disorders, 
only supportive therapy (18).
Mitochondrial tRNA mutations
The mt-tRNA genes comprise ~ 9 %  of the mtDNA in 
total and contain 41% of all the mutations found. In 
contrast, 15% of the mitochondrial genome consists of 
the 12S rRNA and 16S rRNA encoding genes, which 
contain only 5 %  of the mitochondrial mutations (19). 
Mitochondrial tRNA genes can therefore be classified 
as hotspots for mitochondrial pathogenesis. Pathoge­
nic mutations in the protein coding genes affect the 
OXPHOS complexes. A tRNA mutation can affect the 
translation of all mitochondrial encoded proteins to 
some extent.
Pathogenic point mutations in mt-tRNA genes can have 
a large effect on the conformation of the encoded 
tRNA. They can alter the secondary or tertiary structure
Figure 2: Secondary structure of tRNA
Schematic secondary structure of tRNAs. Five different 
domains can be distinguished: the acceptor stem, anticodon 
loop, D-stem/loop, the variable loop and the TyC- 
stem/loop.
of the RNA, leading to instability and a decrease in 
steady-state level. Aminoacyl-tRNA synthetases (aaRS) 
catalyze the aminoacylation of tRNAs, which is the cou­
pling of an amino acid to the 3' end of tRNA. This pro­
cess is highly sensitive to changes in structural ele­
ments and nucleotides of a specific tRNA. The secon­
dary structure of tRNAs is cloverleaf-shaped, as can be 
seen in Figure 2. Five different domains can be distin­
guished: the acceptor stem, anticodon loop, D-stem- 
loop, the variable loop and the TyC-stem-loop. About 
70% of all known pathogenic mutations are localized 
in the stems of the cloverleaf structure (20). In every 
mt-tRNA at least two pathogenic mutations have been 
identified (19).
The criteria for establishing the pathogenicity of mtDNA 
point mutations were described by DiMauro and Schon
(11) and were later adjusted for mt-tRNA mutations by 
McFarland and colleagues, who gave a higher score to 
cybrid cell line experiments (21). A cybrid cell line is a 
fusion of a cell without mtDNA with an enucleated cell 
containing patient mitochondria (22, 23). The canoni­
cal criteria for defining pathogenicity of a mt-tRNA mu­
tation are: 1) The affected nucleotide has to be evolu­
tionary conserved and not a known polymorphism. 2) 
Pathogenic mutations are in almost all cases heterop-
11
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A B
Figure 3: Structural models of the human RNase MRP and RNase P complexes
A: RNase MRP. B: RNase P. The RNA components are in black, proteins are depicted in grey shades. Structural elements of the RNA 
components are designated P1-P19 and J3/4  in accordance with previous definitions. Adapted from Welting et al. (43).
lasmic. 3) The proportion of mutated mtDNA has to be 
higher in patient tissue than in the corresponding tis­
sue from healthy relatives. 4) The proportion of muta­
ted mtDNA should be higher in affected tissues and 
increase with the severity of biochemical defects. 5) 
The mutated tRNA has to cause defects in mitochon­
drial protein synthesis and the respiratory chain and 
this should be measurable in cybrid cell lines. However, 
not all pathogenic mtDNA mutations meet all of these 
rules. Some are homoplasmic; other mutations do not 
affect evolutionary conserved bases. To establish if a 
mutation is truly pathogenic is a challenging task. For 
some mt-tRNA mutations, direct consequences of the 
mutation can be measured, for example a decrease in 
the steady-state level or an altered structure.
The most prevalent pathogenic mt-tRNA mutation is the 
A3243G substitution in the mitochondrial tRNALeu(UUR) 
gene, which is most frequently associated with MELAS 
syndrome (24). This mutation is also associated a.o.
with MERRF syndrome, Leigh syndrome, maternally in­
herited diabetes and deafness (MIDD), chronic external 
ophthalmoplegia, or Kearns-Sayre syndrome (25). The 
A3243G substitution causes a decreased steady-state 
level of the tRNALeu(UUR) and a reduction in the fraction 
of aminoacylated tRNALeu(UUR) (26-28). Overexpression 
of human mitochondrial leucyl tRNA synthetase (LeuRS) 
suppresses the respiratory chain defects and translation 
defects associated with this particular mutation in 
human cells. This is due to an increased amount of ami­
noacylated tRNALeu(UUR) and stability of mtDNA enco­
ded proteins (29, 30).
Another disease-associated mt-tRNA mutation is the 
A8344G substitution in the mitochondrial tRNALys gene 
that is the cause of MERRF syndrome in 90% of the 
cases (31). This mutation severely inhibits the transla­
tion rate of most mitochondrial mRNAs and causes ac­
cumulation of abnormal translation products (32, 33). 
For this mutation, the aminoacylation efficiency accor-
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Figure 4: The involvement of RNase MRP in biochemical processes
The identified functional activities of RNase MRP are schematically illustrated. See the text for a more detailed description 
of the role of RNase MRP in these processes.
A: RNase MRP cleaves mitochondrial RNA.
B: RNase MRP cleaves the A3 site of the ITS1 in pre-rRNA in yeast.
C: RNase MRP cleaves the 5'-UTR of the CLB2 mRNA in yeast.
D: Human RNase MRP RNA together with the TERT protein forms a complex with RdRP activity,
E: Human RNase MRP cleaves the coding sequence of the viperin mRNA (Chapter 4 of this thesis).
ding to the most recent studies is not reduced (34-36). 
The effects of the mutation are most likely the results 
of a reduction in codon recognition by the affected 
tRNALys (36).
Mitochondrial rRNA mutations
In 1993 the A1555G substitution in the 12S mt-rRNA 
gene was reported to be associated with aminoglyco- 
sidase-induced deafness and nonsyndromic hearing 
loss (37). The mutation changes the secondary struc­
ture of the 12S mt-rRNA into a structure more similar 
to the Escherichia coli 16S rRNA. This leads to an im­
paired protein translation and allows aminoglycoside 
antibiotics to interact with the rRNA and induce an 
more severe defect in protein synthesis (38, 39). The
mutation by itself causes no clinical symptoms, only 
after exposure to aminoglycoside antibiotics or in com­
bination with other factors like a specific genetic back­
ground (40, 41).
Other disease-associated point mutations in the 12S 
mt-rRNA gene have been identified and all of these are 
linked with nonsyndromic sensorineural hearing loss or 
aminoglycoside-induced deafness (19, 42).
In the 16S mt-rRNA gene, seven putative disease-asso­
ciated point mutations have been identified. These 
seem to be associated with Alzheimer's and Parkinson's 
disease, left ventricular noncompaction (LVNC), MELAS 
syndrome or Rett syndrome (19). Their pathogenicity 
has to be determined in future studies with large pa­
tient cohorts.
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RNase MRP
RNase MRP function
RNase MRP is a member of a special class of snoRNPs. 
It is an essential eukaryotic endoribonuclease that con­
tains a single RNA component and several proteins (see 
Figure 3). The highly structured RNA component of the 
human RNase MRP complex consists of 267 nucleoti­
des and supports the interaction with and amongst at 
least 7 protein components: hPop1, hPop5, Rpp20, 
Rpp25, Rpp30, Rpp38 and Rpp40 (43-46). Three ad­
ditional proteins, hPop4, Rpp21 and Rpp14, have been 
reported to be associated with at least a subset of 
RNase MRP complexes (45).
RNase MRP was originally identified in mouse cells by 
virtue of its ability to cleave the mitochondrial RNA that 
functions as a primer for mitochondrial DNA replication. 
Subsequent biochemical studies revealed that the ac­
tivity was associated with a ribonucleoprotein particle 
and that the nuclear encoded RNA component is es­
sential for this activity (47, 48). Since then, RNase MRP 
has been demonstrated to act as an endoribonuclease 
on multiple substrates, as illustrated in Figure 4. It is 
the mitochondrial function that led to the name RNase 
MRP: ribonuclease for Mitochondrial RNA Processing. 
Later it was found that RNase MRP also exerts this func­
tion in the yeast, rat and bovine systems (47, 49-51 ). 
Paradoxically, the vast majority of the cellular RNase MRP 
pool was found to localize in the nucleolus, which is the 
major subcellular compartment for ribosome biosynthesis. 
This suggested a role for RNase MRP in ribosome matu­
ration. Indeed, in 1993 it was reported that depletion of 
RNase MRP RNA in Saccharomyces cerevisiae affected 
the posttranscriptional processing of the pre-5.8S rRNA
(52). RNase MRP cleaves the A3 site in the first internal 
transcribed spacer (ITS1) of the rRNA precursor, which 
leads to the generation of the short form of 5.8S rRNA
(53). The formation of the long form of 5.8S rRNA is 
independent of RNase MRP activity (52, 54). Recently, 
Lindahl and collaborators demonstrated that S. cerevi­
siae RNase MRP is a key enzyme for the initiation of 
the canonical pre-rRNA processing pathway (55).
In addition to these two housekeeping functions, a third, 
more specific function was identified. In S. cerevisiae, 
RNase MRP is involved in the regulation of the cell 
cycle by cleaving the 5'UTR of the cyclin B2 (CLB2) 
mRNA (56). Upon RNase MRP cleavage the transcript 
becomes susceptible to exoribonucleolytic degradation 
by XRN1. This leads to downregulation of cyclin B2 syn­
thesis, resulting in exit from mitosis. This RNase MRP 
activity was identified because increased CLB2 mRNA 
levels were observed in RNase MRP RNA mutants that 
displayed an "exit from mitosis" delay phenotype (57). 
Also in human fibroblasts, evidence has been obtained 
that cyclin B2 mRNA levels are regulated by RNase 
MRP (58). Recently, we identified the mRNA of viperin 
(RSAD2) as another mRNA substrate for human RNase 
MRP (Chapter 4).
Interestingly, RNase MRP RNA was recently reported 
to form a complex with the telomerase-associated re­
verse transcriptase (TERT). The TERT-RNase MRP RNA 
complex displays RNA-dependent RNA polymerase 
(RdRP) activity and produces double-stranded RNA 
comprising the RNase MRP RNA. These double-stran­
ded molecules appeared to be processed into siRNAs 
by Dicer which are able to downregulate the cellular 
RNase MRP RNA level (59). In this way the association 
with TERT can regulate RNase MRP RNA levels by a 
negative-feedback mechanism. Whether RNase MRP 
protein subunits interact with this regulatory complex 
is not known.
Although a wide variety of RNA substrates has been 
identified for RNase MRP, researchers have not been 
able to determine shared substrate recognition sequen­
ces. In general, it is believed that secondary and terti­
ary structural elements play an important role in RNase 
MRP substrate recognition.
RNase MRP structure and similarity to RNase P
Human RNase MRP shares all of its known proteins 
with RNase P, which is involved in the maturation of 
tRNA by cleaving the 5' leader of pre-tRNA (Figure 5) 
(60). RNase P has also been reported to play a role in 
RNA polymerase I and III transcription (61, 62) and the
14
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maturation of intron-encoded Box C/D snoRNAs (63). 
In contrast to RNase MRP, which has only been found 
in eukaryotes, RNase P is present in almost all cellular 
organisms (64). Bacterial RNase P consists of an RNA 
component (M1 RNA) and a single protein component 
designated C5. Together with the self-splicing rRNA 
(group I intron) of Tetrahymena thermophila the Ml 
RNA was the first ribozyme that was identified and for 
these discoveries Sydney Altman and Thomas Cech were 
awarded the Nobel Prize in Chemistry in 1989 (65, 66). 
Although the primary sequence conservation between 
the RNA components of RNase MRP and RNase P is 
generally low, they fold into very similar secondary and 
tertiary structures with a cage-shaped core (67). Inte­
restingly, the P3 domain (important for nucleolar ac­
cumulation of both RNase MRP and RNase P (68, 69)) 
and the P4 domain (important for their endoribonuc- 
lease activity (70, 71)) do show a relatively high se­
quence similarity between the two RNAs and in S. 
cerevisiae it has been shown that the P3 domains can 
be exchanged between RNase MRP and RNase P wit­
hout loss of specificity or function (72). The comparison 
of a large number of RNase MRP and RNase P RNA se­
quences from different organisms substantiated the si­
milarity of their (predicted) secondary structures. This, 
and the very similar protein subunit composition (Fi­
gure 3) led to the proposal by several scientists that 
these two snoRNPs are evolutionarily related (73-75). 
RNase P RNA probably evolved from the ancient RNA 
world and, throughout evolution, acquired an increa­
sing number of protein subunits in more complex, euka­
ryotic cells. With increasing cellular complexity, RNase 
MRP evolved from RNase P by a gene duplication event 
to a specialized RNase for the tasks described above 
(reviewed in (76)).
The hPopl protein was the first human RNase MRP pro­
tein that was identified by comparison with yeast and 
C. elegans Popl and is the largest protein component 
with a molecular mass of 115 kDa (77). In a 6-year pe­
riod after the identification of hPop1, the other human 
RNase MRP and RNase P associated proteins were iden­
tified; hPop5, Rpp14, Rpp20, Rpp21, Rpp25, Rpp29
A RNase P B Box C/D snoRNA
D I
u cs  18S 5.8S 28S
Figure 5: RNase P function
The identified functional activities of RNase P are 
schematically illustrated.
A: RNase P cleaves the 5'-leader of pre-tRNAs.
The secondary structure represents any pre-tRNA.
B: RNase P is involved in the maturation of Box C/D 
snoRNAs in Saccharomyces cerevisiae. (TATA = TATA box; 
TSS = transcription start site).
C: RNase P is required for RNA polymerase III transcription. 
D: RNase P is required for RNA polymerase I transcription 
(UCS = upstream control sequence).
(hPop4), Rpp30, Rpp38 and Rpp40 (78-84). The Rpp29 
(hPop4), Rpp14 and Rpp21 proteins appear to interact 
more stably with RNase P than with RNase MRP (45). 
Six of the protein components, hPop1, Rpp20, Rpp21, 
Rpp25, Rpp29 and Rpp38, have been shown to bind 
directly to the RNase MRP and RNase P RNA. Rpp20 
and Rpp25 specifically bind to the P3 domains of both 
complexes and Rpp38 to the P12 region (43, 46, 85). 
In several studies, using various methods to study pro­
tein-protein interactions, many direct interactions be­
tween protein components were identified (43, 86, 87). 
Combined data from UV-crosslinking and GST-pull­
down experiments were used to create structural mo­
dels for human RNase MRP and RNase P complexes, 
which are shown in Figure 3 (43). A very stable pro­
tein-protein interaction was found between the Rpp20 
and Rpp25 proteins (43, 44). Rpp20 and Rpp25 are 
both members of the Alba superfamily of proteins, the 
prototype of which (Alba) is a chromosomal protein in 
certain archaea (88). Recently, it was reported that the
15
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formation of the Rpp20-Rpp25 heterodimer is a prere­
quisite for binding the P3 domain (89). Interestingly, 
Rpp20 and Rpp25 only interact with RNase MRP com­
plexes that are not associated with high molecular 
weight pre-ribosomal complexes (45).
The exact roles of the individual proteins are poorly 
described but they are believed to play roles in the sub­
cellular localization of the complexes, support the ribo- 
zyme function of the catalytic RNA by binding sub­
strate RNAs, and maintain the structural integrity of the 
complex.
Cellular localization of RNase MRP and RNase P
It has been shown by indirect immunostaining that the 
protein components hPopl, hPop5, Rpp14, Rpp20, 
Rpp25, Rpp29 (hPop4) and Rpp38 are localized pre­
dominantly in the nucleolus (44, 77, 82, 83). The latter 
two proteins and Rpp21 have also been detected in 
Cajal bodies (84, 90). The majority of Rpp21 is localized 
throughout the nucleoplasm (79). Interestingly, Rpp20- 
Rpp25 dimerization is required for the localization of 
Rpp20 to the nucleolus (44). Basic domains in hPopl, 
Rpp29 (hPop4) and Rpp38 are responsible for their nu­
cleolar accumulation. This localization does not depend 
on the association of the proteins with the RNase P and 
RNase MRP complexes (91 ). The vast majority of RNase 
MRP RNA (99%) is nucleolar, while RNase P RNA is lo­
calized both in the nucleoplasm and nucleolus (68, 69, 
92). The P3 domain of both RNA components is impor­
tant for their nucleolar localization (68, 69). There has 
been considerable debate about whether RNase MRP 
exerts a function in the mitochondria. Puranam and At­
tardi have shown that there exist only 6 to 15 molecules 
of RNase MRP RNA per cell in the mitochondria. They 
also detected between 33 and 175 molecules of RNase 
P RNA per cell in the mitochondria (93). Recently, the 
lab of Rossmanith found that human mitochondrial 
RNase P does not contain an RNA subunit (94). Instead, 
it consists of 3 proteins that do not show any homology 
with the nuclear RNase P proteins. They did not find 
any nuclear RNase P or RNase MRP-associated proteins 
in any of their purifications. This implies that there is
no nuclear RNase P in the mitochondria, making the 
findings of Puranam and Attardi that a small subset of 
the "nuclear" RNase MRP and RNase P resides in the 
mitochondria questionable.
RNase MRP and autoimmune diseases
A subset of patients suffering from scleroderma (sys­
temic sclerosis, SSc), systemic lupus erythematosus, 
Raynaud's phenomenon, polymyositis or idiopathic pul­
monary fibrosis develop autoantibodies against protein 
subunits of the RNase MRP and RNase P complexes (95, 
96). It was with the aid of such autoantibodies that the 
RNA components of human RNase MRP and RNase P 
were first identified. These autoantibodies were origi­
nally designated anti-Th and anti-To and precipitated 
the RNA components of both RNase MRP and RNase P 
from cell lysates (97-99). However, it was shown that 
it was not possible to precipitate the RNA components 
from a deproteinated cell extract (proteins were removed 
by phenol extraction or treatment with proteinase K). 
Therefore it was concluded that both complexes share 
at least one autoantigenic protein (100). One of the 
co-precipitating proteins had an apparent molecular 
mass of 40 kDa and was accordingly named Th-40 (92, 
97, 101-103). Many years later, Rpp38 was identified 
as the Th-40 autoantigen and it was shown that most 
anti-Th/To positive patient sera also frequently contain 
autoantibodies recognizing hPop1 and Rpp25 (77, 85). 
Other RNase MRP and RNase P autoantigenic protein 
components are Rpp14, Rpp20, Rpp30, Rpp40 and 
hPop5 (85). Patients suffering from SSc with limited 
cutaneous involvement that carry anti-Th/To auto-an­
tibodies show decreased survival compared to pa­
tients with anti-centromere autoantibodies (ACA), 
which also frequently occur in the sera of SSc patients 
(104, 105). In addition, it has been reported that Japa­
nese patients with anti-Th/To reactivity show better sur­
vival compared to Caucasian or black African patients 
carrying the same autoantibodies (106).
It is unknown whether the anti-Th/To autoantibodies 
play a role in the pathophysiology of these diseases. 
Under normal conditions the antigens, RNase MRP and
16
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RNase P, will be inaccessible for the antibodies due to 
their intracellular localization, and therefore it is unli­
kely that the antibodies interfere with the biological 
function of these complexes. However, under unusual 
conditions like massive cell death, possibly in combi­
nation with impaired clearance of remnants of dying 
cells, the antigens may be released from the cells and 
immune complexes may be formed, which in turn may 
stimulate an inflammatory response. As for many other 
autoantigens, the mechanism by which immunological 
tolerance to RNase MRP and RNase P is broken remains 
unknown. The polyclonality of the anti-Th/To response 
suggests that, possibly after an initial trigger that leads 
to the first production of anti-Th/To antibodies, the 
RNase MRP and/or RNase P particles are directly invol­
ved in spreading of the response to other components.
The RMRP gene and cartilage-hair hypoplasia
In 2001 it was reported that mutations in the RMRP 
gene are the cause of the autosomal recessive inherited 
disease cartilage-hair hypoplasia (CHH, MIM #250250) 
(107). CHH was first described by Victor McKusick in 
1965 in the Old Order Amish and is therefore also re­
ferred to as McKusick-type metaphyseal chondrodyspla­
sia (108). In addition to the characteristic short-limbed 
dwarfism and sparse hypoplastic hair, patients show 
predisposition to certain cancers (non-Hodgkin lym­
phoma, squamous cell carcinoma and basal cell carci­
noma), and often are affected by Hirschprung's disease, 
childhood anaemia, bronchiectasis, decreased sperma­
togenesis and defective T-cell immunity (109-113). The 
first symptoms of CHH are already evident at birth, 
with height being lower than that of unaffected si­
blings (114). CHH patients have a shorter life expec­
tancy, most often caused by defective immunity (115). 
A subset of CHH patients present with severe combi­
ned immunodeficiency (SCID) (107) and these can be 
successfully treated by bone marrow transplantation. 
However, this does not improve the skeletal phenotype 
(116, 117). Treatment with growth hormone does not 
improve height or immune function of CHH patients 
(118). Nevertheless, one case has been reported in which
treatment with growth hormone did improve length, 
but an explanation for the different response to growth 
hormone treatment has not been found (119).
The incidence of CHH is particularly high among the 
Amish and the Finnish populations, 1 in 1340 births 
and 1 in 23,000 births, respectively (120, 121), whereas 
in the rest of the world, it is very rare. Mutations in 
RMRP are also found in patients suffering from meta­
physeal dysplasia without hypotrichosis (MDWH, MIM 
#250460), anauxetic dysplasia (AD, MIM #607095), 
and Omenn syndrome (OS, MIM #603554) (58, 122, 
123). However, in OS the involvement of RMRP has not 
been indisputably confirmed. OS patients normally do 
not present a skeletal phenotype, whereas OS patients 
that carry RMRP mutations do (122), which suggests 
that RMRP mutations contribute to the severity of the 
disease. The difference between CHH and MDWH is 
that patients suffering from the latter disorder do not 
have hypoplastic hair. After confirming that all MDHW 
patients carry mutations in the RMRP gene, Bonafe 
and colleagues concluded that MDWH is a variant of 
CHH (123). AD patients display a shorter stature than 
CHH patients and suffer from mild mental retardation 
and hypodontia (58, 124).
CHH-associated RMRP mutations
During the past 8 years many mutations in the RMRP 
gene have been identified in CHH patients. These mu­
tations can be classified into 2 categories. The first ca­
tegory comprises insertions, duplications or triplications 
in the promoter of the RMRP gene between the TATA 
box and the transcription initiation site. These mutati­
ons result in inefficient transcription initiation or a 
complete abrogation of RMRP transcription. Since the 
RMRP gene is transcribed by RNA polymerase III, the 
relative distance between the TATA box and the tran­
scription initiation site is crucial for efficient transcrip­
tion. The second category consists of mutations in the 
transcribed region and thus in the RNA molecule that 
is associated with the RNase MRP particle. In this respect, 
it is important to note that this RNA does not undergo 
post-transcriptional processing (107). By now, more
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Position Mutation Disease Ref.
1_16 dupGTTCGTGCTGAAGGCC CHH (126)
oCN_
ro dupTCGTGCTGAAGGCCTGTA CHH (126)
4C T CHH/
CHH+OS
(125)
9T C CHH (127)
14G A CHH (58)
T CHH (127)
35C T CHH (128)
40G A CHH (128)
45_53 dupTGTTCCTCC CHH (128)
57_64 dupTTCCGCCT CHH (125)
63C T CHH (125)
64T C CHH (128)
A CHH (129)
68-69GG TT CHH (136)
70A G CHH (107)
76C T CHH (136)
77C T CHH (134)
79G A CHH (125)
T CHH (129)
80G A CHH (127)
89C G CHH (127)
90-91AG GC AD (58)
91G, 101 C* A, T* CHH (127)
9 2_93 insA CHH (128)
93G C CHH (128)
94_95 delAG CHH (125)
96_97 dupTG CHH (107)
97G A CHH (128)
111_112 insACGTAGACATTCCT AD (58)
116A G CHH (127)
118A G CHH (125)
124C T CHH (127)
126C T CHH (125)
127G A CHH (128)
146G A CHH (125)
C CHH (128)
[continued]
Position Mutation Disease Ref.
152A G CHH (125)
154G T CHH (125)
C CHH (130)
168G A CHH (126)
08_197 insC CHH (127)
180G A CHH (125)
182G A CHH (131)
C CHH (125)
T CHH (128)
193G A CHH (107)
193_194 insA CHH (125)
195C T CHH (123)
194_195 insT CHH (132)
211 C G CHH (125)
213C G CHH (128)
214A G CHH (131)
T CHH (125)
217C T CHH (126)
218A G CHH (131)
220T C CHH (128)
230C T CHH (125)
236A G CHH (125)
238C T CHH (123)
240A C CHH+OS (122)
242A G CHH (125)
243C T CHH (125)
244G A CHH (128)
248C T CHH (128)
254C G AD (58)
254_263 delCTCAGCGCGG AD (124)
256_265 delCAGCGCGGCT CHH (127)
260C G CHH (128)
261C G CHH (128)
T CHH (125)
262G C CHH (127)
T CHH (107)
264C A CHH (125)
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Table 1B: CHH-associated RMRP mutations in the RMRP promoter region
Position Mutation Disease Ref.
LO
 ' 1
1.0
CN d u pTACTACT CTGT GAAG CT 
GAGAA
CHH (127)
ro' 1 
LO
 
CN d u pACTACT CTGT GAA CHH (130)
-25_-11 t ri pACTACT CTGTGAAG C CHH (107)
-25_-11 d u pACTACT CTGT GAAG C CHH (135)
o
_-5-2 tri pACTACTCTGTGAAG CT CHH (128)
1.0_-5-2 d u pACTACTCTGTGAAG CTGAGA CHH (127)
-5_-5-2 d u pACTACT CTGT GAAG CTGAGGA CHH (128)
- 2 4_-1 dupCTACTCTGTG CHH (127)
5_-
ro-2 dupTACTCTGTG CHH (128)
14_-
ro-2 dupTACTCTGTGA CHH (107)
-4_-
ro-2 dupTACTCTGTGAAGCTGAGGAC CHH (119)
O
_-2-2 d u pACT CTGT GAAG CT CHH (128)
-21_-14 tripCTCTGTGA CHH (130)
-21_-1 dupCTCTGT GAAG CTGAGGACGTG CHH (127)
2 o - 4 dupTCTGTGA CHH (125)
2 o - -P* dupTCTGT GAAG CTGGGGAC CHH (131)
-20_-4 dupTCTGT GAAG CT GAG GAC CHH (107)
-16_-7 dupTGAAGCTGAG CHH (125)
-15_-8 dupGAAGCTGA CHH (127)
-14_-13 insATCTGTG CHH + OS (122)
-14_-7 dupAAGCTGAG CHH (125)
-14_-3 dupAAGCTGAGGACG CHH (123)
-14_-1 d u pAAG CTGAGGACGTG CHH (125)
-11_-10 i n sTACT CTGT GAAGTACT CTGT GAAG CTGA CHH + OS (122)
-11_-5 delCTGAGGAins28bp ** CHH (130)
-9_-2 dupGAGGACGT CHH (130)
-8_-1 dupAGGACGTG CHH (128)
-7_-6 insCCTGAG CHH (107)
-5_-4 insGGACGTGGTT CHH (125)
-4_-1 dupCGTG CHH (130)
Table 2: RMRP polymorphisms 
and rare variants
Position Ref.
-282A G (127)
-149T A (125)
-58T C (123)
-56A G (123)
- 55T C (133)
-48C A (123)
- 25 A G (133)
-24C G (123)
- 22 A C (133)
-21 C G (133)
- 13 A C (133)
- 11 C T (133)
-6G A (123)
- 4 C T (133)
36T G (131)
55_56 insC (131)
57_58 insA (123)
119C T (133)
127G C (128)
156G C (123)
162C T (131)
172C T (131)
175G A (133)
177C T (123)
227C T (133)
250C T (123)
ins = insertion
dup = duplication
trip = triplication
del = deletion
AD = Anauxetic dysplasia
CHH = Cartilage-hair hypoplasia
OS = Omenn syndrome
* both pointmutations on one allele
** nucleotides not specified in reference
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than 70 distinct mutations have been identified in the 
RMRP transcribed region of CHH patients, whereas 30 
different CHH-associated RMRP promoter mutations 
have been reported (58, 107, 117, 119, 122-136). All 
published CHH-associated mutations and RMRP poly­
morphisms are listed in Table 1 and Table 2 (see page 
18-19), respectively.
In general, CHH patients are characterized by either a 
combination of a promoter mutation in one allele and 
a RMRP mutation in the other allele, or a combination 
of two RMRP mutations in both alleles. A combination 
of two promoter mutations has only been found in one 
case (see below), which is most likely reflecting the le­
thality in the absence of any RNase MRP RNA. In Fi­
gure 6, the two-dimensional structure of RNase MRP is 
shown with all published polymorphisms and CHH-as- 
sociated mutations; the conservation of individual nu­
cleotides is also indicated. The CHH-associated muta­
tions are more frequently found in conserved regions 
of the RNase MRP RNA. These regions are involved in 
base pairing, interactions with protein subunits or ca­
talysis. The genetic polymorphisms identified during 
these studies generally reside in less conserved parts 
of the molecule (123, 127 ,131, 133). Taken together, 
these data indicate that the RMRP gene is highly po­
lymorphic and it is striking that so many CHH-associa- 
ted mutations have been identified in the transcribed 
region (30% of the nucleotides).
In addition to direct effects on particle assembly, sub­
cellular localization, substrate recognition and enzyma­
tic activity, the mutations may also affect the steady 
state levels of RNase MRP. It has been reported that 
some mutations in the transcribed sequence diminish 
the stability of the RNA resulting in an increased turn­
over rate of the RNA molecule (137, 138). For several 
promoter duplications and insertions it has been shown 
that the affected allele was indeed not detectably ex­
pressed or expressed at significantly reduced levels (58, 
107, 137, 138). The lack of patients carrying duplica­
tions or insertions in the promoter of both alleles sug­
gests that at least a certain level of RNase MRP RNA 
is required for cells to survive. Kavadas and colleagues
recently described a CHH-patient that carried alterati­
ons between the TATA box and the RMRP transcription 
initiation site on both alleles (130). Because one of 
these alleles contains a duplication of only 4 nucleoti­
des, which is the smallest of all promoter alterations 
identified, and because these four nucleotides are im­
mediately upstream of the transcription initiation site, 
which is observed for only one of the other cases, the 
possibility exists that this allele is still expressed to suf­
ficient levels. It would be interesting to investigate whe­
ther in this case an alternative transcription initiation 
site is used, which would lead to a 5'-extended and thus 
mutated RNase MRP RNA.
The CHH-associated RMRP mutation that is most pre­
valent is 70A>G. It has been found in most, if not all 
Amish patients and in over 90% of the Finnish patients 
analyzed so far. This mutation originates from a foun­
der effect that presumably took place 3900 to 4800 
years ago (125). The 70A>G substitution is also the 
most common CHH-causing mutation in other Euro­
pean populations, but has not been identified in Japa­
nese patients yet (126). Through haplotype analysis, 
Hirose and colleagues identified two founder mutati­
ons for the Japanese population, a 17-bp duplication 
at +3 and the substitution 218A>G; the duplication is 
only found in Japanese patients (126).
What can be the consequence of mutations in the RNase 
MRP RNA? Besides direct effects on its secondary and 
tertiary structure, nucleotide substitutions and small 
insertions or deletions can affect interactions with 
other molecules. These include RNase MRP protein su­
bunits, substrate molecules, factors that regulate the 
activity of RNase MRP and factors involved in the as­
sembly of higher order complexes, such as assemblies 
required for proper rRNA processing. In addition, the 
RNA component of RNase MRP is expected to be di­
rectly involved in catalysis and therefore mutations 
may also diminish its enzymatic activity. In this respect, 
one of the best characterized CHH-associated mutati­
ons is the 70A>G mutation. 70A is located in the pu­
tative catalytic pocket (J3/4 domain, see Figure 3) and 
is 100% conserved among RNase MRP from all sequen-
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Figure 6: RMRP mutations associated with CHH that affect the structure of the RNase MRP RNA
CHH-associated mutations are marked by the arrows (single nucleotide substitutions and insertions) and boxes (duplications 
and deletions) combined with the identity of the mutation; polymorphisms are indicated by circled residues. Conservation of 
nucleotides has been determined by Thiel and collaborators (124) based upon the RNase MRP RNA sequences from 9 species 
(human (Homo sapiens), mouse (Mus musculus), rat (Rattus norvegicus), rabbit (Oryctolagus cuniculus), dog (Canis familiaris), 
armadillo (Dasypus novemcinctus), elephant (Loxodonta africana), opossum (Monodelphis domestica), and pipid frog (Xenopus 
tropicalis)). Black nucleotides in the RNase MRP RNA sequence are 100% conserved among these species; dark grey nucleotides 
mark conservation in 8 species; light grey nucleotides are conserved in 6-7 species; outlined nucleotides are conserved in less 
than 6 species.
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ced eukaryotes. Importantly, the putative catalytic poc­
ket of the eukaryotic RNase P RNA is identical to that 
of RNase MRP RNA and for eubacterial (E. coli) RNase 
P RNA it has been shown that the J3/4 domain is in­
volved in binding of Mg2+ ions which are crucial for the 
endoribonucleolytic cleavage by the ribozyme (70, 71). 
Based on this functional and evolutionary evidence we 
hypothesize that the 70A>G mutation directly affects 
the RNase activity of the RNase MRP complex. Evi­
dence for this hypothesis has been obtained by several 
investigators (58,138). Of course, also other RNase MRP 
RNA mutations may affect its enzymatic activity. Thiel 
and colleagues found that AD patient fibroblasts 
and lymphocytes (heterozygous for 14G>A and 90- 
91AG>GC) showed an impaired pre-5.8S rRNA proces­
sing (58). The pre-5.8S rRNA maturation in patient 
fibroblasts was restored to normal levels when wild type 
RNase MRP RNA was transiently expressed in these 
cells. In another report it was shown that transient ex­
pression of the 70A>G mutant of RNase MRP RNA in 
healthy human fibroblasts significantly affected the ex­
pression of cyclin B2 mRNA (124). Interestingly, similar 
experiments with other RNase MRP RNA mutants did 
not affect the cyclin B2 mRNA levels. Paradoxically, a 
microarray expression study performed with material 
from a homozygous 70A>G CHH patient did not show 
upregulation of human B-cyclin homologs at the mRNA 
level (138). Therefore, more experimental data will be 
required to clarify whether mRNA of human B-cyclin ho­
mologs is a target for RNase MRP and whether changes 
in the regulation of expression of these genes caused 
by malfunctioning of RNase MRP are involved in CHH. 
To gain more insight into the effect of CHH-associated 
mutations on the assembly and structure of the RNase 
MRP complex, several CHH-associated (and other) mu­
tations were introduced into the P3 domain. NMR ana­
lyses demonstrated that the 40G>A substitution altered 
the structure of the P3 apical stem-loop, which, in con­
trast to the wild type P3 domain is not efficiently bound 
by the Rpp20-Rpp25 heterodimer. Also other P3 do­
main mutations appeared to diminish the binding of 
the Rpp20-Rpp25 heterodimer (139). In another study
it was found that for the mutations 168G>A and 
218A>G no decreased binding of Rpp25, Rpp38 or 
hPop1 to RNase MRP RNA was observed (137). Ridan- 
paa et al. showed by immunoprecipitation using ex­
tracts from CHH patient cells that the mutations 
70A>G and 98dupTG do not lead to decreased binding 
of hPop1, Rpp30, Rpp38 and Rpp29 (hPop4) to the 
RNase MRP complex (107). Most likely the function of 
RNase MRP is affected by another mechanism in case 
of these mutations.
The recent identification of the TERT-RNase MRP RNA 
complex raised the question whether CHH-associated 
RMRP mutations somehow interfere with the regula­
tion of RNase MRP levels suggested by Maida and col­
leagues (59). It would be interesting to study the effect 
of different CHH mutations on the in vitro RdRP acti­
vity of the TERT-RNase MRP RNA complex.
Genotype-phenotype correlations
The very high degree of heterogeneity in RMRP muta­
tions found in CHH patients raises the question whe­
ther all of these mutations lead to the same phenotype 
or whether distinct functional activities of RNase MRP 
are (in part) differentially affected by the different mu­
tations. Mutations affecting the catalytic centre, for in­
stance, may have different effects than mutations inter­
fering with the recognition of specific substrate RNAs. 
Because of the high variability and the relatively poor 
knowledge of the exact role of the different RNase MRP 
RNA domains it is impossible to predict the biological 
consequences of each individual mutation and their 
pathogenic effects (128). Nevertheless, several resear­
chers tried to find genotype-phenotype correlations 
which might explain the different clinical features of 
CHH and the other RMRP related disorders mentioned 
above. Indeed, this turned out to be very difficult. In 
one case, three affected siblings (all containing a 21 bp 
duplication in the promoter of one allele and a nucleo­
tide substitution at position 146 in the other) showed 
very different clinical and immunological phenotypes. 
One suffered from SCID, one had classic CHH and the 
third progressive immunodeficiency without any typical
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CHH characteristics (short stature or hypoplastic hair) 
(130). In this study, which included 12 patients, it was 
hypothesized that patients with promoter mutations 
may have a higher predisposition to severe immunode­
ficiency. Rider and colleagues screened a cohort of 25 
Amish patients who were all homozygous for the 
70A>G substitution (140). Also in this study no geno- 
type-phenotype correlation could be found. This implies 
that other factors contribute to the phenotype of the 
disease, and currently it is unclear whether this involves 
genetic, environmental or other factors. Another study, 
conducted by Thiel et al. (124), focused on a genotype- 
substrate correlation and compared this to phenotype. 
The authors concluded that the P3 and P4 domains of 
the RNase MRP RNA are predominantly involved in 
pre-5.8S rRNA processing, whereas the other domains 
are involved in cyclin B2 mRNA cleavage. The pre-5.8S 
rRNA processing defect was linked to the severity of 
bone dysplasia and the cyclin B2 mRNA cleavage de­
fect was linked to immune deficiency. Although this is 
the first report describing a possible genotype-pheno- 
type correlation, it is difficult to reconcile this with the 
idea that the J3/4 domain, which resides between the 
P3 and P4 domains, is located in the catalytic pocket. 
RMRP mutations that cause AD do not overlap with 
CHH-associated mutations. This suggests that pheno- 
type-genotype correlations do exist (58, 124), although 
AD and CHH share clinical features. Notably, the ske­
letal phenotype of AD patients is more severe than that 
of CHH patients. Taken the small number of AD patients 
into consideration, AD-associated RMRP mutations may 
lead to embryonic lethality. In this regard, it should, ho­
wever, also be noted that the analysis of more patients 
may lead to the identification of mutations that are 
found both in CHH and in AD.
In S. cerevisiae, Shadel and colleagues have mutated 
the gene encoding the RNA component of RNase MRP, 
NME1 (141). Distinct nuclear phenotypes (rRNA pro­
cessing) were observed for specific mutations. This im­
plies that in yeast a phenotype-genotype correlation 
may indeed exist.
Cartilage-hair hypoplasia and dyskeratosis congenita
In the same year in which it was reported that CHH is 
caused by mutations in RMRP, mutations in another 
nuclear encoded structural RNA, TERC, were described 
to cause the rare syndrome dyskeratosis congenita (DC)
(142). TERC is the RNA component of the telomerase 
complex which consists of two molecules each of TERC, 
telomerase reverse transcriptase (TERT) and dyskerin
(143). Telomerase was first discovered by Carol Greider 
and Elizabeth Blackburn in Tetrahymena thermophila 
(144,145). The complex adds telomere repeats (TTAGGG) 
to the ends of chromosomes, using the TERC RNA as a 
template (146). Telomerase thereby maintains telo­
mere length and chromosomal integrity in fast dividing 
cells (embryonic stem cells, lymphocytes, germ line cells, 
adult stem cells and cancer cells). In somatic cells, telo­
merase expression is very low or absent (147). In this 
way, the telomeres of somatic cells shorten with each 
round of cell division until they reach a threshold 
length and the cells enter senescence (148).
The most common form of DC is X-linked DC, caused 
by mutations in the dyskerin gene (DKC1 ). DC can also 
be inherited in an autosomal recessive manner. Muta­
tions in TERT or TERC are responsible for the autosomal 
dominant form of the disease. Mutations in these genes 
have also been identified in patients suffering from idio­
pathic pulmonary fibrosis (149, 150). DC is characteri­
zed by bone marrow failure, leukoplakia, nail dystrophy, 
abnormal skin pigmentation, and predisposition to 
cancer. Short stature in DC has also been reported in 
19.5% of the patients (151). The first symptoms are 
usually nail dystrophy and abnormal skin pigmenta­
tion, which appear in childhood, followed by bone mar­
row failure in 90% of the cases around the age of 30 
(152). The disease symptoms vary in severity and age of 
onset. In families with DC, symptoms get worse in every 
consecutive generation, since the offspring inherits 
shorter telomeres than the previous generation (153). 
The recent report describing a functional molecular in­
teraction between the RNase MRP RNA and TERT sug­
gests that there might be an interesting link between 
CHH and DC (59). DC-associated mutations in TERT
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might influence the level and function of the TERT- 
RNase MRP RNA complex. Alternatively, a subset of 
CHH mutations has been shown to reduce the cellular 
RNase MRP levels (107, 137, 138), which may also lead 
to lower levels of the TERT-RNase MRP RNA complex. 
Thus, it is tempting to speculate about a role of the TERT- 
RNase MRP RNA complex in the overlapping pheno­
type of DC and CHH.
Outline of this thesis
The aim of the studies described in this thesis was to 
gain more insight in the effect of ncRNA mutations, in 
particular of CHH-associated mutations, on the func­
tionality of the RNase MRP complex. In Chapter2, the 
consequences of two newly identified pathogenic mi­
tochondrial tRNA mutations are discussed. These mu­
tations lead to a decreased steady state level and a 
structural alteration of the corresponding mt-tRNA. 
When the work described in this thesis started, nothing 
was known about the effect of CHH-associated muta­
tions on protein binding to the RNase MRP RNA. We 
have investigated several CHH-associated mutations 
in the conserved P3 domain of the RNase MRP RNA 
and the results are described in Chapter 3. The results 
of the experiments described in this chapter show that 
several of these mutations reduce the binding effi­
ciency of the Rpp20-Rpp25 dimer. The 40 G>A muta­
tion, which is located in the apical stem-loop of the P3 
domain, leads to a structural alteration, as demonstra­
ted by NMR experiments. This is most likely the expla­
nation for the inability of the Rpp20-Rpp25 dimer to 
bind to the 40 G>A P3 domain. Although the cyclin B2 
mRNA had been reported to be cleaved by RNase MRP 
in yeast, no mRNA substrates had been found for the 
human RNase MRP Chapter4 describes the identifica­
tion of viperin mRNA as a new substrate for the human 
RNase MRP complex. This mRNA was first identified by 
microarray analyses of the transcriptome of human 
cells after depletion of the hPop1 or Rpp40 protein su­
bunits. The results of an in vitro activity assay show that 
human RNase MRP can directly cleave the viperin mRNA 
at two distinct sites in the coding sequence. The invol­
vement of RNase MRP in human rRNA processing was 
studied by an siRNA-mediated knock down approach, 
the results of which are presented in Chapter 5. Since 
dwarfism is one of the main features of CHH, an im­
portant role for RNase MRP has been proposed in 
growth plates, areas at each end of long bones of chil­
dren and adolescents, which are crucial for bone growth. 
In Chapter 6, preliminary data are shown that impli­
cate RNase MRP as a critical player in growth plate de­
velopment by regulating chondrocyte terminal hyper­
trophic differentiation. The implications of the results 
that are presented in this thesis for our understanding 
of the impact of mutations in small non-coding RNAs 
in health and disease are discussed in Chapter 7.
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Mitochondrial tRNATrp and tRNAArg mutations
Combined oxidative phosphorylation (OXPHOS) system deficiencies are a group of mitochon­
drial disorders that are associated with a range of clinical phenotypes and genetic defects. They 
occur in approximately 30% of all OXPHOS disorders and around 4%  are combined complex I, 
III and IV deficiencies. Here we present two mutations in the mitochondrial tRNATrp (MT-TW) and 
tRNAArg (MT-TR) genes, m.5556G>A and m.10450A>G respectively, which were detected in two 
unrelated patients displaying combined OXPHOS complex I, III and IV deficiencies and progres­
sive multisystemic diseases. Both mitochondrial tRNA mutations were almost homoplasmic in 
fibroblasts and muscle tissue of the two patients and not present in controls. Patient fibroblasts 
displayed a general mitochondrial translation defect. The mutations resulted in lowered steady- 
state levels and altered conformations of the tRNAs. Cybrid cell lines showed similar tRNA defects 
and impairment of OXPHOS complex assembly as patient fibroblasts. Our results demonstrate 
that these tRNATrp and tRNAArg mutations cause the combined OXPHOS deficiencies of the pa­
tients, adding to the still expanding group of pathogenic mitochondrial tRNA mutations.
Introduction
Combined oxidative phosphorylation (OXPHOS) system 
deficiencies, in which two or more enzyme complexes 
show a decrease in activity, occur in around 30%  of all 
OXPHOS disorders diagnosed at our centre and ap­
proximately 4 %  consist of combined complex I, III and 
IV defects (1). Candidate genes for these deficiencies 
are, among others, all genes encoding proteins and 
RNAs involved in mitochondrial translation. Protein 
synthesis in the mitochondrion, which is responsible for 
the production of 13 polypeptides of the OXPHOS com­
plexes I, III, IV and V, is executed by mitochondrial DNA 
(mtDNA) encoded rRNAs and tRNAs and a multitude 
of nuclear-encoded factors. Although tRNA-encoding 
genes make up only 9 %  of the entire mitochondrial ge­
nome, over 40%  of all point mutations reported in the 
mtDNA are located in tRNA genes (2). In contrast, rRNA 
sequences cover 15% of the mtDNA, but mutations in 
the two rRNAs account for only 4 %  of all mtDNA mu­
tations. Additionally, in recent years mutations in vari­
ous nuclear-encoded proteins involved in the mito­
chondrial translation process have been found and this 
group of gene defects is expanding rapidly (3).
This study describes two mutations, m.5556G>A in the
tRNATrp and m.10450A>G in the tRNAArg gene, that 
lead to combined OXPHOS deficiencies and demon­
strates their pathogenicity.
Material and methods
Case reports 
Patient T
This female child was born at term as the first child of 
healthy unrelated parents. She had feeding problems 
from birth and gastroesophageal reflux disease was 
suspected. From the age of 7 months a regression of 
psychomotor functioning was noted and she became 
somnolent. In addition, she developed a severe consti­
pation. There was failure to thrive; weight decreased 
from 0 to -2.5 SD, length from 0 to -1 SD, and head 
circumference from +1 to -1 SD from the age of 1 
month to the age of 10 months. Physical examination 
at the age of 10 months showed an irritable child with 
marked generalized hypotonia. She could not sit with­
out support and demonstrated no intentional hand 
function. Fundoscopy was normal. Gavage feeding was 
initiated. Laboratory studies revealed a metabolic aci­
dosis. Plasma lactate was 12.3 mmol/l (N: <2.1 mmol/l)
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with an increased lactate/pyruvate ratio and CSF lac­
tate was 12.5 mmol/l (N: <1.4 mmol/l). Additional la­
boratory studies, including liver function tests, were 
normal. Muscle biopsy was performed at the age of 11 
months. Immunohistochemistry and electron micros­
copy were normal. She became comatose and died at 
the age of 13 months due to respiratory insufficiency. 
Autopsy or additional studies were not performed.
Patient A
The male patient was born at 37 weeks of gestation 
with a birth weight of 2.118 kg (< -2.5 SD), length 
44.5 cm (< -2.5 SD) and head circumference 32.4 cm 
(-2 SD) as a first child of healthy, non-consanguineous 
parents. He was admitted to the neonatal unit for se­
vere generalized hypotonia, respiratory insufficiency, 
feeding difficulty and anemia. He was further evalua­
ted at the age of four months for severe psychomotor 
retardation, growth retardation, visual dysfunction, epi­
lepsy (West syndrome) and chronic lactic acidemia. He 
received a gastric tube placement and started on nu­
tritional intervention. A cranial MRI reported hypoplas­
tic corpus callosum and abnormal signal intensity of 
the basal ganglia, including the globus pallidus and 
the nucleus caudatus. A follow-up cranial MRI showed 
progressive cerebral and cerebellar atrophy. EEG and 
VEP were severely abnormal. EEG showed generalized 
seizure activity; no burst suppression pattern was pre­
sent. The VEP showed severe central visual perception 
loss. Metabolic studies showed markedly elevated lac­
tate both in blood (3.6-7 mmol/l, N: <2.1 mmol/l) and 
CSF (3.8 mmol/l, N: <1.4 mmol/l), hyperalaninemia 
(860 pmol/l, N: <460 pmol/l), and increased urinary 
lactate and Krebs cycle intermediates. Additional labo­
ratory studies were normal. At the age of 8 months, 
the time of the surgical muscle biopsy, he had severe 
microcephaly; other growth parameters were normal. 
No internal organ dysfunction was noted. He had severe 
generalized hypotonia and hyporeflexia. The psycho­
motor development of the patient remained at the level 
of a three-month-old baby. He had no visual contact 
with the surroundings and was suffering from intrac­
table Blitz-Nick-Salaam (BNS) type seizures. By histolo­
gic investigations a homogenously decreased staining 
of COX activity was confirmed with a residual activity 
of 15-25%. No fiber type disproportion, lipid storage 
or ragged red fibers were detected. The patient is cur­
rently 4.5 years old, has no acoustic or visual contact, 
is severely retarded and fully tube fed.
Cell culture
Skin fibroblasts were cultured in M199 medium (Gibco) 
supplemented with 10% fetal calf serum (FCS) and an­
tibiotics. Transmitochondrial cybrid cell lines were con­
structed as described elsewhere (4). The cybrids were 
grown in Dulbecco's modified Eagle's medium (DMEM) 
containing 4.5 mg/ml glucose and supplemented with 
10% FCS, 110 pg/ml pyruvate, and antibiotics; for the 
mtDNA-less 143B206 cells this medium was additio­
nally supplemented with 50 pg/ml uridine and 100 
pg/ml bromodeoxyuridine. The human osteosarcoma 
cell line 143B (TK-) was cultured in Eagle's minimum 
essential medium (EMEM) with Earle's BSS supplemen­
ted with 10% FCS and 15 pg/ml bromodeoxyuridine.
Enzyme measurements
The activities of the OXPHOS enzyme complexes were 
measured in skin fibroblasts and muscle tissue of the 
patients as described previously (5,6).
Molecular genetic analysis
DNA was isolated from cultured skin fibroblasts, mus­
cle tissue or blood using salt extraction (7). The entire 
mtDNA of the patients was amplified and sequenced 
according to the protocol of Taylor et al. (8) with minor 
adaptations. Percentage heteroplasmy was quantified 
using the Pyrosequencing™ technology (Biotage AB, 
Uppsala, Sweden). Pyrosequencing was performed on 
the PSQ96TMMA platform according to the protocol of 
the manufacturer. Primer sequences are available upon 
request.
Analysis of mitochondrial protein synthesis
In vitro pulse labeling of mitochondrial translation was
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performed as described elsewhere (9), with a few adap­
tations. In short, cells were labeled for 60 min at 37 ° C 
in methionine-free DMEM with 10% dialyzed FCS, 200 
|Ci/ml [35S]methionine (Tran35S-Label, MP Biomedic­
als) and 100 ig/ml emetine, and subsequently chased 
for 10 min in regular DMEM with 10% FCS. Total cel­
lular protein (100 ig ) was resuspended and incubated 
for 10 min in PBS containing 2 %  lauryl maltoside. Un­
solubilized material was removed by centrifugation at 
10,000g for 10 min and loading buffer was added to 
the supernatant to a final concentration of 100 mM 
Tris-HCl (pH 6.8), 20% glycerol, 1%  SDS, 0.02% Coo- 
massie Blue G-250, and 1 %  mercaptoethanol. Samples 
were run on 16% polyacrylamide gels (10), which were 
subsequently scanned on a FLA5100 (Fujifilm Life 
Science) and analyzed with ImageQuant software (GE 
Healthcare). Equal protein loading was confirmed by 
Coomassie blue staining (data not shown).
Blue-native PAGE and complex I in-gel activity assay
Blue-native PAGE was used for separation of the OX- 
PHOS complexes on 5%-15% polyacrylamide-gradient 
gels as described before (11). After electrophoresis of 
40 ig  protein from fibroblast and cybrid cells, gels were 
further processed for in-gel activity assays and Western 
blotting. Assembly of the OXPHOS complexes was in­
vestigated using monoclonal antibodies against subu­
nits of complexes I, III, V (Molecular Probes), II, and IV 
(MitoSciences).
Northern blot analysis
Total RNA samples (10 ig ) isolated from cultured fibro­
blast and cybrid cell lines using RNA-Bee (Tel-Test) were 
separated on a 15% denaturing UREA-PAGE gel and 
transferred to a Hybond-N membrane (Amersham 
Pharmacia Biotech) by electroblotting. For the confor­
mational analysis, total RNA samples were separated 
in 24 hours at 4 ° C on a non-denaturing 15% poly­
acrylamide gel. Denaturing was performed by placing 
the gel for 10 minutes in 0.2 M Na0H/0.5 M NaCl. 
Before electroblotting to a Hybond-N membrane (Amers­
ham Pharmacia Biotech), neutralization was carried out
by washing twice for 10 minutes in 5xTBE and twice 
for 10 minutes in 1xTBE. After hybridization with the 
tRNAArg probe, the membrane was washed and subse­
quently rehybridized with the tRNATrp probe.
For the detection of tRNATrp and tRNAArg, templates for 
hybridization probes were generated by PCR using oli­
gonucleotides containing the T7 RNA polymerase pro­
moter sequence in the reverse primer. Primer sequences 
are available upon request. For in vitro transcription, the 
gel-purified PCR template was incubated for 2 hours 
at 37 ° C in 60 ml of buffer containing 40 mM Tris-HCl 
(pH 7.9), 6 mM MgCh, 2 mM spermidine, 10 mM NaCl, 
10 mM dithiotreitol, 1 mM each of ATP, CTP and UTP, 
0.1 mM GTP, 60mCi [a-32P]GTP and 45 U T7 RNA po­
lymerase. Imaging was performed using a Phosphor-I- 
mager; signal intensities for tRNATrp and tRNAArg were 
normalized to each other for each sample.
Results
Enzyme measurements
The biochemical assays of OXPHOS enzyme activities 
demonstrated clear combined complex I, III and IV de­
ficiencies in patients T and A (Table 1). The activities 
measured as percentage of the lowest control value 
ranged from 15-59% in patient T and from 19-44% 
in patient A, excluding complex III activity, which was 
not decreased considerably in patient A.
Molecular genetic analysis
Sequence analysis of the entire mitochondrial genome 
revealed 18 (patient T) and 39 (patient A) known po­
lymorphic variants compared with the revised Cam­
bridge Reference Sequence (12), and two mutations: a 
G to A transition at position m.5556 in the tRNATrp 
gene (MT-TW) in patient T and an A to G transition at 
position m.10450 in the tRNAArg gene (MT-TR) in pa­
tient A. The levels of the mutations were nearly hom- 
oplasmic in both patients, in muscle tissue as well as 
cultured fibroblasts (Table 2). In blood of the mothers 
the mutations could not be detected, whereas in fibro­
blasts of patient A's mother the m.10450A>G mutation
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Table 1: OXPHOS enzyme activities in skeletal muscle and fibroblasts
ACTIVITIES (mU/U CITRATE SYNTHASE) IN 
SKELETAL MUSCLE
ACTIVITIES (mU/U CITRATE SYNTHASE) IN 
FIBROBLASTS
Complex Patient T Patient A Control range Complex Patient T Patient A Control range
26 31 70 - 251 I 39 39 100 - 310
II 387 455 335 - 749 II 774 544 520 - 845
III 1306 1870 2200 - 6610 III 571 1383 1320 - 2610
IHM 386 420 300 - 970 II+III 140 218 110 - 470
IV 322 157 810 - 3120 IV 102 223 680 - 1190
Samples were supernatants obtained after 600g centrifugation of skeletal muscle or mitochondrial enriched fractions from fibroblasts.
Decreased activities as compared to controls are in bold.
Table 2: Percentages of mutant mtDNA 
as determined with pyrosequencing
Subject Sample m.5556G>A m.10450A>G
Patient Fibroblasts 92 92
Skeletal muscle 93 93
Cybrid clone 1 90 91
Cybrid clone 2 93 90
Cybrid clone 3 96 88
Mother Blood 0 0
Fibroblasts not dertermined 18
was present with 18% heteroplasmy. The two mutati­
ons were not reported before and were found neither 
in 84 healthy control subjects or 31 patients with a 
combined OXPHOS complex I, III and IV deficiency (tes­
ted by PCR) nor in haplogroup-matched controls, 499 
controls of haplogroup H for tRNATrp and 121 controls 
of haplogroup T for tRNAArg (database search) (13). Po­
sition m.5556 is located in the variable region of the 
tRNATrp structure and position m.10450 is located in 
the T-stem of tRNAArg (Figure 1 a and 1 b). The nucleotide 
mutated in tRNATrp is entirely conserved in mammals 
(14) and also in several lower species (Figure 1 c). The 
mutation in tRNAArg, on the other hand, affects a base 
that is conserved in many mammalia, but not in lower 
species (Figure 1 c) (14).
Analysis of mitochondrial protein synthesis
As shown in Figure 2, both patients displayed a marked 
reduction in radioactive labeling compared to controls, 
indicating that the rate of mitochondrial protein syn-
Table 3: Level of mitochondrial protein synthesis
Polypeptide Patient T Patient A
COI 28 12
Cytb/ND2 56 86
ND1 35 82
COIII/COII 22 68
ATP6 124 163
ND6/ND3 82 89
ND4L/ATP8 126 94
The values represent percentages of the average incorporation 
of [35S]methionine measured in two controls. 
COI-COIII=subunits of cytochrome c oxidase; cyt 
b=cytochrome b subunit; ND1-6=subunits of NADH CoQ 
oxidoreductase; ATP6-8=ATP synthase subunits 6 and 8.
thesis is decreased. The total incorporation of [35S]me- 
thionine was 45%  (patient T) and 57% (patient A) of 
that in controls; however, different polypeptides were 
affected to variable extents (Table 3). In patient T, the 
rate of mitochondrial translation ranged from 22% to 
126% and the three subunits of complex IV (COI-COIII) 
were most severely affected. In patient A, synthesis of 
COI showed by far the strongest decrease (12%) and 
the other polypeptides were affected only minimally 
with incorporation rates of 68% or higher. In both pa­
tients, the synthesis levels of the two ATP synthase su­
bunits (ATP6 and ATP8; the latter migrated in a band 
together with ND4L) were comparable to or even hig­
her than the levels in controls.
Blue-native PAGE and complex I in-gel activity assay
To determine whether the combined OXPHOS deficien-
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Figure 1 : Schematic representation of the tRNATrp (a) 
and tRNAArg (b) cloverleaf structures, showing the 
location of the mutations
Comparison of the sequences of the variable region of 
the tRNAT,p gene (c) and the T-stem of the tRNAA,g gene 
(d) across different species; the mutated bases are depicted 
in bold.
cies in the patients were indeed caused by a mtDNA 
defect, we investigated the assembly of all OXPHOS 
complexes in fibroblasts and cybrid cell lines using 
blue- native PAGE analysis. Patient fibroblasts showed 
reduced levels of fully assembled complexes I, III (only 
in patient T), IV and V as well as decreased complex I 
activities (Figure 3), which is consistent with the defi­
ciencies detected in the enzyme measurements (Table 
1). This pattern was also found in the different cybrid 
clones, proving the mitochondrial origin of the OX­
PHOS defect. In addition to the fully assembled com­
plex V, two subcomplexes were observed in most 
samples with raised levels in the patient samples. 
These subcomplexes are often increased in patients 
with a defect in the mtDNA, but sometimes they are 
entirely absent. This was the case for the experiment 
with fibroblasts from patient A and the control, which 
was probably caused during the preparation of the 
samples.
Figure 2: In vitro labeling of mitochondrial translation 
products
Fibroblasts from the patients (P t and Pa) and controls (C1 
and C2) were labeled with [35S]methionine in the presence 
of emetine. The mitochondrial translation products are 
indicated on the left of the autoradiogram. COI—COI II= 
subunits of cytochrome c oxidase; cyt b=cytochrome 
b subunit; ND1 —6=subunits of NADH CoQ oxidoreductase; 
ATP6-8=ATP synthase subunit 6 and 8.
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Figure 3: Blue-native PAGE and complex I in-gel 
activity assay
Fibroblasts and cybrid clones from patient T (PT) and 
A  (PA) and controls (Cl —3 and 143B) were analyzed. The 
blue-native PAGE gels were immunoblotted with antibodies 
directed against specific individual subunits to assess 
the amount of each of the five fully assembled OXPHOS 
complexes. Complex II was used as a loading control. 
IGA=in-gel activity.
Northern blot analysis
To investigate the effect of both mutations on tRNA 
stability, steady-state levels of tRNATrp and tRNAArg were 
determined by Northern blot hybridization in cultured 
fibroblasts and cybrid cell lines of the two patients. The
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amounts of mutant tRNA were markedly decreased (Fi­
gure 4): in patient T the tRNATrp levels were reduced to 
29% (fibroblasts) and 33%  (cybrids) and in patient A 
the tRNAArg levels were reduced to 29% (fibroblasts) 
and 50% (cybrids) (after normalization to the tRNAArg 
or tRNATrp levels, respectively, and relative to average 
control values).
Additionally, native gel electrophoresis provided insights 
into whether the mutations affect tRNA structure. Whe­
reas on a denaturing gel the tRNA mutants migrated 
at the same rate as the wild-type (see steady-state 
data, Figure 4), both tRNA mutations resulted in aber­
rant migration patterns under non-denaturing conditi­
ons (see conformation data, Figure 4), indicating that 
they primarily affect the secondary or tertiary structure 
of the tRNAs. The mutation in tRNATrp led to retarda­
tion of the electrophoretic mobility of the residual 
tRNATrp compared to controls. Analysis of tRNAArg re­
vealed the presence of two different conformations 
with accelerated mobility.
Since the cybrid clones showed similar steady-state le­
vels and migration patterns as found in fibroblasts of 
the patients, these results are again consistent with the 
mitochondrial origin of the OXPHOS defects.
Discussion
Here we clearly demonstrate that the m.5556G>A and 
m.10450A>G mutations are pathogenic and are the 
cause of the combined OXPHOS disorders found in the 
two patients. This conclusion is based on the following 
evidence: 1) the mutations are not present in healthy 
controls or in asymptomatic maternal relatives (or with 
a low mutant load), 2) the mutations affect evolutio­
nary conserved bases (applies more to the tRNATrp mu­
tation than the mutation in the tRNAArg gene), 3) 
patient fibroblasts have a general mitochondrial trans­
lation defect, 4) tRNA steady-state levels and confor­
mation are affected by the mutations, (5) transmito­
chondrial cybrids show similar OXPHOS complex and 
tRNA defects as patient fibroblasts.
Although the mutation in the tRNATrp gene was not
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Figure 4: Steady-state levels and conformation of 
tRNATrP and tRNAArg
Fibroblasts and cybrid clones from patient T (P t) and A  (Pa) 
and controls (C1 -3 and 143B) were analyzed by high­
resolution Northern blot under denaturing (steady-state) 
and native (conformation) conditions. Signal intensities 
for tRNAT,p and tRNAA,g were normalized to each other for 
each sample, as shown in the column charts (only relevant 
steady-state levels are depicted). Asterisks indicate the 
position of altered conformations of mutant tRNATrp and 
mutant tRNAArg.
found in blood of the patient's mother, we cannot con­
clude that it is a de-novo mutation. Mutation load can 
vary greatly between tissues causing the mutation to 
be undetectable in for instance blood, as was the case 
for the tRNAArg mutation. In patient A the mutation 
was present at 92%  heteroplasmy, while his mother 
had a mutant load of only 18% in fibroblasts, which is 
apparently below the threshold level for this mutation 
and therefore does not result in clinical disease. 
Approximately 70% of pathogenic mutations occur in 
the stems of the tRNA cloverleaf structure (15,16). Fur­
thermore, the disruption of Watson-Crick base pairing 
is an important characteristic of pathogenic mutations 
located in the stem structures (15). The mutation in the 
tRNAArg gene affects base 50 in the T-stem and disrupts 
Watson-Crick base pairing, which makes it a likely can­
didate for the disease-causing mutation. However, a 
wobble base pair can still be formed with the mutant 
base. The disturbance of Watson-Crick base pairing 
could affect the secondary structure of the tRNAArg, lea­
ding to misfolding and instability of the mutant tRNA. 
This was confirmed by northern blotting, which showed
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reduced tRNAArg steady-state levels and the existence 
of 2 aberrant conformations in the absence of the nor­
mal tRNA. On the other hand, the site that is mutated 
in the tRNAArg gene is conserved merely in mammalia. 
Although most pathogenic tRNA mutations are found 
at highly conserved sites, there are exceptions, indica­
ting that evolutionary conservation is not required for 
a mutation to be pathogenic (16, 17).
The m.5556G>A mutation is located at position 46 in 
the variable region of tRNATrp, which is not a common 
site for pathogenic mutations (15). However, this base 
is highly conserved. Additionally, a potential tertiary 
interaction between nucleotides 13-22-46 in tRNATrp 
has been described (14). This interaction is present in 
all mammalian tRNA families and is part of a set of 
three tertiary interactions that are thought to be mini­
mally required for proper functioning of the mitochon­
drial tRNAs. Nucleotide 46 is N7-methylated in many 
tRNAs of different species (18). This post-transcriptio­
nal modification together with hydrogen bonding to 
the bases G22 and C13 results in a positive charge, 
which could be necessary for the L-shaped 3D tRNA 
structure and/or for protein recognition (19). In gene­
ral, the role of modified bases for the maintenance of 
the tRNA tertiary structure is of higher importance in 
mitochondrial tRNAs than in their cytosolic counterp­
arts (20). Certain mitochondrial tRNAs will conse­
quently be completely non-functional when lacking the 
post-transcriptional modification. Northern blot analy­
sis revealed a clear decrease in the amount of mutant 
tRNATrp as well as an altered conformation, indicating 
that the mutation might indeed interfere with the ter­
tiary interaction and thereby disturb the 3D tRNA 
structure and tRNA stability.
Although the MITOMAP database lists the m.5556G>A 
transition as an unpublished polymorphism, our results 
clearly show that this nucleotide change is a pathoge­
nic mutation in our patient (21 ). This underscores the 
importance of functional studies in defining the patho­
genicity of tRNA mutations. Seven pathogenic mutati­
ons have been reported in the mitochondrial tRNATrp 
gene (2). None of these mutations are located near
the m.5556G>A mutation we found. However, the 
m.5532G>A mutation affects base 22, which is suppo­
sedly involved in the tertiary interaction with base 46 
(m.5556) mentioned above (22). Unfortunately, the ef­
fect of this point mutation on tRNA stability and con­
formation has not been investigated. A common 
feature of most tRNATrp mutations is a profound com­
plex IV defect (22-28). In some cases complex IV is se­
lectively decreased, in other cases complex I is affected 
to a similar extent and occasionally complex III is in­
volved as well. Biochemical analysis revealed a com­
bined complex I, III and IV deficiency in patient T, where 
complex IV was most severely affected (on average 
28%  of control levels) followed by complex I (38%) 
and lastly by complex III (51%). The results of the in 
vitro translation assay also supported this as the syn­
thesis rates of COI and COIII/COII showed the stron­
gest decrease compared to control rates. The fact that 
complex IV is more susceptible to tRNATrp mutations 
could be explained by the higher percentage of tryp­
tophan in the subunits COI and COIII compared to 
other complex subunits, as has been proposed before 
(26, 27). Nonetheless, a correlation between the rela­
tive amount of tryptophan in individual subunits and 
the reduction of their mitochondrial translation rates 
in our patient was not evident, which has also been ob­
served by Sacconi et al for the m.5545C>T mutation
(24). They found COI and COIII translation to be most 
severely disturbed, but in contrast to our results ATP6 
showed a profoundly decreased synthesis as well. Inc­
reased synthesis of ATP6 and ATP8, as we observed for 
our tRNATrp and tRNAArg mutations, has been reported 
before (29-32) and has been suggested to be caused 
by the fact that bicistronic mRNAs can be translated 
more efficiently than monocistronic mRNAs, thereby 
giving the translation of ATP6 and ATP8 an advantage 
(32). Many patients with a tRNATrp mutation, including 
our patient, show developmental delay, gastrointes­
tinal symptoms and failure to thrive (22, 24, 25, 28). 
Additionally, visual defects, deafness, epilepsy and neu­
rodegenerative disease are frequently observed in other 
patients (22-28, 33).
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In the mitochondrial tRNAArg gene only 2 pathogenic 
mutations have been reported so far: m.10406G>A and 
m.10438A>G (2). In the patient with the m.10438A>G 
mutation no clear OXPHOS deficiency was found, only 
a minor decrease in complex IV activity (34). In con­
trast, the m.10406G>A mutation caused a marked re­
duction in complex IV activity and complex I and III 
were also affected (35). This is consistent with our fin­
dings, except that complex III was hardly impaired in 
patient A. The clinical phenotypes of the three patients 
carrying tRNAArg mutations are variable; the only com­
mon features are muscle weakness and brain abnor­
malities. Furthermore, visual dysfunction and progres­
sive psychomotor retardation were observed in both our 
patient and for the m.10438A>G mutation (34). The 
clinical presentation of the m.10406G>A mutation is 
considerably different with Asperger syndrome and nor­
mal cognitive function (35). Our patient manifested the 
most severe symptoms in a progressive multisystem dis­
order. The variability in clinical phenotypes could be 
explained by the fact that all three mutations are lo­
cated in different domains of the tRNA cloverleaf struc­
ture. A distinct correlation seems not to exist between 
clinical presentation and the specific tRNA that is mu­
tated (16,36). For our m.10450A>G mutation, the dis­
proportionate decrease in synthesis of some poly­
peptides (mainly COI synthesis was impaired) is not 
correlated with the arginine content of the polypepti­
des. The effects on translation have not been investi­
gated for the other tRNAArg mutations.
In conclusion, we demonstrate that the mutations in 
the mitochondrial tRNATrp and tRNAArg genes are pa­
thogenic. The effect of the mutations on the tertiary 
(tRNATrp) or secondary (tRNAArg) structure will likely 
lead to misfolding and instability, resulting in increased 
degradation and possibly also in impaired aminoacy- 
lation. Consequently, the scarcity and malfunctioning 
of the tRNAs cause a combined OXPHOS deficiency 
through reduced rates of mitochondrial protein synthe­
sis. This gives rise to a progressive multisystem disease 
in both patients, marked by failure to thrive, lactic aci­
dosis, feeding difficulties, gastrointestinal problems, ge­
neralized muscle hypotonia, progressive psychomotor 
retardation and microcephaly.
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CHH mutations affect RNase MRP assembly
Cartilage-hair hypoplasia (CHH) is caused by mutations in the gene encoding the RNA compo­
nent of RNase MRP. Currently it is unknown how these mutations affect the function of this 
endoribonuclease. In this study we investigated the effect of mutations in the P3 domain on 
protein binding and RNA folding. Our data demonstrate that a number of P3 nucleotide sub­
stitutions reduced the efficiency of its interaction with Rpp25 and Rpp20, two protein subunits 
binding as a heterodimer to this domain. The CHH-associated 40G>A substitution, as well as 
the replacement of residue 47, almost completely abrogated Rpp25 and Rpp20 binding in dif­
ferent assays. Also other CHH-associated P3 mutations reduced the efficiency by which the 
RNase MRP RNA is bound by Rpp25-Rpp20. These data demonstrate that the most important 
residues for binding of the Rpp25-Rpp20 dimer reside in the apical stem-loop of the P3 domain. 
Structural analyses by NMR not only showed that this loop may adopt a pseudo-triloop struc­
ture, but also demonstrated that the 40G>A substitution alters the folding of this part of the 
P3 domain. Our data are the first to provide insight into the molecular mechanism by which 
CHH-associated mutations affect the function of RNase MRP.
Introduction
Cartilage-hair hypoplasia (CHH: OMIM #250250) (1) 
was the first human autosomal recessively inheritable 
developmental disorder described to be caused by mu­
tations in a non-coding structural RNA. The affected 
gene, first identified by Ridanpaa and co-workers (2), 
codes for the 267 nucleotides long RNA component of 
the RNase MRP small nucleolar ribonucleoprotein com­
plex (snoRNP) (3). The major CHH-pathogenic muta­
tion in the RNA component of the RNase MRP complex 
is the single nucleotide substitution 70A>G (2). This 
mutation can be detected in more than 90%  of all re­
ported CHH-cases (4) and was calculated to originate 
from a single mutation event, which took place 3900­
4800 years ago (5, 6). In contrast to most known 
snoRNPs, the RNase MRP complex is not involved in 
posttranscriptional nucleotide modification of ribo- 
somal RNA (rRNA), but in the endonucleolytic cleavage 
of precursor 5.8S rRNA (7) and other ribonucleolytic 
cleavage events (8,9). RNase MRP is highly related to 
the pre-tRNA processing factor RNase P (10), from which 
the RNA subunit was the first RNA for which ribozyme 
activity was described (11).
To understand the molecular mechanism behind CHH 
it is important to know that the major RNase MRP RNA 
mutation that is associated with CHH is situated close 
to the crucial P4 long-range interaction of RNase MRP 
RNA and is part of a short single stranded nucleotide 
stretch referred to as the J3/4 domain (12). The J3/4 
domain is highly conserved among all known RNase 
MRP and RNase P RNA species and previous studies 
on the J3/4 domain in the E. coli RNase P RNA provi­
ded evidence for divalent metal ion binding sites in this 
domain that are crucial for the enzymatic activity of 
the RNA (13). As a consequence, it is likely that the 
major CHH-related mutation 70A>G directly affects the 
catalytic activity of RNase MRP Recently, it was shown 
that overexpression of the RNase MRP RNA 70A>G 
mutant in human fibroblasts indeed reduced the ex­
pression level of 5.8S rRNA (14).
In addition to the 70A>G mutation, a high number of 
other mutations in the RNase MRP RNA gene have 
been described, which are located either in the promo­
ter or in the transcribed region of the gene. In the tran­
scribed part 52 different CHH-associated insertions 
and substitutions have been found to date (14) (reviewed 
by Bonafe et al (4); unpublished data), which means
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that almost 20% of the nucleotides may be implicated 
in CHH. Most of these alleles, like 70A>G, are expected 
to diminish the catalytic activity of RNase MRP Insight 
into the secondary and tertiary structures of RNase 
MRP RNA has been obtained by chemical/enzymatic 
structure probing and phylogenetic comparison (15, 16, 
17) as well as from extrapolation of X-ray crystallogra­
phy data for RNase P (45). Interestingly, the vast ma­
jority of the CHH mutations is located in evolutionarily 
highly conserved regions, many of which are involved 
in intramolecular base pairing (4). Similarly, mutations 
in the RNA component of human telomerase RNA (hTR), 
which are associated with the genetic disorder dyske­
ratosis congenita (DKC), are located in highly conser­
ved domains of hTR. Subtle alternative hTR structures, 
caused by DKC-associated mutations, are thought to 
explain DKC at least in a number of cases (18).
One of the RNase MRP RNA domains, which has been 
reported to be involved in the interaction with protein 
subunits, is the P3 domain. A phylogenetic comparison 
showed that there is a high degree of sequence simila­
rity among the RNase MRP P3 domains of several ver­
tebrate species (4, 44). The hPop1, Rpp20 and Rpp25 
proteins bind to this domain (19, 20, 21), which is es­
sential for the nucleolar localization of the RNase MRP 
RNA (22) and is important for ribonucleoprotein par­
ticle assembly (23). In accordance with these important 
functions, CHH-associated mutations were originally 
not found in the P3 domain (6). However, recently Bo- 
nafé and collaborators showed the occurrence of se­
veral different P3 mutations in CHH patients (4). One 
of the P3 domain-binding proteins, Rpp25, associates 
with the P3 domain in a manner that is dependent on 
the proper folding of this domain (24).
To provide more insight into the molecular mechanism 
by which (CHH-associated) mutations in the P3 do­
main affect RNase MRP function, we investigated the 
effect of these mutations on its recognition by the pro­
tein subunits and on its structure. Our results show that 
a number of P3 domain mutations drastically affect 
the binding of Rpp20 and Rpp25, two protein subunits 
which are likely to play a crucial role in the biological
function of RNase MRP (25, 21 ). At least for some of 
the mutations the interference with Rpp25-binding ap­
pears to be caused by structural alterations in the P3 
domain.
Materials and Methods
In vitro transcription of P3 RNAs
The RNase MRP RNA constructs MRP1 -82 and MRP22- 
67 have been described previously and were linearized 
as described before (19). For in vitro transcription, 1 pg 
template DNA was incubated for 1 hour at 37 °C  in 
20 pl buffer containing 40 mM Tris-HCl, pH7.9; 6 mM 
MgCh; 2 mM spermidine; 10 mM NaCl; 10 mM dithio- 
treitol; 1 mM ATP; 1 mM CTP; 1 mM GTP; 0.1 mM UTP; 
6.6 fmol (20 pCi) [a-32P]UTP and 15 U T7 RNA poly­
merase. After transcription, the RNA was purified by 
phenol/chloroform/isoamylalcohol (25:24:1) extrac­
tion and unincorporated nucleotides were removed 
using a Sephadex G50 spin column. Templates for mu­
tant P3 RNAs were generated by PCR using overlap­
ping oligonucleotides containing the T7 RNA poly­
merase promoter sequence in the 'forward' oligonucleo­
tide. Combinations of the oligonucleotides used (see 
Table 1 ) are as follows: P3: P3f5 x P3r2; P3ggaa: P3f5 x 
P3r7; ggP3: Th-8 x P3r2; GGP3GGAA/wt: Th-8 x P3r7; 1 : 
P3f6 x P3r8; 2: P3f7 x P3r9; 3: P3f8 x P3r9; 4: P3f9 x 
P3r10; 5: Th-8 x P3r11; 6: Th-8 x P3r12; 7: Th-8 x P3r13; 
8: P3f10 x P3r9; 9: P3f11 x P3r15; 10: P3f12 x P3r16; 
11: P3f13 x P3r15; 12: Th-8 x P3r17; 13: TH-8 x P3r18; 
14: Th-8 x P3r19; 15: Th-8 x P3r20. The oligo- nucleo­
tides (50 pmol each) were annealed and elongated 
using Taq DNA polymerase and 0.5 mM dNTPs in a 
standard PCR-buffer. For in vitro transcription and ra­
diolabeling, one pg of purified PCR template was tran­
scribed for 1 hour in transcription buffer supplemented 
with [a-32P]UTP and the products were purified as des­
cribed above.
GST pull-down assay
GST and GST-Rpp25 were bacterially expressed and pu­
rified as described before (26). Protein-RNA interaction
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Table 1: Oligonucleotides used for NMR and mutational analysis of the P3 domain
RNA oligonucleotide Sequence (5’-3’)
P3Bwt
P3B40G>A
GAGGACUCUGUUCCUC
GAGAACUCUGUUCCUC
DNA oligonucleotide Sequence (5’-3’)
Th - 8 GCGAATTCTAATACGACTCACTATAGGCCTAGGCTACACACTGAGG
P3 f  5 TAATACGACTCACTATACCTAGGCTACACACTGAGG
P 3 f  6 GCGAATTCTAATACGACTCACTATAGGCCTTCCCTACACACTGAGGACTCTGTTCC
P3 f 7 GCGAATTCTAATACGACTCACTATAGGCCTAGGCCGTACACTGAGGACTCTGTTCC
P3 f  8 GCGAATTCTAATACGACTCACTATAGGCCTAGGCTACACGTTGAGGACTCTGTTCC
P 3 f  9 GCGAATTCTAATACGACTCACTATAGGCCTAGGCTACACACTGTCCACTCTGTTGG
P 3 f  10 GCGAATTCTAATACGACTCACTATAGGCCTAGGCTACACATTGAGGACTCTGTTCC
P3 f  11 GCGAATTCTAATACGACTCACTATAGGCCTAGGCTACACACTGAGAACTCTGTTCCTCCC
P3 f 12 GCGAATTCTAATACGACTCACTATAGGCCTAGGCTACACACTGAGGTCTCTGTACC
P3 f  13 GCGAATTCTAATACGACTCACTATAGGCCTAGGCTACACACTGAGGATTCTGTTCCTCCC
P3r2 CCTAGGCGGAAAGGGGAGGAACAGAGTCCTC
P3r7 TTTCCCCTAGGCGGAAAGGGGAGGAACAGAGTCCTCAGTGTGTAGCC
P3 r  8 TTTCCCCTTCCCGGAAAGGGGAGGAACAGAGTCC
P 3 r  9 TTTCCCCTAGGCGGAAAGGGGAGGAACAGAGTCC
P3 r 10 TTTCCCCTAGGCGGAAAGGGGTCCAACAGAGTGG
P3 r 11 TTTCCCCTAGGCGGAAAGGGGAGGATCAGACTCCTCAGTGTGTA
P 3 r  12 TTTCCCCTAGGCGGAAAGGGGAGGAGCAGAGTCCTCAGTGTGTA
P 3 r 13 TTTCCCCTAGGCGGTTTGGGGAGGAACAGAGTCCTCAGTGTGTA
P3 rl4  GGCCTAGGCGGAAAGGGGAGGAACAGAGTCC
P3 r 15 TTTCCCCTAGGCGGAAAGGGGAGGAACAGA
P 3 r 16 TTTCCCCTAGGCGGAAAGGGGAGGTACAGAGACC
P 3 r  17 TTTCCCCTAGGCGGAAAGGGGAGGAATAGAGTCCTCAGTGTGTA
P3r 18 TTTCCCCTAAGCGGAAAGGGGAGGAACAGAGTCCTCAGTGTGTA
P3r 19 TTTCCCCTGGGCGGAAAGGGGAGGAACAGAGTCCTCAGTGTGTA
P 3 r  2 0 TTTCCCCTAGGCGGAAAGGGGAGGAACAGGAGGAACAGAGTCCTCAGTGTGTA
P3NMRfwd GGTAATACGACTCACTATAGG
P3NMRrev CCCGGGCCTAGGCGGAAAGGG
MRP-S1-158 CCGCCAAGAAGCGTAATCGATAAAAGGGAGTCGACCGACCAGAATCATGCAAGTGCGTAAGATAGTCGC 
GGGCCGGGGGCGTATTATGTGCGTCTACATCTAGACTCATAAAAATCGATTCCCGCTGAGCGGCG
MRPgenfwd GCTATTCTGCTAGCCACAATGCC
MRPgenrev CGTATGCACGTGGCACTCTCTGC
fwdCHH3 5C>T CCTAGGCTACACATTGAGGACTCTGTTCC
f wdCHH4 0G>A GGCTACACACTGAGAACTCTGTTCCTCC
fwd47T>C CTGAGGACTCTGCTCCTCCCCTTTCC
fwdCHH63C>T CCCCTTTCCGCTTAGGGGAAAGTCC
fwdCHH64T>C CCCCTTTCCGCCCAGGGGAAAGTCC
fwdCHHdup CACTGAGGACTCTGTTCCTCCTGTTCCTCCCCTTTCCGCCTAGGGG
MRPfwd GCGAATTCTAATACGACTCACTATAGTTCGTGCTGAAGGCCTGTATCC
MRPrev GCGAAGCTTGTACAGCCGCGCTGAGAATGAGCC
analysis was performed by coupling 0.5 pmol GST or 
GST-Rpp25 to 10 pl glutathione-Sepharose beads (GE 
Healthcare) in 500 pl PB-200 (20 mM HEPES/KOH, 
pH 7.6; 200 mM KCl; 0.5 mM EDTA; 0.05% Nonidet 
P-40; 1 mM dithioerytritol (DTE); 5 mM MgCh). After 
coupling, the beads were resuspended in 100 pl PB- 
200 and 10 pl RNA mixture (composition: 50 ng radi­
olabeled (mutant) P3 RNA and/or 50 ng radiolabeled 
MRP1-82 RNA; 40 U RNasin; 5 pg E. coli tRNA) was 
added. After incubation for 1 hour under continuous 
agitation at 4 ° C, the beads were washed 3 times with 
500 pl PB-200 and resuspended in 15 pl urea-dye/ 
phenol (7M urea; 1x TBE; 0.083% xylene cyanol FF;
0,083% bromophenol blue; 20%  (v/v) phenol). The 
samples were heated for 5 minutes at 100° C and the 
co-precipitating RNAs were separated by denaturing 
PAGE (15% polyacrylamide gels). RNAs were visualized 
by autoradiography and quantified by phosphorima­
ging. The MRP1 -82 RNA was used as an internal posi­
tive control for precipitation by GST-Rpp25. To deter­
mine the precipitation efficiency of the (mutant) P3 
RNA, the phosphorimaging signals of the precipitated 
MRP1-82 and (mutant) P3 RNA were corrected for the 
GST background and the ratio of the precipitated RNAs 
was compared to the ratio of the input RNAs to calcu­
late the relative pull-down efficiency (RPE).
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Generation of S1 -aptamer tagged RNase MRP RNA
A pcDNA3 (Invitrogen)-based construct encoding an 
S1 streptavidin-aptamer tagged (27) human RNase 
MRP RNA under transcriptional control of the original 
promoter of the human gene for RNase MRP RNA was 
generated. The aptamer tag (104 nucleotides, inclu­
ding flanking residues) was inserted between nucleo­
tides 158 and 159 of RNase MRP RNA by PCR-directed 
mutagenesis using oligonucleotide MRP-S1-158 (see 
Table 1). A spacer element between the RNase MRP 
RNA and the tag was included, as described for a simi­
lar tagged human RNase P RNA construct (23). Similar 
constructs containing mutations in the P3 domain were 
obtained from the tagged wild type RNase MRP RNA 
construct by PCR-based mutagenesis using the follo­
wing oligonucleotides: fwdCHH35C>T, fwdCHH40G>A, 
fwd47T>C, fwdCHH63C>T, fwdCHH64T>C, and 
fwdCHHdup (see Table 1). The products of PCR reacti­
ons with these oligonucleotides in combination with a 
general reverse oligonucleotide (MRPgenrev) were used 
to substitute the corresponding fragment of the wild 
type construct. Sequence analysis confirmed the se­
quence of the constructs described above. Templates 
for in vitro transcription were generated from these con­
structs by PCR using a forward oligonucleotide (MRPfwd) 
corresponding to the 5'end of the RNase MRP RNA and 
containing the promoter sequence for T7 RNA polyme­
rase and a reverse oligonucleotide (MRPrev) comple­
mentary to the 3'end of the RNase MRP RNA. In vitro 
transcription was performed essentially as described 
above. After transcription, the RNA was purified by 
phenol/chloroform/isoamylalcohol extraction and pre­
cipitated with ethanol.
Reconstitution of S1 -tagged RNase MRP complexes
RNase MRP particles were partially purified from a 
HEp-2 cell extract by glycerol density gradient sedimen­
tation as described previously (25). Gradient fractions 
(500 pl) were collected and the separation was moni­
tored by analyzing the presence of RNase MRP RNA, 
U3 snoRNA and RNase P activity in each of the fracti­
ons. Peak fractions 5-9 (12S peak) were pooled and sto­
red in small aliquots at -70°C. The 12S RNase MRP 
complexes were (partially) disrupted by increasing the 
KCl concentration to 1 M (unless stated otherwise) and 
incubating for 30 minutes at 0 °C  (28). One microgram 
of purified S1-tagged (mutant) RNase MRP RNA (see 
above) was added and subsequently the KCl concen­
tration was reduced to 150 mM by adding water and 
buffer components (150 mM KCl; 10 mM HEPES/KOH, 
pH7.6 and 0.5 mM DTE) to a total volume of 7.5 ml. 
Reconstitution was performed for 20 minutes at 30°C. 
Simultaneously, protein A-agarose beads were coupled 
with normal rabbit serum, rabbit anti-U3-55K antise­
rum (29), mouse anti-Rpp20 monoclonal antibody 
(ModiQuest), rabbit anti-Rpp25 antiserum (30) or rab­
bit anti-Rpp38 antiserum (31) in IPP500 (10 mM Tris- 
HCl, pH 8.0; 0.05% NP-40; 500 mM NaCl). The beads 
were washed twice with IPP500 and once with IPP150 
(like IPP500, but with 150 mM NaCl). Immunoprecipi- 
tations were performed with 1250 pl reconstitution 
mixture under continuous agitation at 4 °C  for 2 hours. 
After immunoprecipitation, the beads were washed 
three times with IPP150. RNA was isolated from the 
beads using Trizol reagent (Invitrogen) followed by is­
opropanol precipitation. Co-precipitated RNAs were 
analysed by denaturing PAGE and northern blot hybri­
dization using radiolabeled riboprobes recognizing the 
(S1 -tagged) RNase MRP RNA and the U3 snoRNA. The 
results were quantified by phosphorimaging and pro­
cessed to determine the relative reconstitution efficien­
cies (RRE) of the tagged full-length RNAs with Rpp20, 
Rpp25 and Rpp38. First, the reconstitution efficiency 
of the tagged wild type RNase MRP RNA was determi­
ned by comparing the precipitated S1-tagged MRP 
RNA/endogenous MRP RNA ratio with the ratio of 
these RNAs in the reconstituted material. The reconsti­
tution efficiency for each of the proteins with the mu­
tant RNAs was determined similarly and compared 
with the efficiency of the wild type RNase MRP RNA 
to yield the RREs.
NMR spectroscopy
The 18-mer RNA oligonucleotides representing the wild
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type apical stem-loop of P3 and its 40G>A variant were 
purchased from IBA GmbH (Gottingen, Germany). To 
stabilize the short hairpins used for the NMR studies 
an additional G-C base pair was added to the stems. 
The RNAs were directly dissolved in 90% H20/10% 
D2O, briefly heated for 2 minutes at 85 °C  followed by 
snap-cooling in iced water to promote hairpin forma­
tion. The pH was adjusted to 6.8 (meter reading). Final 
concentration of the RNA samples was 0.5 mM. NMR 
spectra were acquired on Varian Inova 500 MHz and 
800 MHz spectrometers. For the assignment of exchan­
geable imino protons two-dimensional NOESY spectra 
were recorded at 800 MHz with a 300 ms mixing time 
using a jump return pulse for water suppression (32).
Results
Binding of Rpp25 to the P3 domain of RNase MRP
Recently we have shown that Rpp25 and Rpp20 form 
a stable heterodimer that binds to the P3 domain of 
RNase MRP (21,26). Rpp25 displays a higher binding 
affinity for P3 RNA than Rpp20 and is able to interact 
with the P3 domain also in the absence of Rpp20. To 
investigate whether the P3 domain is sufficient for the 
interaction with Rpp25, an RNA molecule comprising 
only the P3 domain was generated and its interaction 
with Rpp25 studied using a GST pull-down approach. 
GGP3AAGCU RNA, derived from a previously described 
transcription construct for the P3 domain (19), contains 
two additional guanosines at the 5'end that form part of 
the T7 RNA polymerase promoter and a residual AAGCU 
sequence at the 3'end that originates from linearizing 
the plasmid DNA template with HindIII. The results in 
Figure 1 (lanes 1 -3) show that this GGP3AAGCU RNA 
interacts specifically with GST-Rpp25. To further inves­
tigate the importance of the additional nucleotides at 
the 5' and 3'ends, a P3 RNA (referred to as P3) lacking 
any extra nucleotides was generated by in vitro tran­
scription. Surprisingly, the absence of flanking nucleo­
tides did not lead to a detectable interaction of the P3 
domain with GST-Rpp25 (lanes 4-6). These data sug­
gested that at least some flanking nucleotides are re-
Figure 1: Binding of GST-Rpp25 to the RNase MRP RNA 
P3 domain
Radiolabeled P3 domain-containing RNAs were transcribed 
in vitro and incubated with recombinant bacteria l ly 
expressed GST-Rpp25 or GST coupled to glutathione- 
Sepharose. Co-precipitating RNAs were analysed by 
denaturing PAGE and autoradiography. For each RNA, 10% 
of the amount used in the pull-down was analysed in paral­
lel. The positions of the RNAs are indicated by asterisks (*). 
Lanes 1-3: P3 RNA transcribed from linearized plasmid 
DNA with two T7 RNA polymerase promoter (5' GG) and 
HindIII restriction site (3' AAGCU) nucleotides (19). Lanes 
4-6: P3 RNA without additional nucleotides. Lanes 7-9: P3 
RNA with four additional 3' nucleotides derived from RNase 
MRP (GGAA). Lanes 10-12: P3 RNA with two additional 
5' nucleotides derived from the T7 RNA polymerase 
promoter (GG). Lanes 13-15: P3 RNA with both GG at 
the 5' end and GGAA at the 3' end.
quired for the binding of Rpp25. Therefore, three addi­
tional P3 RNA variants were generated, containing ei­
ther two G's at the 5'end, four nucleotides at the 3'end 
(GGAA, corresponding to the flanking sequence in the 
wild type RNase MRP RNA), or both. The addition of 2 
G's at the 5'end (lanes 10-12) restored the interaction 
with GST-Rpp25, and the efficiency of precipitation 
was comparable to that observed with GGP3AAGCU. 
In contrast, the addition of GGAA to the 3' end did not 
seem to lead to detectable binding (lanes 7-9). Howe­
ver, the combination of 5'GG and 3'GGAA further en­
hanced the efficiency of binding (lanes 13-15) to levels 
comparable with those observed with the complete 
RNase MRP RNA (not shown). These results show that 
additional bases at the 5' and 3' end of the P3 domain 
are required for the efficient interaction between 
Rpp25 and the P3 domain of RNase MRP RNA in vitro.
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Because the identity of these nucleotides, at least at 
the 3'end, did not seem to be important, these effects 
may be explained by stabilization of the P3 structure 
by the flanking nucleotides. Because of its high preci­
pitation efficiency we decided to use the GGP3GGAA 
configuration for further analysis of the P3 mutants.
The effect of P3 mutations on Rpp25 binding
All reported CHH-associated mutations in the P3 do­
main of RNase MRP RNA occur in sequences which are 
completely conserved among vertebrate RNase MRP 
RNAs ((4) and Supplementary Figure 1). Based on these 
conservation data we not only analysed the effect of 
CHH-associated P3 mutations on protein binding, but 
also mutated other conserved nucleotides to study their 
importance. In total, 15 different P3 RNA mutants, 5 
of whom corresponded to CHH-associated mutations, 
were generated (Figure 2A). As a control, wild type 
MRP1-82 RNA was transcribed from a plasmid tem­
plate and combined with each of the P3 mutants in 
the GST pull-down assay. The relative pull-down effi­
ciencies (RPE) calculated from the results of three in­
dependent experiments are shown in Figure 2B. Most 
of the P3 mutations had no or only a small effect (less 
than two-fold change) on the precipitation efficiency by 
GST-Rpp25. Interestingly, the substitution of nucleoti­
des 29-31 (UAC to CGU; mutant no. 2) and the substi­
tution of nucleotide 35 (C to U; mutant no. 4) had a 
positive effect on the precipitation efficiency. It should, 
however, be noted that mutant no. 2 displayed a great 
variability in precipitation efficiency. Although mutant 
no. 4 was bound more efficiently than wild type P3 
RNA, the substitution of both nucleotides 34 and 35 
(AC to GU; mutant no. 3) had almost no effect on bin­
ding of Rpp25. For 5 mutants we observed relative pre­
cipitation efficiencies of less than 50% as compared 
to wild type P3 RNA. These mutations are: 40G>A (no.
5), 42C>G/47U>A (no. 8), 46G>C (no. 9), 47U>C (no. 
10) and 63C>U (no. 13). Because the 47U>C substitu­
tion reduced the precipitation efficiency to 12% and 
the 42C>U (no.7) substitution has only a moderate ef­
fect (72% RPE), it is very likely that the low precipita-
Figure 2: Interaction of human RNase MRP RNA P3 
mutants with Rpp25
A. Schematic representation of the secondary structure of 
the P3 domain (nucleotides 22-67) of human RNase MRP 
RNA with the sequence and numbering of the nucleotides 
(italic numbers) and mutations indicated.
B. Radiolabeled (mutant) RNAs were transcribed in vitro 
and incubated with recombinant GST-Rpp25 or GST cou­
pled to glutathione-
Sepharose. Co-precipitating RNAs were analysed by 
denaturing PAGE and quantified by phosphor-imaging.
For each mutant the relative pull-down efficiency (RPE) was 
determined for three independent experiments. The error 
bars indicate the standard deviation (note that the stan­
dard deviation of mutant 13 is very small). The numbers 
below the graph correspond to the numbering of the 
mutants, as depicted in Figure 2A. The results for 
CHH-associated mutants are indicated in dark grey,
tion efficiency (13%) observed for the mutant in which 
both residues are changed, 42C>G/47U>A (no. 8), is 
caused by the alteration at position 47. Also the 
46G>C (no. 9) substitution significantly reduced the 
precipitation efficiency (37%). Both residues 46 and 
47 are located in the apical loop of the P3 domain and 
are among the most highly conserved residues in the 
P3 domain of the vertebrate RNase MRP RNA (Supple­
mentary Figure 1). The guanosine at position 40 is part 
of the P3b stem. Although the nucleotides in this stem 
are not completely conserved, a guanosine is found at 
this position in each of the RNase MRP RNAs and a
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Figure 3: Reconstitution of RNase MRP in HEp-2 cell fractions
A. Partially purified 12S RNase MRP particles from HEp-2 cells were disrupted by increasing KCl-concentrations, as indicated 
below the lanes. In vitro transcribed S1 -tagged human RNase MRP RNA was added and allowed to reconstitute at 150 mM KCl. 
Reconstituted complexes were subjected to immunoprecipitation using polyclonal antibodies specifically recognizing hPop1, 
Rpp25 or Rpp38. As controls normal rabbit serum (NRS) and anti-55K serum were used. Co-immunoprecipitated RNAs were 
isolated and separated by denaturing PAGE. RNAs were detected by northern blotting using radiolabeled riboprobes and 
visualized by autoradiography. The positions of the RNAs are indicated on the left. From 10% of the reconstituted material RNA 
was isolated and analysed in parallel (10% input).
B. RNase MRP reconstitution was performed after disassembly of 12S particles in the presence of 1.0 M KCl. In vitro transcribed 
S1 -tagged (mutant) human RNase MRP RNA was reconstituted and analysed as described above. The positions of the RNAs are 
indicated on the left. Lanes 1 -6: wild type S1 -tagged MRP RNA, Lanes 7-12: mutant 35C>U, Lanes 13-18: mutant 40G>A, Lanes 
19-24: mutant 47U>C, Lanes 25-30: mutant 63C>U), Lanes 31 -36 mutant 64U>C.
C. The results of the reconstitution as shown in B were quantified by phosphor-imaging. For each mutant the relative reconstitu­
tion efficiency (RRE) with Rpp20, Rpp25 or Rpp38 was determined for two independent experiments. The error bars indicate the 
spreading. CHH-associated mutations are indicated in grey.
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substitution is always compensated by a complemen­
tary substitution, maintaining the capacity to form a 
stem.
Recently, we have demonstrated that Rpp20 does not 
bind to the P3 domain in the absence of Rpp25 (21). 
As expected, also the mutant P3 RNAs were not bound 
by the Rpp20 protein, as demonstrated by the results 
of GST pull-down analyses (data not shown).
The effect of P3 mutations on RNase MRP complex 
formation
To investigate whether the reduced binding efficiency 
of Rpp25 with some of the P3 mutants also affected 
RNase MRP particle assembly, mutations were introdu­
ced into the full-length human RNase MRP RNA and 
the capacity to reconstitute into RNase MRP complexes 
was investigated. Reconstitution of RNase MRP com­
plexes was performed with RNase MRP complexes par­
tially purified from a HEp-2 cell extract and was moni­
tored by the analysis of RNAs co-immunoprecipitated 
with antibodies to RNase MRP protein subunits. To dis­
criminate between the endogenous (HEp-2 cell) and 
exogenous RNA, an S1-aptamer (104 nucleotides, in­
cluding flanking residues) was introduced into the lat­
ter between nucleotide 158 and 159. The insertion of 
the S1 aptamer tag at this position did not affect Rpp38 
binding (data not shown and Figure 3A). To allow re­
constitution to take place, the RNase MRP complexes 
in the HEp-2 cell fractions were disrupted by increasing 
the KCl concentration to 1 M. After the addition of the 
in vitro transcribed S1-tagged RNAs recon- stitution 
was initiated by adjusting the salt concentration to 
physiological levels. The concentration of KCl required 
for this reconstitution procedure was empirically deter­
mined by performing a reconstitution experiment at 
different KCl concentrations. We observed efficient re­
constitution with S1-tagged human RNase MRP RNA 
after complex dissociation with 1 M KCl and subse­
quent dilution (Figure 3A, lane 17). Under these con­
ditions not only Rpp25, but also hPop1 and Rpp38 
were found to associate with the S1-tagged RNase 
MRP RNA (lanes 16, 18). Although the reconstitution
efficiency was even higher after treatment with 1.5 M 
KCl, for practical reasons we decided to choose 1 M 
KCl for the analysis of P3 mutants. The specificity of 
this assay was established by the lack of RNase MRP 
RNA coprecipitation with anti-U3-55K antibodies (di­
rected to a U3 snoRNP component which is also pre­
sent in RNase MRP containing fractions used for this 
experiment) and the lack of U3 snoRNA co-precipita­
tion with antibodies against hPopl, Rpp25 and Rpp38. 
Additional evidence for the correct assembly of the tag­
ged RNA into RNase MRP complexes comes from gly­
cerol gradient sedimentation analyses, which demon­
strated that the tagged RNA assembles into complexes 
that co-fractionate with the wild-type RNA in the gra­
dients (results not shown).
Five P3 mutations, 35C>U (mutant 4), 40G>A (mutant 
5), 47U>C (mutant 10), 63C>U (mutant 13) and 
64U>C (mutant 14), which were CHH-associated and/ 
or had a significant effect on Rpp25-binding to the P3 
domain, were introduced into the S1-tagged RNase 
MRP RNA and their reconstitution was analysed by co- 
immunoprecipitation with Rpp20, Rpp25 and Rpp38. 
Note that, whereas Rpp25 directly interacts with the 
P3 domain, the association of Rpp20 with this domain 
is strongly dependent on its heterodimerization with 
Rpp25 (21) and that Rpp38 interacts with another part 
of the RNase MRP RNA and was included as a control. 
As negative controls normal rabbit serum and rabbit 
anti-U3-55K serum were used. Figure 3B shows the 
northern blot hybridization data of the reconstitution 
experiments with these mutants. Again the endoge­
nous RNase MRP RNA was efficiently precipitated, as 
is the wild type S1-tagged RNase MRP RNA (lanes 4­
6). After quantification by phosphorimaging, the rela­
tive reconstitution efficiency (RRE) of the wild type 
S1-tagged RNase MRP RNA with Rpp20, Rpp25 and 
Rpp38 was calculated. Subsequently, these ratios were 
used to determine the RRE of the mutant RNase MRP 
RNAs (lanes 7-36). As expected, the P3 mutations had 
no or only a small effect on Rpp38 association with 
full-length RNase MRP RNA. However, the P3 muta­
tions significantly affected the association of Rpp20
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and Rpp25 with full-length RNase MRP RNA (Figure 
3B/C). Relatively low levels of reconstitution were obser­
ved for mutants 35C>U, 40G>A, 47U>C and 63C>U, 
whereas the reconstitution with 64U>C was compara­
ble to that of the wild type RNA. These reconstitution 
data correlate well with GST pull-down data, with the 
striking exception of mutant 35C>U, which appeared 
to enhance the binding of GST-Rpp25 to the P3 do­
main (Figure 2B), but had a negative effect on the re­
constitution with full-length RNase MRP RNA. The 
results obtained with the anti-Rpp20 antibodies were 
very similar to the results for the anti-Rpp25 antibo­
dies, which is most likely related to the stable hetero- 
dimerisation of Rpp20 and Rpp25. With regard to this 
it is important to note that 1 M KCl will not lead to the 
dissociation of the Rpp25-Rpp20 dimer itself (21). Nei­
ther (S1 -tagged) RNase MRP RNA nor U3 snoRNA was 
precipitated with the normal rabbit serum and only U3 
snoRNA was specifically precipitated from the recon­
stitution mixture with anti-U3-55K antibodies. The spe­
cificity of this assay was further confirmed by the lack 
of U3 snoRNA coprecipitation with the antibodies to 
Rpp20, Rpp25 and Rpp38.
The effect of the 40G>A mutation on the structure 
of the P3 hairpin
The effect of mutations on the association of protein 
subunits may be either due to the loss of direct con­
tacts and the resulting decrease in binding affinity, or 
to structural changes in the conformation of the RNA 
molecule caused by the nucleotide substitutions. For 
obvious reasons, conformational changes are more li­
kely caused by the alteration of nucleotides involved 
in basepairing interactions. The secondary structure of 
the P3 domain depicted in Figure 2 is supported by 
both phylogenetic and biochemical structure probing 
data. In addition, NMR analysis of the complete P3 
RNA domain supported the base pairing illustrated in 
Figure 2A, and thus argues against the formation of 
alternative conformations for this RNA (results not 
shown). The data presented above indicate that the 
binding of Rpp25 to the P3 domain is primarily media-
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Figure 4: Secondary structure of the apical 
stem-loop of the P3 domain
The upper panel shows the mfold structure prediction of 
the apical stem-loop of the wild type (wt) P3 domain of the 
human RNase MRP RNA and the potential pseudo-triloop 
structure of this RNA domain. The numbers correspond to 
the nucleotides of the complete human RNase MRP RNA. 
The lower panel shows the mfold structure prediction of 
mutants 47U>C and 40G>A. For mutant 40G>A two 
possible structures with similar free energy values were 
predicted. Note that for NMR analysis an additional 
G-C clamp was placed at the ends of the RNAs (G at 3'end 
and C at 5'end).
ted by interactions with the apical hairpin of the P3 
domain. One of the CHH-associated mutations situated 
in the stem of this hairpin, 40G>A, had a drastic effect 
on Rpp25-binding and RNase MRP complex formation. 
To shed more light on the potential structural changes 
induced by this mutation, we decided to study the struc­
ture of the apical stem-loop in more detail by NMR.
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Figure 5: Analysis of the structure of the apical 
stem-loop of P3 by nuclear magnetic resonance
A. One-dimensional 1H NMR spectra (imino proton region) 
of the wild type apical stem-loop (upper panel) and mutant 
40G>A (lower panel) recorded at 5 °C  at 800 MHz. The 
assignment of peaks to residues numbered in Figure 5 is 
indicated. Single or double asterisks in the lower panel 
indicate connected imino protons observed as NOE cross 
peaks in the 2D NOESY experiment.
B. Section of the 2D NOESY spectrum of the P3 wild type 
apical stem-loop recorded at 5 °C  at 800 MHz, showing 
the imino proton region. Assignments of the diagonal peaks 
are indicated by residue type and number. The sequential 
imino proton walk is traced out.
First the structural effect of the 40G>A substitution was 
evaluated by using the mfold algorithm (33). We also 
looked at the effect of a loop mutation, 47U>C, which 
also strongly affected Rpp25-binding. Two alternative 
structures for the wild-type RNA were obtained, which 
differ by a single base pair formed between 42C and 
46G (Figure 4). Whereas the 47U>C substitution in the
hairpin loop did not lead to a potential alternative se­
condary structure of the hairpin, the mfold prediction 
of the 40G>A stem variant revealed two alternative se­
condary structures, both different from the predicted 
wild type hairpin structures (Figure 4). Two structures 
are predicted for this variant by possible slippage of a 
G-C base pair with the bulged C. RNA molecules corres­
ponding to the wild type and 40G>A P3 RNAs were 
synthesized and investigated by NMR.
The existence of the proposed structure of the wild type 
apical P3 hairpin was confirmed by the NMR spectra. 
The 1-dimensional (1 D) spectrum reveals five strong 
peaks between 12 and 15 ppm, i.e. in the region where 
typically the imino protons of Watson-Crick base pairs 
resonate (Figure 5A). Four of these could be assigned 
to specific residues from a classic sequential imino to 
imino proton walk in the 2D NOESY spectrum (Figure 
5B). Besides the five strong peaks also two weak peaks 
are visible in the 1 D spectrum. One at 14 ppm, a typical 
position for a uridine imino proton involved in an U-A 
base pair, and another at 10.8 ppm, in the region 
where typically imino protons of non-canonical base 
pairs resonate. These probably originate from U48 and 
a loop uridine, respectively. The strong peak at 13.4 
ppm, which does not show a connectivity in the 2D 
NOESY spectrum most probably arises from the loop 
G46 residue, forming a base pair with the loop C42 re­
sidue. Formation of this G46-C42 base pair leaves a 
so-called pseudo-triloop with the UCU residues in the 
loop and bulged U47.
The NMR spectra of the 40G>A variant are markedly 
different from the wild type, and feature characteristics 
corresponding to the predicted structural differences 
(Figure 4). The 1 D imino proton spectrum of the 40G>A 
hairpin shows enhanced broadening of several reso­
nances (Figure 5A). This broadening effect originates 
from enhanced imino proton exchange with solvent 
water, most probably caused by weakening of the stem 
due to the introduction of a bulged C. The 2D NOESY 
of this hairpin only shows connectivities between two 
different G-C/A-U base pair steps (results not shown). 
Again interruption of the sequential walk, preventing
56
CHH mutations affect RNase MRP assembly
assignment of resonances, is caused by the presence 
of the bulged C, which renders the imino proton signals 
of adjacent base pairs too weak to be detected in this 
experiment. Thus, although we were not able to assign 
these spectra or to distinguish between the proposed 
forms, the NMR data clearly indicate structures diffe­
rent from the wild type hairpin and satisfactorily match 
the structures depicted in Figure 4.
Discussion
The most frequently occurring CHH-associated mutation 
in the human RNase MRP RNA, 70A>G, which is located 
in a region of the RNA (the J3/4 domain) that is pre­
dicted to be essential for its catalytic activity (34), has 
been suggested to impair the RNase MRP function di­
rectly (2). In addition to 70A>G, currently 57 other CHH- 
associated mutations in the coding sequence of the 
RMRP gene have been reported (4, 35). The mecha­
nisms by which these mutations affect the structure 
and function of RNase MRP have not been addressed 
experimentally yet. Here we present for the first time 
evidence for an impairment of RNase MRP assembly 
by CHH-associated (and other) mutations in the P3 do­
main.
The P3 domain of RNase MRP RNA
Several lines of evidence indicate that the P3 domain 
is among the most important elements of the RNase 
MRP RNA. The P3 domain belongs to the most highly 
conserved elements of this RNA (36), it contains the 
major binding sites for protein subunits and is required 
for assembly of the ribonucleoprotein particles (19) and 
its nucleolar accumulation (22). Its secondary structure 
consists of a hairpin of which the stem is interrupted by 
an internal loop. The results of our NMR experiments 
strongly suggest that a pseudo-triloop is formed in the 
apical stem-loop of the RNase MRP P3 domain as a re­
sult of basepairing between C42 and G46. A compa­
rable pseudo-triloop present in the encapsidation 
signal of hepatitis B virus yields a comparable chemical 
shift signature (37) giving further support to our inter­
pretation of the spectra. In this respect it is also impor­
tant to note that the C residue at the most 5' position 
and the G residue at the one but last position in the 
hairpin loop of the P3 domain are fully conserved in 
vertebrate RNase MRP and RNase P RNA (Supplemen­
tary Figure 1 ). This distinct loop folding principle (38, 
39) has been recognized as a protein recognition site 
in various RNA-protein complexes and was found to be 
essential for hepatitis B virus and brome mosaic virus 
replication (37, 38). A pseudo-triloop has also been re­
ported to occur in another nucleolar endoribonuclease, 
the S. cerevisiae U3 snoRNA (40). Besides being invol­
ved in protein-binding, the RNase MRP P3 pseudo-tri­
loop may also play a role in tertiary interactions.
To understand the effects of CHH-associated mutati­
ons on RNase MRP function, it is important to know 
whether they induce structural alterations in the fol­
ding of the RNA. The nucleotide substitutions at posi­
tions 35 and 63, and the duplication of nucleotides 
45-53 are not predicted to alter the secondary struc­
ture. However, mutations 40G>A and 64U>C are ex­
pected to have more severe effects, because they 
disrupt the basepairing at these positions. Our NMR 
analysis of mutant 40G>A indeed confirmed the exis­
tence of an alternative secondary structure in the api­
cal stem-loop of P3. Importantly, although a regular 
triloop is formed, the bulged nucleotide is not present 
in this mutant and therefore the pseudo-triloop struc­
ture is not formed in the alternative configurations of 
this mutant.
The binding of the Rpp25-Rpp20 dimer to 
the P3 domain
Previously, we have demonstrated that the Rpp25 and 
Rpp20 subunits of RNase MRP form a stable heterodi­
mer for which the main binding site resides in the P3 
domain (20, 21 ). Our data also suggested that the as­
sociation of the Rpp25-Rpp20 dimer with RNase MRP 
is transient. The Rpp25-Rpp20 dimer was proposed to 
dissociate from RNase MRP either before or during its 
assembly with pre-ribosomes and to reassociate after 
the RNase MRP catalysed processing event of pre-rRNA
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(25). Rpp25 directly contacts the P3 domain of the 
RNase MRP RNA (20, 21, 24). The results we obtained 
with the P3 mutants suggest that the main determi­
nants for Rpp25 binding reside in the apical stem-loop 
of the P3 domain, because a strong reduction of the 
Rpp25 binding efficiency was observed with mutants 
40G>A, 47U>C, 46G>C and 42C>G/47U>A, whereas 
mutations in other regions of P3 had no or weaker ef­
fects. Moreover, these data are fully consistent with the 
binding of Rpp25 to the putative pseudo-triloop struc­
ture, because each of these mutations will interfere 
with the formation of the latter structure. Note that the 
42C>U mutation, which had only a minor effect on 
Rpp25 binding, still allows the pseudo-triloop to be for­
med, although it may be less stable. The sequence of the 
stem of the apical stem-loop is probably not very im­
portant for Rpp25 binding, because mutations 6 and 
11, which alter the sequence of the stem but still allow 
basepairing, appeared to have only mild effects on 
Rpp25 binding. Due to the sequence complementarity 
between distinct molecules, the in vitro transcribed P3 
RNAs might form dimers or multimers. This possibility 
was investigated by non-denaturing gel electrophoresis 
and the results showed that, although dimer formation 
was observed for a subset of molecules, the dimer:mo- 
nomer ratio observed for the various mutants was very 
similar to that of the wild-type RNA (results not shown). 
The electrophoretic mobility of these molecules also did 
not indicate the existence of multiple structural forms. 
Therefore, the effects of the mutations on Rpp25 bin­
ding are not due to changes in dimer formation as a 
result of the mutations.
Taken together, our data strongly suggest that 42C-46G 
basepairing generates a pseudo-triloop-like structure 
which is required for Rpp25 binding, and that the bul­
ged U-residue (47U) is critically important for this in­
teraction.
In the cellular environment, Rpp25 most likely binds 
as part of the Rpp25-Rpp20 heterodimer to the P3 do­
main of RNase MRP RNA. In agreement with this, the 
effects of the RNase MRP RNA mutations on the asso­
ciation of Rpp25 and Rpp20 in the reconstitution assay
(Figure 3) are very similar. Rpp20 is predicted to con­
tribute to the binding of the Rpp25-Rpp20 dimer to 
the P3 domain, because close contacts between Rpp20 
and the RNA have been detected by UV-crosslinking 
and Rpp20 enhances the efficiency of Rpp25 binding 
to the P3 domain (19,20,21 ). Our data do not provide 
insight into the region of the P3 domain that might be 
contacted by Rpp20. However, based upon a compari­
son of the results of the GST pull-down and the ribo- 
nucleoprotein particle reconstitution experiments, it is 
tempting to speculate that residue 35C is involved in 
the Rpp20-RNA interaction. Mutation of this residue 
into a U significantly reduced the efficiency of recon­
stitution, whereas this mutation did not reduce the bin­
ding by GST-Rpp25.
CHH-associated mutations in the P3 domain
Up to now, five CHH-associated mutations have been 
reported to occur in the P3 domain of RNase MRP RNA. 
The effect of each of these mutations on the binding of 
Rpp25 was investigated in the present study. In agree­
ment with the structure of the proposed binding site 
for Rpp25 (see above) the 40G>A mutation severely 
affected the binding of this protein to the RNA, whe­
reas the other four mutations had no or much less ef­
fect. Only 63C>U partially reduced the efficiency by 
which GST-Rpp25 binds to the P3 RNA. This effect may 
be caused by a destabilisation of the proximal P3 stem. 
Indeed the results presented in Figure 1 suggest that 
the stability of the secondary structure in this region is 
important for Rpp25 binding. However, 64U>C is ex­
pected to reduce the stability of the proximal stem 
more severely than 63C>U, but this mutation did not 
detectably affect the binding of Rpp25. Therefore, the 
molecular basis for the reduced binding efficiency of 
Rpp25 to mutant 63C>U is currently unclear.
In the reconstitution assay all CHH-associated P3 mu­
tations analysed affected the association of both Rpp25 
and Rpp20, whereas the association of Rpp38, which 
is known to interact with another region of the RNase 
MRP RNA (19, 26), was not affected. These results indi­
cate that in the context of the complete RNase MRP
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RNA and in the presence of all RNase MRP proteins 
not only 40G>A, but also the CHH-associated mutati­
ons 35C>U, 63C>U and 64U>C reduce the binding ef­
ficiency of Rpp25 and Rpp20, which under our expe­
rimental conditions most likely bind as a dimer. These 
data suggest that most, if not all of the CHH-mutations 
in the P3 domain interfere with the assembly of the 
RNase MRP ribonucleoprotein particle. Since the Rpp25- 
Rpp20 dimer is believed to go through a cycle of dis­
sociation and reassociation during the conversion of a 
substrate RNA by RNase MRP, the P3 mutations will 
interfere with this cycle, thereby reducing the functio­
nal activity of RNase MRP. It should be noted that also 
the hPop1 protein has been reported to require the P3 
region for its association with RNase MRP (26,41). This 
protein may either bind to the P3 RNA directly or to 
proteins, e.g. Rpp25 and/or Rpp20 which bind to the 
P3 RNA. Although we did not find an effect on the 
hPop1 interaction efficiency for any of the P3 mutati­
ons tested (our unpublished data), further studies will 
be required to investigate to what extent the CHH-as- 
sociated P3 mutations affect the association with hPop1. 
The lack of interference of the P3 mutations that affect 
Rpp25-Rpp20 binding with hPop1 association and the 
association of hPop1 with 60-80S pre-rRNA complexes
(25), which are devoid of Rpp25-Rpp20, strongly sug­
gest that hPop1 associates with the P3 domain in a 
Rpp25-Rpp20 independent manner.
In most CHH patients a mutation in the coding se­
quence of the RNase MRP RNA is accompanied by a 
mutation in the promoter region of the other allele. The 
latter mutation is believed to silence this allele, mea­
ning that only the mutated RNA is expressed in such 
patients. An interesting exception is a patient in which 
one allele carries the 40G>A and the other the 63C>U 
mutation (4). In this patient probably two mutant RNase 
MRP RNAs are expressed, both of which display an im­
paired P3-dependent ribonucleoprotein assembly phe­
notype.
In conclusion, our data not only shed more light on the 
interaction of the Rpp25 (and Rpp20) protein with the
RNase MRP RNA, but also provide insight into the mo­
lecular mechanism by which mutations in the P3 domain 
of RNase MRP may lead to cartilage-hair hypoplasia. 
It will be interesting to investigate whether such me­
chanisms are also relevant for other diseases caused 
by mutations in (structural) RNAs (e.g. dyskeratosis 
congenita (42) and myotonic dystrophy (43)).
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RNase MRP/P cleaves viperin mRNA
RNase MRP is a conserved endoribonuclease, in humans consisting of a 267-nucleotide RNA 
associated with 7-10 proteins. Mutations in its RNA component lead to several autosomal re­
cessive skeletal dysplasias, including ca rtilage-hair hypoplasia (CHH). Because the known sub­
strates of mammalian RNase MRP, pre-ribosomal RNA and RNA involved in mitochondrial DNA 
replication, are not likely involved in CHH, we analyzed the effects of RNase MRP (and the 
structurally related RNase P) depletion on mRNAs using DNA microarrays. We confirmed the 
upregulation of the interferon-inducible viperin mRNA by RNAi experiments and this appeared 
to be independent of the interferon response. We detected two cleavage sites for RNase MRP/ 
RNase P in the coding sequence of viperin mRNA. This is the first study providing direct evidence 
for the cleavage of a mRNA by RNase MRP/RNase P in human cells. Implications for the invol­
vement in the pathophysiology of CHH are discussed.
Introduction
The RNase MRP complex is a ubiquitously expressed, 
essential eukaryotic ribonucleoprotein particle consis­
ting of an RNA component and at least 7 proteins 
(hPop1, hPop5, Rpp20, Rpp25, Rpp30, Rpp38 and 
Rpp40) (1 -3). Three additional proteins are associated 
with at least a subset of RNase MRP particles: Rpp14, 
Rpp21 and Rpp29 (hPop4) (2). RNase MRP is localized 
primarily in the nucleolus and functions as an endori­
bonuclease. It is responsible for the generation of the 
RNA primer that is needed for mitochondrial DNA re­
plication^), mediates cleavage of the ITS1 (internal 
transcribed spacer 1) sequence in pre-rRNA, a step in 
the maturation of rRNA (5), and, in yeast, is required 
for entry of the precursor rRNA into the canonical pro­
cessing pathway (6). In addition, RNase MRP has been 
implicated in the cell cycle as a result of its capacity to 
cleave the 5'UTR of the cyclin-B2 mRNA (7). Interes­
tingly, it was recently reported that the RNA component 
of human RNase MRP, RMRP, forms a complex with the 
telomerase-associated reverse transcriptase (TERT) (8). 
The TERT-RMRP complex exhibits RNA-dependent RNA 
polymerase (RdRP) activity and produces dsRNAs that 
are processed into siRNAs by Dicer. One of these si R- 
NAs is directed against the RMRP itself. This way the 
level of RNase MRP RNA is controlled by the associa­
tion with TERT via a negative-feedback mechanism (8).
So far, there is no substrate recognition sequence iden­
tified for RNase MRP. Secondary and tertiary structural 
elements are believed to play an important role in the 
substrate selection by RNase MRP 
Human RNase MRP shares all of its known protein 
components with RNase P, an evolutionary related en­
doribonuclease which cleaves the 5' leader of pre- 
tRNA, and thus is involved in tRNA maturation (9). In 
addition, human RNase P has been demonstrated to 
play a role in transcription by polymerase I and III (10, 
11). Bacterial RNase P consists of a RNA component 
(M1 RNA) and the protein C5. Throughout evolution 
from prokaryotes to eukaryotes, RNase P acquired an 
increasing amount of protein subunits (12). The human 
RNase P complex contains at least 10 associated pro­
teins.
The human genetic disorder CHH (OMIM250250) (13) 
is caused by mutations in the RMRP gene (14). CHH is 
inherited in an autosomal recessive manner and pa­
tients are characterized by a short stature, hypoplastic 
hair and short limbs. In addition, they show a predis­
position to lymphomas and other cancer types (prima­
rily haematopoietic), Hirschprung's disease, bronchi­
ectasis, childhood anaemia and suffer from a defective 
T-cell immunity (15-20). CHH-associated mutations are 
either located in the transcribed sequence or in the pro­
moter region of the RMRP gene. So far, more than 70 
different CHH-associated mutations have been identi­
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fied in the 267 nt long coding region. Between the 
TATA box and the transcription initiation site, 25 dif­
ferent insertions, duplications and triplications have 
been reported (21). Promoter mutations lead to a di­
minished or abrogated synthesis of RNase MRP RNA 
(14). CHH patients either have a combination of two 
RNase MRP RNA mutations in both alleles or a combi­
nation of a RNase MRP RNA mutation in one allele and 
a promoter mutation in the other allele, although re­
cently a patient has been reported that carries a com­
bination of two promoter mutations (22). RMRP muta­
tions lead to a very large heterogeneity in clinical phe­
notypes, even between family members with the same 
mutations (23, 24). In addition to CHH, RMRP mutati­
ons have also been found in anauxetic dysplasia (AD, 
MIM #607095). AD patients suffer from mild mental 
retardation and hypodontia and display a shorter sta­
ture than CHH patients (21, 25).
The aim of this study was to identify mRNA targets of 
human RNase MRP RNase MRP levels were reduced by 
siRNA-mediated knock-down of its protein subunits 
and a global mRNA analysis revealed the upregulation 
of a.o. the viperin mRNA. The upregulation of viperin 
was confirmed at both the mRNA and protein level. 
The results are consistent with the direct cleavage of 
the viperin mRNA by RNase MRP
Materials and Methods
Cell culture and reagents
HEp-2 and HeLa were maintained in DMEM + Gluta- 
max supplemented with 10% heat-inactivated fetal 
calf serum (FCS) in a humidified 37° C, 5 %  CO2 incu­
bator. We purchased Interferon-aA/D and poly(I:C) 
from Sigma.
Antibodies
Monoclonal antibodies used: Rpp20-specific antibody 
(IFII, Modiquest), GST-specific antibody (2A9, Modi- 
quest), y-tubulin-specific antibody (GTU-88, Abcam) 
and viperin-specific antibody (MaPVIP) (25). Polyclonal 
rabbit sera against hPop1, Rpp25 and Rpp40 were a
kind gift of Sidney Altman. Polyclonal rabbit sera 
against hPop4 and U3-55K were described previously 
(27, 28).
Immunoblotting
For immunoblot analysis, proteins were separated by 
SDS-PAGE and transferred to nitrocellulose membranes 
by electroblotting. As secondary antibodies, we used 
the IRDye 800CW Goat Anti-Mouse Secondary Anti­
body (LiCOR Biosciences) and IRDye 800CW Goat 
Anti-Rabbit Secondary Antibody (LiCOR Biosciences). 
We used the Odyssey imaging system (LiCOR Biosci­
ences) for imaging and quantifying of signals.
RNA interference
The siRNAs against Rpp20, Rpp25 and hMtr4 were pu­
blished previously (29, 30). We purchased the siRNAs 
against hPop1 (5'-GAAU U UAACCGUAGACAAAdT dT- 
3'), Rpp40 (5'-CCUUAAACUUGGAUUCUAAdTdT-3') 
and EGFP (5'-CGAGAAGCGCGAU CACAU GdT dT-3 ') from 
Eurogentec.
For a typical siRNA experiment in 6-well plates, 1.25 x 
105 cells were transfected with 20 pmol of siRNA using 
Oligofectamine reagent (Invitrogen) according to the 
manufacturer's instructions with the exception that the 
medium contains 10% FCS during transfection. Cells 
were harvested 48 hours after siRNA transfection.
Transfection
The pcDNA3.1 constructs containing the coding region 
of human viperin or the coding region flanked by the 
5' and 3'-UTRs were generated by PCR amplification 
using gene-specific primers (GenBank accession num­
ber NM_080657) containing EcoRI and BamHI restric­
tion sites and cDNA from human foreskin fibroblasts 
as a template. The purified PCR products were digested 
with EcoRI and BamHI and cloned into the EcoRI and 
BamHI restriction sites of pcDNA3.1.
We transfected HeLa cells with the viperin constructs 
and the pEBG plasmid encoding GST (31 ) (transfection 
control) using FuGENE 6 (Roche) according to the ma­
nufacturer's instructions. Twenty-four hours after trans­
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fection with plasmids, the cells were treated with the 
siRNAs as described above.
In vitro activity assays
PCR was performed to generate the RNA substrates for 
in vitro transcription by T7 RNA polymerase, using the 
following primers. For viperin 151-250: 5'-GGGTAATAC 
GACTCACTATAGGGCTGGTCCTGAGAGGGCC-3' and 5'- 
TGCACT GGCGAGT GAAGT GATAGTT GACGC-3'; for 
viperin 401-500: 5'-GG GTAATACGACT CACTATAGGG 
AATACCTGGGCAAGTTG-3' and 5'-TGGAACCACCTCT 
CCCG-3'; for viperin 451-550: 5'-GGGTAATACGACTC 
ACTATAGGGAGCGTGAGCATCGTGAGC-3' and 5'-CAA 
AGCTGT CACAGGAG-3'; for viperin 751 -850: 5'-GGGTA 
ATACGACTCACTATAGGGCTCTTAATTGAGGGTG-3' and 
5'-TGTGGCGCTCCAAGAATCTTTCAAATTC-3' and for 
viperin 851-950: 5'-GG GTAATACGACT CACTATAGGG 
AAGAAGTGTCCTGCTTG-3' and 5'-CGTCCCTTTCTACA 
GTTC-3'. The resulting templates were in vitro transcri­
bed by T7 RNA polymerase using 32P-labeled UTP. For 
the pre-tRNA substrate the yeast suppressor precursor 
tRNASer (pSupS1) plasmid (32) was linearized with TaqI 
and in vitro transcribed by SP6 RNA polymerase in the 
presence of 32P-labeled UTP.
Antibodies were coupled to Protein-A agarose beads, 
which were used for immunoprecipitation of RNase 
MRP/P from HEp-2 cell extracts as described elsewhere 
(2). 12.5 pl of 2x cleavage buffer (40 mM HEPES-KOH, 
pH 7.6, 20 mM MgCh, 100 mM KCl, 2 mM DTT, and 
100 pg/ml BSA) was added to the immunoprecipitates 
still attached to the beads. Then 12.5 pl radiolabeled 
RNA substrate solution containing 0.3 U/pl RNasin 
(Promega) was added to the beads and the reaction 
mixtures were incubated at 37 ° C (10 minutes for pre- 
tRNA, 60 minutes for viperin mRNA). The reaction was 
terminated by adding Trizol (Invitrogen). Subsequently, 
the RNA was isolated and analyzed on an 8 %  (v/v) 
denaturing polyacrylamide gel. A phosphor-imager was 
used to visualize the radiolabeled RNA in the gel.
Inactivation by micrococcal nuclease
Antibodies against hPop4 or pre-immune serum were
coupled to Protein A-agarose beads for the immuno­
precipitation of RNase MRP/P from HEp-2 cell extracts 
as described elsewhere (2). The precipitates were pre­
incubated in a 4 pl volume containing 1 mM CaCh, or
1 mM CaCl2 plus micrococcal nuclease (0.5 U/pl), or 
micrococcal nuclease (0.5 U/pl) plus 20 mM EGTA for 
15 minutes at 37°C. Subsequently, 1 pl of 0.1 M EGTA 
was added. As a control, half of the reactions that had 
been incubated with CaCh and micrococcal nuclease 
did not receive EGTA to monitor the effect of active mi- 
cococcal nuclease on the viperin substrates. After the 
addition of 12.5 pl of 2x cleavage buffer and 7.5 pl of 
radiolabeled substrate RNA solution containing 0.3 
U/pl RNasin (Promega), the reaction mixtures were in­
cubated for one hour at 37°C. RNA was then isolated 
and analysed as described above.
Northern blot hybridization
We performed northern blotting and hybridization as 
described previously (2). Hybridization with internally 
32P-labeled antisense riboprobes against the RNA com­
ponents of RNase MRP and RNase P was performed at 
65°C, for 32P-end-labeled antisense oligonucleotides 
complementary to U1 snRNA (5'-GCGCGAACGCAGTC 
CCCCACTACCAC -3') at 42 °C.
Microarray analysis
We performed four independent transfections of HEp-
2 cells with siRNAs against EGFP, hPop1 and Rpp40. 
Cells were harvested 48 hours after transfection. Knock­
down of hPop1 and Rpp40 was monitored by western 
blotting. RNA was isolated using Trizol (Invitrogen) and 
purified using the RNeasy kit (Qiagen). The resulting 
RNAs were subjected to microarray analysis in the la­
boratory of Prof. Frank Holstege (Utrecht University, 
The Netherlands) using human 70-mer oligos (Operon, 
Human V2 AROS) spotted onto Codelink Activated sli­
des (Surmodics) 21 K arrays. Two sets of two biological 
replicates were analyzed with reverse fluoro-chromes. 
The expression profiles obtained with material of 
sihPop1- and siRpp40-treated cells were com- pared 
with that obtained for the control siEGFP-treated ma­
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terial. RNA amplifications, labeling and hybridisations 
were performed as described (33). cRNA (2500 ng) cou­
pled to Cy3 and Cy5 fluorophores (Amersham) were 
hybridized on a Tecan HS4800PRO and scanned on an 
Agilent scanner (G2565BA) at 100% laser power, 30% 
PMT. After data extraction using Imagene 8.0 (Bio- Dis­
covery), printtip Loess normalization was performed
(34) on mean spot-intensities without background sub­
traction. Data was analysed using ANOVA (R version 
2.2.1/MAANOVA version 0.98-7) (www.r-project.org)
(35). In a fixed effect analysis, sample, array and dye 
effects were modeled. P-values were determined by a 
permutation F2-test, in which residuals were shuffled 
5000 times globally. Genes with p < 0.05 after family 
wise error correction were considered significantly 
changed. Microarray data have been deposited with 
ArrayExpress under accession no. E-TABM-981.
Results
siRNA-mediated RNase MRP and RNase P depletion
To investigate whether the levels of RNase MRP in HEp-
2 cells can be reduced by an siRNA-mediated knock­
down approach, we transfected the cells with siRNAs 
against the hPop1, Rpp20, Rpp25 and Rpp40 mRNAs. 
Forty eight hours after transfection the cells were lysed 
and the proteins analyzed by western blotting. The le­
vels of each of the targeted proteins appeared to be 
reduced by the respective siRNA treatments, although 
the efficiency of knock-down varied and the si Rpp2 5 
appeared to be the least effective (Figure 1A). Since 
the reduced levels of these proteins may affect the sta­
bility of the complex, we monitored the level of the 
RNA component of RNase MRP by northern blot hybri­
dization, using U1 snRNA as a control. The reduction 
of hPop1, Rpp20, Rpp40 and, to a lesser extent, Rpp25 
led to a concomitant decrease of RNase MRP RNA levels 
(Figure 1 B). These results indicate that a depletion of 
one of the protein components leads to destabilization 
and as a result reduced levels of the whole complex. 
Because the depleted proteins are also associated with 
the RNase P complex, the effects on RNase P RNA le-
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Figure 1 : siRNA-mediated knock-down of RNase 
MRP and P protein components leads to complex 
instability
A. Immunoblotting using antibodies against hPopl, Rpp20, 
Rpp25, Rpp40 and y-tubulin (loading control).
B. Northern blot hybridization analysis of total RNA. U1 
snRNA was used as a loading control and MRP and P RNA 
levels after siRNA treatment are depicted relative to those 
observed after siEGFP treatment. Results are presented as 
the mean of 3 independent experiments +/- s.e.m.
vels were investigated as well. As expected, very similar 
effects were observed for the levels of RNase P RNA 
(Figure 1 B).
Gene expression profiles after hPopl or Rpp40 
knock-down
To identify mRNA substrates for the human RNase 
MRP complex, we examined the effects of siRNA-me- 
diated depletion of RNase MRP (and RNase P) on the 
transcriptome of HEp-2 cells. We knocked-down the ex­
pression of two RNase MRP protein components, 
hPop1 and Rpp40, and after 48 hours isolated mRNA 
from these cells as well as from cells transfected with 
an siRNA targeting the GFP mRNA (siEGFP), which was 
used as a control. The expression levels of mRNAs were 
analyzed on a genome-wide scale using 21 K microar­
rays. When compared with the control, 95 genes dis­
played at least 2-fold differences after knocking-down 
either hPop1 or Rpp40 (Supplementary Table 1 and Sup­
plementary Table 2 online). Seven of these were more 
than 2-fold upregulated in both datasets (RSAD2,
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Table 1: Differentially expressed genes after siRNA-mediated knock-down of hPop1 or Rpp40 in HEp-2 cells 
compared to control transfected cells
Gene symbol Description hPopl* Rpp40* GO-term biological process**
RSAD2 Viperin 3.6 2.0 defense response to virus
SYPL1 Synaptophysin-like protein 1 3.2 2.5 transport /  synaptic transmission
ARPC1A Actin-related protein 2/3 
complex subunit 1A
2.5 2.9 actin cytoskeleton organization
CASP7 Caspase-7 precursor 2.5 2.1 release of cytochrome c from mitochondria /  apoptosis
H3F3A Histone H3.3 2.5 2.9 nucleosome assembly
DDT D-dopachrome decarboxylase 2.4 2.4 melanin biosynthetic process from tyrosine
CAPNS1 Calpain small subunit 1 2.3 2.0 positive regulation of cell proliferation
NQO1 NAD(P)H dehydrogenase 
[quinone] 1
-4.6 -3.0 xenobiotic metabolic process /  nitric oxide biosynth. 
process /  response to oxidative stress /  synaptic 
cholinergic /  toxin resp. /  neg. regulation of catalytic 
activity /  oxidation reduction
HMOX1 Heme oxygenase 1 -3.5 -3.5 heme oxidation
IL8 Interleukin-8 precursor -2.3 -3.4 angiogenesis /  immune response /  cell motion /  
inflammatory response /  cell-cell signaling /  negative 
regulation of cell proliferation /  cell adhesion
GCLM Glutamate--cysteine ligase 
regulatory subunit
-2.0 -2.1 cysteine metabolic proc. /  glutathione metabolic 
process /  neg. regulation of apoptosis /  regulation of 
blood vessel size
* Only genes more than 2-fold up- or down-regulated by both the hPopl and Rpp40 knock-downs are shown. 
** GO-terms listed are from the Gene Onthology Consortium (35).
CASP7, CAPNS1, SYPL1, H3F3A, DDT  and ARPC1A) 
and 4 genes were more than 2-fold downregulated 
(HMOX1, NQO1, IL8 and GCLM) (Table 1). In accordance 
with previously reported CHH patient microarray data, 
the differentially expressed genes are primarily associ­
ated with the immune system and apoptosis (36).
Viperin upregulation upon RNase MRP/RNase P 
knock-down
Direct mRNA targets for RNase MRP are predicted to 
be upregulated upon a reduction of RNase MRP func­
tion. Only a single mRNA was found to be upregulated 
more than 2-fold in both datasets (hPopl and Rpp40 
knock-down) as well as in four CHH patients, from 
which leukocyte mRNA was analyzed in two indepen­
dent microarray studies ((37) and P. Hermanns, unpu­
blished results). This prompted us to investigate the
effects of RNase MRP on this transcript in more detail. 
This mRNA is transcribed from the RSAD2 gene and is 
translated into the anti-viral protein viperin (38). First, 
we analyzed whether RNase MRP depletion affected 
the expression of this gene at the protein level by wes­
tern blotting. In agreement with the microarray data, 
the viperin protein was indeed upregulated in HEp-2 
cells, not only upon siRNA-mediated knock-down of 
hPopl and Rpp40, but also after knock-down of two 
other RNase MRP protein components, Rpp20 and 
Rpp25 (Figure 2). The effects observed for depletion of 
the latter protein were modest, which is in agreement 
with the generally poor reduction in Rpp25 and RNase 
MRP RNA levels (Figure 1). These results demonstrate 
that the expression of viperin also at the protein level 
is modulated by RNase MRP and/or RNase P
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Figure 2: Viperin protein level is upregulated after 
RNase MRP/P knock-down
A. Western blot analysis of viperin 48 hours post siRNA 
treatment of HEp-2 cells. y-tubulin was used as a loading 
control.
B. Viperin protein signals on the western blots were 
quantified and are depicted relative to the levels observed 
upon treatment with the siEGFP. Results are presented as 
the mean of 3 independent experiments +/- s.e.m.
Viperin upregulation is not affected by interferon
The expression of viperin is known to be induced by 
type I interferons (38). Indeed, interferon-a (IFN-a) treat­
ment of HEp-2 cells resulted in elevated viperin expres­
sion levels, which appeared to be even higher when the 
cells were also exposed to poly(I:C), a well documented 
inducer of interferon (Figure 3). To investigate whether 
viperin upregulation by RNase MRP depletion was in­
dependent of upregulation by the interferon response, 
we stimulated siRNA-treated HEp-2 cells with IFN-a 
for 16 hours prior to harvesting. Also after interferon 
induction the levels of both viperin protein and mRNA, 
as determined by quantitative RT-PCR, were elevated 
upon RNase MRP knock-down (Figure 3A and data not 
shown). Moreover, the cumulative induction of viperin 
expression was also evident when the cells were expo­
sed to both IFN-a and poly(I:C) (Figure 3B). These re­
sults are consistent with the elevation of viperin 
expression at the transcriptional level by interferon and 
at the post-transcriptional level by RNase MRP
Figure 4: Viperin upregulation is not due to rRNA 
processing defects
HEp-2 cells treated with the indicated siRNAs were 
stimulated with 1000 U/ml IFN-a for 16 hours prior to 
harvesting the cells. Forty-eight hours after siRNA 
transfection, cell lysates were analysed by immunoblotting, 
using y-tubulin as a loading control. by immunoblotting, 
using y-tubulin as a loading control.
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Figure 5: The coding region of the viperin mRNA 
is sufficient for its elevated translation in cells 
depleted of RNase MRP/P
A. Viperin expression in HEp-2 and HeLa cells that were 
subjected to increasing concentrations of IFN-a for 16 hours 
before harvesting was analysed by immunoblotting. The 
concentration of IFN-a ranged from 0-1000 U/ml. As a 
control, Y-tubulin was analysed in parallel.
B. HeLa cells were transfected with a pcDNA3.1 construct 
containing the coding sequence of viperin with or without 
the 5' and 3' UTRs. The cells were co-transfected with a 
GST-coding plasmid, which served as a transfection control. 
After 24 hours, the cells were treated with the indicated 
siRNAs. Forty-eight hours after siRNA transfection, cell 
lysates were analyzed by immunoblotting using antibodies 
specific for viperin and GST
Viperin upregulation is not due to rRNA processing 
defects
To exclude that viperin upregulation after RNase MRP
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Figure 3: Viperin upregulation by RNase MRP/P knock-down also occurs in IFN-a and poly(I:C) stimulated cells
A. siRNA-treated HEp-2 cells were stimulated with 1000 U/ml IFN-a 16 hours prior to harvesting the cells. 48 hours after siRNA 
transfection, the cells were lysed and viperin expression was analyzed by immunoblotting, using Y-tubulin as a loading control.
B. siRNA-treated HEp-2 cells were stimulated with 5000 U/ml IFN-a and where indicated also with 100 pg/ml poly(I:C) 16 hours 
prior to harvesting the cells. Forty-eight hours after siRNA transfection, the cells were lysed and viperin expression was analyzed by 
immunoblotting, using Y-tubulin as a loading control.
knock-down is due to rRNA processing defects (arising 
from the RNase MRP knockdown), we transfected HEp-2 
cells with an siRNA against Mtr4, in parallel with siRNAs 
for EGFP, hPop1 and Rpp20. Mtr4 is an exosome-asso- 
ciated protein, and depletion of this protein causes the 
accumulation of 5.8S rRNA precursors (29). Sixteen 
hours prior to harvesting of the cells, IFN-a (1000 U/ 
ml) was added to the medium. No viperin upregulation 
was observed after knock-down of Mtr4 (Figure 4). In 
addition, in a separate study, in which we targeted 
hXrn1 (a 5'-3' exoribonuclease), hDis3 (a 3'-5' exoribo- 
nuclease), hRrp41 or hPM/Scl-100 (exosome compo­
nents) by siRNA in HEp-2 cells and analyzed the effects 
on mRNA expression by microarrays, no upregulation of 
viperin mRNA was observed (unpublished data). These 
results strongly suggest that the observed changes in 
viperin expression are not due to indirect effects of in­
terfering with RNase MRP/P function.
Viperin upregulation does not require non-coding 
sequences
Viperin expression cannot be induced in HeLa cells, not 
even after stimulation with IFN-a (Figure 5Aand (38)). 
This implies that the HeLa cell line is very suitable for 
transfection experiments, in which viperin is ectopically 
expressed, since the endogenous protein will not affect 
the interpretation of the results. To study the impor­
tance of coding sequence and UTRs for the regulation 
of viperin expression by RNase MRP/P, we transfected 
HeLa cells with constructs containing the viperin co­
ding sequence either with or without the 5' and 3' 
UTRs. Subsequently, we subjected the cells to siRNA- 
mediated knock-down of RNase MRP/P components. 
Western blot analysis of cell lysates showed that with 
both constructs viperin was upregulated in the siRNA 
treated cells (Figure 5B). These results indicate that the 
induction of viperin by RNase MRP/P knock-down is 
not dependent on UTR sequences and also confirm that 
this phenomenon does not require the promoter of the
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Figure 6: Cleavage of viperin mRNA fragments by RNase MRP/P in vitro
HEp-2 cell extracts were subjected to immunoprecipitation by immobilized antibodies against hPop4, Rpp25, the U3-55K protein 
and antibodies from normal rabbit serum (NRS). The resulting precipitates were incubated with pre-tRNA, which was used as 
a positive control and 5 different segments of the viperin coding sequence. Numbers indicate the 5' and 3' nucleotides of these 
segments and correspond to their position in the coding sequence. The reaction products were analyzed by denaturing 
gelelectrophoresis. The numbers on the left indicate the size of the pre-tRNA, 110 nts, the cleaved tRNA, 82 nts, the cleaved 
5' leader, 28 nts, and the viperin segments, 100 nts. The input lanes contain the radiolabeled RNAs that were not incubated 
with the precipitated material. The most prominent cleavage products are marked by asterisks.
viperin gene. As a consequence, the coding sequence 
of viperin mRNA most likely contains the putative clea­
vage site(s) for RNase MRP/P
RNase MRP or RNase P cleaves viperin mRNA in vitro
The results of transfection experiments with constructs 
encoding distinct parts of the 1086 nt long coding se­
quence of viperin mRNA suggested that the region tar­
geted by RNase MRP/P is located in the central part 
of the coding sequence (data not shown). To investi­
gate whether RNase MRP or RNase P is indeed capable 
to cleave the viperin mRNA in this region, we incubated 
radiolabeled segments of the coding sequence of the 
viperin mRNA with RNase MRP/P in vitro. We immuno- 
precipitated RNase MRP and RNase P from HEp-2 cell 
extracts by antibodies against hPop4 and Rpp25. As 
controls, we used normal rabbit serum and an antibody 
against the 55K protein component of the U3 snoRNP 
in parallel. Several 100 nucleotides long viperin mRNA 
segments and pre-tRNA as a control were transcribed
72
RNase MRP/P cleaves viperin mRNA
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Figure 7: The viperin mRNA cleavage activity of 
RNase MRP/P in vitro is nuclease-sensitive
HEp-2 cell extracts were subjected to immunoprecipitation 
by immobilized antibodies against hPop4 and antibodies 
from normal rabbit serum (NRS) as a control. The 
immunoprecipitates were subjected to incubation with 
micrococcal nuclease, as described in the Materials and 
Methods section. Subsequently, the precipitates were 
incubated with different segments of the viperin mRNA. 
Numbers indicate the 5' and 3' nucleotides of these 
segments and correspond to their position in the coding 
sequence. The reaction products were analyzed by 
denaturing gelelectrophoresis. The input lanes contain 
the radiolabeled RNAs that were not incubated with 
the precipitated material. S: standard reaction, no pre­
incubation; C: pre-incubation with CaCh, addition of EGTA 
prior to the cleavage reaction; MN: pre-incubation with 
micrococcal nuclease and CaCh, no addition of EGTA prior 
to cleavage reaction; MNE: pre-incubation with micrococcal 
nuclease and CaCh, addition of EGTA prior to cleavage 
reaction; PMN: pre-incubation with micrococcal nuclease, 
CaCh and EGTA. The most prominent cleavage products are 
marked by asterisks. The numbers on the left indicate the 
positions of a 82 nts tRNA, a 28 nts 5' leader of pre-tRNA, 
and the 100 nts viperin mRNA segments.
in vitro and added to the immuno-precipitates. The im- 
munoprecipitated RNase MRP/P efficiently converted 
the pre-tRNA substrate in the expected products of 28 
and 82 nucleotides, corresponding to the 5' leader and 
tRNA body, respectively (Figure 6). In three of the 100 
nt viperin mRNA substrates cleavages were observed 
after incubation with the precipitates of the antibodies 
against hPop4 and Rpp25. Importantly, the correspon­
ding cleavage products did not appear after incubation 
with the precipitates obtained with the normal rabbit 
and 55K-specific antibodies. Since two of the three
cleaved substrates contained overlapping sequences, 
these results are consistent with the presence of two 
RNase MRP/P cleavage sites, one located between nu­
cleotides 451 and 500 of the coding sequence of vi­
perin mRNA and the other located between nucleo­
tides 851 and 950. Additional controls with similarly 
sized segments of the mRNAs encoding peptidylargi- 
nine deiminase 2 and tissue transglutaminase 2, two 
unrelated mRNAs, the expression levels of which were 
not altered upon RNase MRP/P depletion (microarray 
data), confirmed the specificity of viperin mRNA clea­
vage, because no cleavage of these RNAs could be de­
tected (results not shown).
To obtain additional evidence that the cleavage of vi­
perin mRNA is due to the activity of RNase MRP/P, 
which will be dependent on its RNA component, the 
immunoprecipitated RNase MRP/P was pre-incubated 
with micrococcal nuclease (Figure 7). Micrococcal nuc­
lease treatment followed by inactivation of this enzyme 
by the addition of EGTA prior to the in vitro cleavage 
reaction abrogated the cleavage of viperin mRNA seg­
ments by RNase MRP/P. This effect was not due to the 
presence of calcium during the pre-incubation with mi­
crococcal nuclease, nor to other activities present in the 
micrococcal nuclease preparation, as demonstrated by 
the controls. As expected, when micrococcal nuclease 
was not inactivated by the addition of EGTA, this en­
zyme led to additional cleavages in the viperin mRNA 
segments. Taken together, these results indicate that 
an intact RNA component in the RNase MRP/P prepa­
ration is essential for the cleavage activity.
Discussion
The results of this study identify the viperin mRNA as 
a new substrate for the human RNase MRP and/or 
RNase P complex. We have shown that viperin expres­
sion is induced both at the protein and at the mRNA 
level in human cell lines after knock-down of RNase 
MRP- and RNase P-associated proteins. Viperin upre- 
gulation by RNase MRP/P depletion appeared to be 
independent of IFN-a and poly(I:C), two well-known in­
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ducers of interferon responsive genes, a.o. viperin. In 
agreement with the ribonuclease activity of RNase 
MRP/P the observed induction of viperin expression is 
not dependent on non-transcribed elements of the vi­
perin gene. In addition, this phenomenon does not 
seem to be due to specific sequence elements in the 
UTRs of the viperin mRNA. Taken together, our data in­
dicate that viperin expression is repressed by RNase 
MRP or RNase P as a result of endoribonucleolytic clea­
vages in the coding sequence of the viperin mRNA.
Although the number is relatively low, our microarray 
data identified several other putative mRNA substrates 
for the human RNase MRP/P. Interestingly, the cyclin- 
B2 mRNA, which was reported by Thiel and coworkers 
to be modulated by the human RNase MRP (25), was 
not upregulated upon hPop1 or Rpp40 knock-down. 
This discrepancy will be further discussed below. Among 
the genes upregulated upon RNase MRP/P depletion 
a number of interferon-regulated genes can be discer­
ned. Currently, it is unclear whether this is a common 
feature related to the activities of RNase MRP/P, or 
whether this is caused by the siRNA treatment. Interes­
tingly, an enrichment of interferon-regulated genes was 
also observed in the dataset obtained with material 
from CHH-patient cells (37). Future studies will clarify 
whether the other putative mRNA substrates are in­
deed modulated by RNase MRP/P and whether they 
are directly cleaved by this enzyme.
The in vitro cleavage experiments provide evidence for 
two RNase MRP/P cleavage sites in the coding se­
quence of the viperin mRNA. The possibility that in ad­
dition to the cleavages in the mature mRNA, also 
cleavages in introns present in the viperin pre-mRNA 
affect its expression cannot be excluded.
An important question that is not directly answered by 
the results of our experiments is whether the viperin 
mRNA is cleaved by RNase MRP or RNase P. Our stra­
tegy to reduce RNase MRP levels by siRNA-mediated 
knock-down of its protein components leads to the si­
multaneous depletion of RNase P. To distinguish be­
tween these two ribonucleases we tried to reduce their 
levels by siRNAs targeting their RNA components. Alt­
hough these are not mRNAs, the feasibility of this ap­
proach was recently demonstrated by Maida and 
colleagues, who used RNase MRP RNA-specific siRNAs 
to knock-down the levels of RNase MRP (8). However, 
none of the 4 siRNAs that we used, one of which cor­
responds to that successfully applied by Maida and col­
leagues, showed a significant effect on RNase MRP RNA 
or RNase P RNA levels (data not shown). Currently, it 
is unclear why the previously reported RNase MRP 
RNA-specific siRNA does not work in our hands. In 
spite of the lack of direct evidence, we propose that the 
post-transcriptional regulation of viperin expression is 
mediated by RNase MRP and not by RNase P. This is 
most strongly supported by previously published obser­
vations that viperin mRNA levels are upregulated in 
cells from CHH patients, in which the function of 
RNase MRP is affected as a result of mutations in the 
RNase MRP RNA gene, whereas the function of RNase 
P is unaffected (37). In addition, the recently reported 
association with TERT can regulate RNase MRP RNA 
levels by a negative-feedback mechanism (8). When 
TERT is overexpressed, RNase MRP RNA levels are 
downregulated. If RNase MRP, and not RNase P, con­
trols viperin mRNA expression, this messenger is expec­
ted to be induced upon TERT overexpression. Indeed, 
when TERT was transduced into CD4-positive T-cells, 
viperin mRNA levels were elevated (39). Future studies, 
in which for example the wild type RNase MRP RNA 
gene in mammalian cells is replaced by a CHH-like mu­
tant gene, will have to provide further evidence to sup­
port the involvement of RNase MRP and not that of 
RNase P
The levels of RNase MRP/P as a result of knocking- 
down hPop1 or Rpp40 are similar to what would be 
expected in heterozygous carriers of RMRP promoter 
mutations, which display no phenotypes. The diffe­
rence might be explained by the fact that, in contrast 
to the cells of such carriers, siRNA-treated cultured cells
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will show much more heterogeneity with regard to the 
remaining levels of RNase MRP/P. In addition, rapidly 
dividing cultured cells may be more critically depen­
dent on RNase MRP/P levels than cells of such carrier 
individuals. In this context it is important to mention 
that retarded growth was indeed observed for the cells 
in which RNase MRP/P was downregulated. The role 
of RNase MRP/P in the regulation of viperin expression 
is further supported by the observation that the effi­
ciency of knocking-down RNase MRP/P components 
inversely correlates with the efficiency of viperin upre- 
gulation (compare the results in Figure 1 with those in 
Figure 2).
RNase MRP is localized predominantly in the nucleolus, 
which raises the question where the viperin mRNA, and 
possibly other mRNAs, are cleaved by RNase MRP. In 
Saccharomyces cerevisiae RNase MRP has been repor­
ted to localize to specific cytoplasmic temporal asym­
metric MRP bodies (TAM-bodies) after the initiation of 
mitosis (40). It is possible that RNase MRP degrades 
specific mRNAs in these TAM-bodies. In human cells 
RNase MRP components appear to be regulated in a 
cell-cycle dependent manner, but it is not known whe­
ther TAM bodies exist in mammalian cells as well (11). 
The nucleolar association of human RNase MRP does 
not appear to be very strong, because upon actinomycin 
D treatment (to block transcription) or adenoviral in­
fection hPop1 translocates from the nucleolus to the 
nucleoplasm (41, 42). These data do not rule out the 
possibility that low concentrations of RNase MRP reside 
in the cytoplasm of human cells and that this concen­
tration is increased upon cell physiological changes. 
Therefore, it is currently impossible to predict in which 
subcellular compartment the viperin mRNA is cleaved 
by RNase MRP
Viperin is an anti-viral protein that is induced by type 
I and II interferons, LPS or viral infections (38). It is 
highly conserved between mammals and lower verte­
brates (38, 43). The expression of this protein inhibits 
influenza A virus release from the plasma membrane 
of infected cells, and also has been demonstrated to
interfere with the replication of hepatitis C virus and 
human cytomegalovirus (26, 38). Viperin localizes to 
the cytoplasmic side of the endoplasmic reticulum and 
to lipid droplets via its N-terminal amphiphatic a-helix. 
Overexpression of viperin may lead to a crystalloid ER 
and has been demonstrated to reduce protein secretion 
from HepG2 cells (44, 45). The regulation of viperin ex­
pression by RNase MRP/P raises the question whether 
some of the symptoms of CHH are due to altered vipe­
rin expression levels. Viperin knockout mice show an 
impaired Th2 response and T-cell receptor mediated ac­
tivation of NF-k B and AP-1 (46). In another mouse 
study, it was shown that viperin is expressed at higher 
levels in Th2 cells compared to Th1 cells (47). These re­
sults suggest that viperin may play an important role 
in the immune system. An inflammatory trigger may 
enhance the expression of viperin via interferon signal­
ling and this may be needed for an efficient T-cell res­
ponse. Subsequently, cells might have to recover from 
the protein secretion inhibitory effects of viperin over­
expression, by reducing the levels of viperin and this 
can at least in part be achieved by degradation of its 
mRNA. At this stage RNase MRP may become activa­
ted or may get access to the mRNAs, e.g. by a subcel­
lular redistribution, to enhance the degradation of 
viperin mRNA. Interestingly, CHH patients indeed ex­
press higher levels of viperin in leukocytes compared 
to healthy controls (37).
The higher expression levels of viperin in CHH patient 
leukocytes might result in higher levels of activated NF- 
k B and AP-1 as well. Constitutive NF-k B activation has 
been observed in various hematological malignancies 
and solid tumours (48). Although it remains to be de­
monstrated, it is tempting to speculate that the possi­
bly elevated levels of active NF-k B due to higher viperin 
expression in CHH patient T-cells are associated with 
the increased risk to develop hematological cancers.
In rats, the viperin homolog BEST5 is expressed in 
bone-forming osteoblast cells during their differentia­
tion (49). This suggests that viperin plays a role in the 
proliferation or differentiation of osteoblasts. No vipe­
rin induction was seen in rat chondrocytes. Chondrocy­
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tes are cells that differentiate into mineralized hyper­
trophic chondrocytes before undergoing apoptosis. Os­
teoblasts and osteoclasts then remodulate the remai­
ning mineralized matrix leading to bone deposition. 
Since RNase MRP is strongly upregulated in mouse hy­
pertrophic chondrocytes, and because of the short lim­
bed dwarfism phenotype of CHH, it is expected to exert 
an important function in these cells (37). In spite of 
these observations, more research is required to inves­
tigate whether the deregulation of viperin expression 
is involved in the dwarfism phenotype of CHH.
In accordance with the CHH patient microarrays data 
mentioned above, the dataset of our microarray analy­
ses did not show upregulation of human B-type cyclins 
after RNase MRP depletion. In addition, we have exa­
mined several CHH patient-derived fibroblasts and fi­
broblasts from their relatives, and did not find altered 
cyclin-B1 or cyclin-B2 expression levels (unpublished 
data). Thiel and coworkers have transfected healthy 
human fibroblasts with constructs encoding different 
RNase MRP RNA mutants and analyzed the cyclin-B2 
mRNA levels by quantitative RT-PCR. Their results 
showed that transient expression of the 70A>G mutant 
of RNase MRP RNA significantly increased the expres­
sion of the cyclin-B2 mRNA. Interestingly, for most other 
mutations tested, they observed a decrease in cyclin- 
B2 mRNA levels (25). Taken together, these data do 
not support a role for RNase MRP in the regulation of 
B-type cyclin expression in human cells.
We conclude that the present study for the first time 
provides direct evidence for the cleavage of a mRNA 
by a human small nucleolar ribonucleoprotein complex. 
Cleavage of the viperin mRNA by RNase MRP/P regu­
lates the expression of viperin post-transcriptionally 
and the altered expression levels of viperin upon a re­
duction of RNase MRP activity may be directly involved 
in the pathogenesis of CHH.
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The role of RNase MRP/P in rRNA synthesis
The aim of this study was to elucidate the role of RNase MRP and/or RNase P in ribosomal RNA 
processing in human cells. Ribosomal RNA processing was studied by metabolic labeling and 
northern blot hybridisation of total RNA extracted from HeLa cells using a series of probes spe­
cific for either the mature rRNAs or processing intermediates. An RNAi approach was chosen 
to interfere with the functional activities of RNase MRP and RNase P. The mRNAs encoding se­
veral protein subunits were targeted by siRNAs to reduce the levels of protein subunits hPop1, 
Rpp20, Rpp25, Rpp38 and Rpp40. Although two of these siRNAs strongly affected pre-rRNA 
processing, the use of alternative siRNAs for these RNase MRP/RNase P subunits indicated 
that these effects could not be ascribed to the interference with the functional activity of RNase 
MRP/RNase P. The results of these experiments indicate that RNA interference does not seem 
to be the most suitable technique to study the role of RNase MRP and RNase P in pre-rRNA 
processing. Nevertheless, depletion of Rpp25 consistently led to a reduction of processing in­
termediates, which may be due to a repression of RNA polymerase I transcription, a lack of 
entry of the 47S rRNA precursor into the canonical processing pathway, aberrant processing of 
pre-rRNA, or a combination of these.
Introduction
The first step in ribosome biogenesis is the transcription 
of ribosomal RNA (rRNA) followed by a series of pro­
cessing steps to generate the mature rRNA components 
of the ribosome. In mammalian cells, three of the four 
ribosomal RNAs, 18S, 5.8S and 28S rRNA, are transcri­
bed by RNA polymerase I as a long precursor molecule, 
in which the rRNAs are separated by two internal tran­
scribed spacers (ITS1 and ITS2) and which contains two 
external transcribed spacers at the 5' end and the 3' 
end (5'ETS and 3'ETS). The fourth rRNA, 5S rRNA, is 
transcribed by RNA polymerase III. By a series of endo- 
ribonucleolytic cleavages, exonucleolytic degradation 
and RNA modification steps, the 47S rRNA precursor of 
the three rRNAs is processed into the mature 18S, 5.8S 
and 28S rRNAs that are incorporated in the ribosome.
In HeLa cells two processing pathways have been iden­
tified (Figure 1) (1, 2).
The human RNase MRP complex consists of a unique 
267 nt long noncoding RNA component and at least 
7 protein components. Mutations in the RNA compo­
nent of RNase MRP are the cause of the disease carti-
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lage-hair hypoplasia (CHH, MIM #250250) (3, 4). The 
characteristic features of CHH are short-limbed dwar­
fism and hypoplastic hair. In addition, patients show pre­
disposition to certain cancers, childhood anemia, Hirsch- 
prung's disease and defective T-cell immunity (reviewed 
in (4)). To date, more than 70 CHH-associated mutati­
ons have been identified in patients in the transcribed 
region of the RNA component of RNase MRP In addi­
tion, 30 different promoter mutations have been des­
cribed (4). RNase MRP is able to cleave the mitochon­
drial RNA to generate the primer for mitochondrial DNA 
replication. In addition, it is involved in pre-rRNA pro­
cessing and cleaves several mRNAs in a highly specific 
fashion (5-7, Chapter 4).
RNase MRP is closely related to the endoribonuclease 
RNase P and shares all of its protein components with 
this complex, which has a unique RNA component of 
342 nt. Human RNase P is involved in tRNA maturation 
and RNA polymerase I and III transcription (8-10). A 
Saccharomyces cerevisiae strain harbouring a mutation 
in a conserved part of RNase P RNA accumulated a 3' 
extended form of the 5.8S rRNA (11). Furthermore, it 
also contained slightly elevated levels of 5.8S rRNA
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Figure 1 : Pre-rRNA processing in human cells
Schematic representation of the different steps and pathways in the processing of pre-rRNA in HeLa cells. ETS: external transcribed 
spacer; ITS: internal transcribed spacer; the different cleavage sites are indicated below the processing intermediates. Modified 
from Gerus et al (28).
precursors containing 5' ends in the ITS1 region (11). 
In S. cerevisiae, the endonucleolytic cleavage at the A3 
site in ITS1 is performed by the RNase MRP complex 
(7). This processing event links RNase MRP to the pro­
duction of the short form of 5.8S rRNA (5.8Ss), one of 
the two isoforms of this rRNA that differ at the 5' end. 
Interestingly, RNase MRP was recently reported to be 
required for the entry of the 35S rRNA precursor (the 
yeast equivalent of the vertebral 47S precursor) into 
the canonical processing pathway in S. cerevisiae (12). 
In this study, we investigated the effects of siRNA-me- 
diated knockdown of several RNase MRP and RNase P 
protein components on human rRNA processing to ob­
tain more insight into the role of these enzymes in this 
process.
Results
Effect of RNase MRP/RNase P depletion 
on newly synthesized rRNA (precursors)
To study the role for RNase MRP and RNase P in rRNA 
processing in human cells the expression levels of pro­
tein components of these complexes were reduced by 
RNA interference. HeLa cells were transfected with siRNAs 
against hPopl, Rpp20, Rpp25, Rpp38 or Rpp40. As 
controls, we used siRNAs targeting EGFP, luciferase or 
Mtr4. Mtr4 is an exosome associated protein, which 
has previously been demonstrated to be involved in
5.8S rRNA maturation (13). Two days after transfection 
cells were harvested and the respective protein levels 
were monitored by western blotting. The results showed
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Figure 2: Effect of RNase MRP/RNase P depletion on newly synthesized (pre-)rRNAs in HeLa cells
HeLa cells were transfected with siRNAs against EGFP, luciferase (siLuc), hPopl, Rpp20, Rpp25, Rpp38, Rpp40 or Mtr4. Whole 
cell extracts were prepared 48 hours post-transfection and analyzed by immunoblotting. In parallel, cells were metabolically 
labeled as described in Experimental Procedures.
A: Immunoblotting using antibodies against hPopl, Rpp40, Rpp38, Rpp25, Rpp20 and y-tubulin (loading control) as 
indicated on the right.
B: Total RNA from metabolically labeled cells was separated on a denaturing agarose gel, transferred to a membrane and 
visualized by phosphorimaging. The two lower panels show the results of hybridizing the blots with antisense oligonucleotides 
specific for the 28S and 18S rRNAs. The positions of precursor and mature rRNAs are indicated on the right.
C: Quantification of signals of newly synthesized 18S and 28S rRNA as determined by phosphorimaging. The ratios of 28S:18S 
rRNA were calculated and are depicted as a percentage of the ratio observed after treatment with the control siLuc. Values 
are displayed as the mean +/- range for siRpp20 (n = 2), siRpp25 (n = 2), siRpp38 (n = 2), siRpp40 (n = 2), siMtr4 (n = 2), 
except for mock (n =1).
D: Ratio of total amounts of 28S and 18S rRNAs. 18S and 28S signals on the northern blots were quantified by phosphor­
imaging. The ratios of 28S:18S rRNA were calculated and are depicted as a percentage of the ratio observed after treatment 
with the control siLuc. Results are presented as the mean of at least 3 independent experiments +/- 2 times the standard 
deviation.
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Figure 3: Northern blot analysis of large rRNA precursors from siRNA-treated HeLa cells
HeLa cells were transfected with siRNAs against EGFP, luciferase, hPopl, Rpp20, Rpp25, Rpp38, Rpp40 or Mtr4. Nuclear RNA 
was isolated, separated on a denaturing 1 %  agarose gel and transferred to a membrane. Antisense oligonucleotides were used 
to detect processing intermediates and mature rRNAs: A: 1788-ETS1 ; B: 18S; C: 5'-ITS1 ; D: 3 '-ITS1 ; E: 5.8S; F: 5'-ITS2; G: 28S; B', 
E' and G': shorter exposure of the 18S, 5.8S and 28S rRNA signals of panels B, E and G, respectively. H: schematic representa­
tion of the 47S rRNA precursor. The hybridization positions of the probes are indicated with arrows and names are given in bold.
that the levels of each of these proteins were diminished 
upon treatment with the corresponding siRNAs (Figure 
2A). From these cells, nuclear RNA was isolated and 
analyzed by northern blot hybridization (see next two 
sections). In parallel, cells were pulse-labeled with 32P- 
labeled inorganic phosphate in growth medium con­
taining dialyzed fetal calf serum for 60 minutes fol­
lowed by a 90 minutes chase in regular growth medium. 
Total RNA extracted from these cells was separated by 
agarose-formaldehyde gelelectrophoresis and transfer­
red to nitrocellulose by northern blotting. The radio­
labeled RNAs were visualized by phosphorimaging (Fi­
gure 2B). 32P-labeled oligonucleotides complementary 
to the 18S and 28S rRNAs were used as probes to vi­
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sualize the relative levels of these ribosomal RNAs 
(lower panels in Figure 2B).
The levels of all newly synthesized (pre-)rRNAs appea­
red to be lower in the cells treated with siRNAs against 
Rpp20 and Rpp25. This might be explained by the im­
pairment of RNA polymerase I transcription upon de­
pletion of RNase P (9). The ratio 28S:18S of both newly 
synthesized and total RNA was reduced upon Rpp25 
depletion, which suggests that Rpp25 is required for 
28S rRNA maturation (Figure 2C and 2D). Rpp20 de­
pletion led to hardly any detectable radiolabeled 18S 
rRNA, which suggests an important function for Rpp20 
in 18S rRNA maturation (Figure 2B and C).
Large rRNA precursors affected by 
RNase MRP/RNase P depletion
Nuclear RNA was isolated from the cells described in 
the previous section and analyzed by northern blot 
hybridization using 32P-labeled oligonucleotide probes 
complementary to distinct regions of the pre-rRNA pre­
cursor (Figure 3). A schematic representation of the po­
sitions of the probes is given in Figure 3H. The most 
striking effects on the levels of rRNA precursors were 
observed for Rpp25 depletion, whereas interference 
with the other siRNAs did not significantly affect the 
levels of these precursors. More specifically, after knock­
down of Rpp25, the 41S precursor accumulates, which 
is consistent with impaired cleavage at site 2 in ITS1 
(Figure 1). In addition, a 32S precursor appeared to be 
accumulating (Figure 3D). Since this molecule was de­
tected with the 3'-ITS1 probe, which hybridizes with a 
sequence at the 5' side of cleavage site 2, this molecule 
is not identical to the 32S precursor depicted in Figure 
1. Compared to the canonical 32S precursor this mole­
cule appears to be extended in the ITS1 region, which 
is also in agreement with the slightly retarded migration 
of this precursor compared to the 32S precursors seen 
in Figures 3E and 3F.
Formation of the 30S precursor was strongly diminis­
hed upon Rpp25 depletion, which is in accordance with 
a block of cleavage at site 2. Moreover, after knockdown 
of Rpp25, the level of the 18S-E precursor was increa-
Figure 4: Northern blot analysis of small rRNA 
precursors from siRNA-treated HeLa cells
HeLa cells were transfected with siRNAs against EGFP, 
luciferase, hPopl, Rpp20, Rpp25, Rpp38, Rpp40 or Mtr4. 
Nuclear RNA was isolated, separated on a denaturing 
polyacrylamide gel and transferred to a membrane. 
Antisense oligonucleotides (see Figure 3H) were used to 
detect processing intermediates and mature rRNAs: A: 5.8S; 
A': shorter exposure of 5.8S rRNA signal of panel A; B: 5'- 
ITS2. 5.8S L=long form of 5.8S rRNA; 5.8S S=short form of 
5.8S rRNA; 5.8S VL= very long form of 5.8S rRNA.
sed, indicating that cleavage at site 3 in ITS1 was in­
hibited (Figure 3C). Rpp25 depletion also led to a re­
duction of the 12S precursor, which is most likely due 
to an impaired formation of this precursor resulting from 
the impairment of an earlier processing step (cleavage 
3' in Figure 1).
Small rRNA precursors affected by 
RNase MRP/RNase P depletion
To investigate the effects of RNase MRP and RNase P 
protein depletion on small rRNA precursors, we sepa­
rated the nuclear RNA of siRNA treated cells described 
in the previous sections on denaturing polyacrylamide 
gels. The RNA was subsequently analyzed by northern 
blot hybridization using 32P-labeled oligonucleotide pro­
bes complementary to distinct regions of the pre-rRNA 
precursor (Figure 4). As for the large rRNA precursors, 
differences in pre-rRNA processing can be seen after 
knockdown of distinct RNase MRP and P protein com­
ponents. Upon knockdown of Rpp25, the levels of all 
precursors were diminished. After knockdown of Mtr4,
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Figure 5: Northern blot analysis of large rRNA 
precursors from actinomycin D-treated HeLa cells
HeLa cells were transfected with siRNAs against EGFP, 
luciferase, hPop1, Rpp20, Rpp25, Rpp38, Rpp40 or Mtr4. 
48t hours post transfection, the medium was replaced with 
1 ml of medium containing 10% FCS. Where indicated (+) 
the medium also contained 40 ng/pl actinomycin D. After 
incubation at 3 7 ° C for one hour, nuclear RNA was 
isolated, separated on a denaturing 1 %  agarose gel and 
transferred to a membrane. Antisense oligonucleotides (see 
Figure 3H) were used to detect processing intermediates 
and mature rRNAs.
an RNA containing 5.8S and ITS2 sequences accumu­
lates, in agreement with previous observations (13). 
This has been designated the very long form of 5.8S 
(5.8S VL). As a result of cleavage at site A3 in the rRNA 
precursors in yeast, RNase MRP is involved in the for­
mation of the short form of 5.8S rRNA. Currently, there 
is no evidence for a similar function in mammals. Inte­
restingly, the ratio of the long and short form of 5.8S 
rRNA appeared to be reproducibly increased upon 
Rpp25 depletion, supporting a role for this RNase MRP/ 
RNase P protein in the formation of the short form of
5.8S rRNA.
Knockdown of Rpp25 inhibits both rRNA synthesis 
and processing
It is has been reported that knockdown of Rpp25 inhi­
bits RNA polymerase I transcription (9). Indeed, the re­
sults of the metabolic labeling experiment (Figure 2) 
show that the rate of pre-rRNA synthesis is reduced 
upon Rpp25 depletion. In an attempt to discriminate 
between the effects of Rpp25 depletion on rRNA tran­
scription and on pre-rRNA processing, Actinomycin D 
was added to the cells 1 hour before harvesting to block 
RNA polymerase I transcription. Like before, the effi­
ciency of knockdown of RNase MRP/RNase P proteins 
was determined by western blotting (data not shown). 
Nuclear RNA was isolated and analyzed by northern 
blot hybridization (Figure 5). The elimination of RNA 
polymerase I transcription upon Actinomycin D treat­
ment was demonstrated by the disappearance of the 
47S precursor. Because this was observed for all siRNAs 
used, the early processing steps, i.e. the cleavage at sites 
A0 and 2 (Figure 1), do not seem to be affected by the 
depletion of RNase MRP/RNase P components. The 
knockdown of Rpp25 again resulted in the most severe 
effects on pre-rRNA processing, as illustrated by the ac­
cumulation of the 41S precursor (Figure 5), both with 
and without Actinomycin D treatment. This is in accor­
dance with the inhibition of the pre-rRNA processing 
at site 2 (Figure 1). It should be noted that there was 
a difference between the effects of the control siRNAs 
for EGFP and luciferase, because the processing of the 
30S precursor seemed to occur faster after transfection 
with the latter siRNA. In addition, the signals of the 
32S precursor are weaker after treatment with the 
siRNA for luciferase compared to the siRNA for EGFP
Knockdown of RNase MRP/P protein components 
does not lead to lower U3 and U8 snoRNA levels
The U3 snoRNA is essential for 18S rRNA formation and 
is a component of the small subunit (SSU) processome 
together with more than 40 proteins (reviewed in (14)). 
U3 snoRNA exists as a 12S ribonucleoprotein particle, 
which can be associated with 80S complexes represen­
ting the SSU processome (14). Another snoRNA, the 
U8 snoRNA, is involved in both 5.8S and 28S rRNA 
processing in metazoans (15). It is possible that RNase 
MRP or RNase P is somehow involved in the maturation 
of the U3 or U8 snoRNA, although this is not supported 
by experimental evidence at this moment. To exclude 
that the defect in 18S maturation (after knockdown of 
Rpp20) and 28S maturation (after knockdown of 
Rpp25) is due to an indirect effect on U3 or U8 matu-
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Figure 6: Northern blot analysis of snRNA and 
snoRNA levels
HeLa cells were transfected with siRNAs against EGFP, 
luciferase, hPopl, Rpp20, Rpp25, Rpp38, Rpp40 or Mtr4. 
Nuclear RNA was isolated, and analyzed by northern blot 
hybridization with riboprobes for RNase P RNA, RNase MRP 
RNA, U1 snRNA, U3 snoRNA and U8 snoRNA.
ration, we monitored U3 and U8 snoRNA levels by 
northern blot hybridization (Figure 6). As a loading 
control, the U1 snRNA was measured. The results in Fi­
gure 6 show that the levels of neither the U3 nor the 
U8 snoRNA were downregulated upon knockdown of 
hPopl, Rpp20, Rpp25, Rpp38 or Rpp40. In contrast, 
the levels of both RNase MRP and RNase P RNA were 
reduced in all cases, except for siRpp25 treatment. 
These results indicate that the effects on pre-rRNA pro­
cessing described above are not due to alterations in 
the levels of the U3 and U8 snoRNAs.
siRNAs against Rpp25 and Rpp20 cause 
off-target effects
To confirm the effects we saw on pre-rRNA processing 
after knockdown of Rpp20 and Rpp25, two additional 
siRNAs targeting different parts of the mRNAs of Rpp20 
and Rpp25 were generated. These siRNAs led to com­
parable knockdown efficiencies as those of the original 
siRNAs for each of these mRNAs (Figure 7A). Nuclear 
RNA was harvested, separated on a denaturing gel and 
analyzed by northern blot hybridization using probes 
for the 5' regions of ITS1 and ITS2 (Figure 7B). The ef­
fects on pre-rRNA processing that were obtained with 
the original siRNAs, siRpp20 (1) and siRpp25 (1), were 
comparable to the results of the experiments described
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Figure 7: Northern blot analysis of large rRNA 
precursors from HeLa cells treated with alternative 
siRNAs for Rpp20 and Rpp25
HeLa cells were transfected with siRNAs against luciferase, 
three distinct siRNAs for Rpp20 and for Rpp25 and without 
siRNA (mock). Cells were harvested 48 hours post 
transfection.
A: Whole cell extracts were analyzed by immunoblotting 
using antibodies against Rpp20, Rpp25 and y-tubulin 
(loading control).
B: Nuclear RNA was analyzed by northern blot hybridization 
with antisense oligonucleotide probes 5'ITS1 and 5'ITS2.
above. However, in spite of the depletion of the respec­
tive proteins, the alternative siRNAs for Rpp20 and 
Rpp25 did not detectably affect pre-rRNA processing, 
although the abundance of all precursors might be 
slightly reduced upon treatment with siRpp20 (2). In 
parallel, cells were metabolically pulse-labeled with 32P- 
labeled phosphate after knockdown of Rpp20 and 
Rpp25 with all available siRNAs (Figure 8A). After 
knockdown of Rpp20 with the new siRNAs, the 18S 
rRNA formation was not disturbed, in contrast to the 
results obtained with the original siRNA. Except for the 
47S precursor, all labeled (pre-)rRNA molecules are de­
creased after knockdown with all three siRNAs for 
Rpp25. This implies impaired RNA polymerase I tran­
scription, a defect in entry of the 47S precursor into
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Figure 8: Effect of alternative Rpp20 and Rpp25 
siRNAs on newly synthesized rRNA (precursors)
A: After pulse-labeling siRNA-treated HeLa cells with 
32P-labeled phosphate, total RNA was separated on a 
denaturing gel, transferred to a membrane and visualized 
by phosphorimaging. The two lower panels show the results 
of hybridization with oligonucleotide probes for 28S and 
18S rRNA, respectively.
B: Signals of total 28S and 18S rRNA obtained by 
hybridization were quantified using a phosphorimager.
The 28S/18S ratios were normalized based upon the ratio 
observed for the material from cells treated with the control 
siRNA (siLuc). Values are displayed as the mean +/- range 
for mock (n=3), siRpp20 (1) (n=5), siRpp20 (2) (n=2), 
siRpp20 (3) (n=2), siRpp25 (1) (n=5), siRpp25 (2) (n=2) 
and siRpp25 (3) (n=2).
C: Signals of newly synthesized rRNA precursors were 
quantified using a phosphorimager. The 47S/(18S+28S+ 
30S+32S) ratios were normalized based upon the ratio 
observed for the material from cells treated with the control 
siRNA (siLuc). Values are displayed as the mean +/- range 
for mock (n=3), siRpp20 (1) (n = 4), siRpp20 (2) (n=2), 
siRpp20 (3) (n=2), siRpp25 (1) (n=4), siRpp25 (2) (n=2) 
and siRpp25 (3) (n=2).
the canonical processing pathway, a defect in pre-rRNA 
processing, or a combination of these possibilities. The 
ratio of mature 28S/18S tends to be lower for all three 
siRNAs against Rpp25 compared to the control siRNAs 
(Figure 8B). The level of labeled 47S precursor is not 
lower for the cells treated with the three siRNAs for 
Rpp20 or Rpp25. However, the ratio of 47S compared 
to all other precursors tends to be higher for all three 
siRNAs targeting Rpp25 (Figure 8C). This may indeed 
be caused by the defective entry of the 47S pre-rRNA
into the canonical processing pathway.
In contrast to the original siRNA for Rpp25, treatment 
of cells with the new siRNAs did not lead to an altered 
ratio of the 5.8S short and long isoforms (data not 
shown).
Discussion
The subcellular localization of the RNase MRP complex 
is almost exclusively nucleolar. In yeast, two nucleolar 
functions have been identified for RNase MRP. It is re­
quired for the cleavage at the A3 site in the ITS1 and, 
as a consequence, for the formation of the short form 
of the 5.8S rRNA molecule (7, 16). In addition, RNase 
MRP is necessary for the entry of the 35S rRNA precur­
sor (the yeast analog of the human 47S precursor) into 
the canonical processing pathway (12). To elucidate the 
nucleolar function of RNase MRP in human cells, we 
applied siRNA-mediated knockdown to various RNase 
MRP/P protein components.
Knockdown of hPop1, Rpp20, and Rpp40 led to com­
plex instability, and as a consequence to downregula- 
tion of the levels of the RNase MRP and RNase P RNA 
components (Chapter 4). Therefore, targeting of the 
mRNAs encoding these proteins was used to study the 
role of the RNase MRP and/or RNase P complexes in 
pre-rRNA processing. Since siRNA-mediated depletion 
of Rpp25 does not lead to codepletion of the RNA sub­
units, the downregulation of this protein subunit will 
provide information on the role of this protein irrespec­
tive of its association with the RNase MRP/RNase P 
complexes. All three siRNAs against Rpp25 led to re­
duced levels of pre-rRNA processing intermediates. This 
suggests that Rpp25 either is involved in pre-rRNA pro­
cessing independent of its association with the RNase 
MRP and RNase P complexes or that the role of RNase 
MRP/RNase P is critically dependent on Rpp25. Se­
veral observations have suggested that some protein 
components of RNase MRP/RNase P exist also in their 
free, non-complex-associated form, which may be in­
volved in processes not supported by RNase MRP/ 
RNase P. Rpp20, for example interacts with the SMN,
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Hsp27 and N4BP1 (KIAA0615) proteins (17, 18). In 
view of pre-rRNA processing it is interesting to note that 
Rpp20 and Rpp25 were not found to be associated 
with the pre-ribosomal 60-80S fractions obtained by 
glycerol gradient fractionation. These observations sug­
gested that these proteins are either not involved in 
pre-rRNA processing or that they have to dissociate from 
RNase MRP/RNase P during SSU-processome, the early 
processing complex formed on the 47S pre-rRNA, as­
sembly (19). Rpp25 has been reported to be involved 
in RNA polymerase I transcription, because it binds to 
rDNA loci in the S-phase and increases transcription of 
pre-rRNA (9). Therefore, it is likely that Rpp25 has 
RNase MRP/P-independent functions.
Knockdown of Rpp25 with three different siRNAs leads 
to diminished levels of newly synthesized pre-rRNA pro­
cessing intermediates (Figure 8). This indicates that 
either RNA polymerase I transcription is impaired, or 
that the 47S pre-rRNA molecule cannot enter the ca­
nonical processing pathway. Either of these two possi­
bilities would be in accordance with published studies. 
A run-on transcription analysis with siRNA treated cells 
might provide insight in the potential involvement of 
RNase MRP/P in transcription by Pol I.
The results of our RNAi experiments do not provide evi­
dence for a role of the RNase MRP and/or RNase P 
complexes in pre-rRNA processing in human cells. Ho­
wever, this does not completely rule out that human 
RNase MRP is involved in this process, because siRNA- 
mediated knock-down does not completely deplete the 
cell of RNase MRP proteins and RNA present. RNase 
MRP proteins accumulate in the nucleolus and there­
fore a sufficient amount of active complex may remain 
in that compartment to process pre-rRNA efficiently. A 
similar situation has been reported by Ploner and col­
leagues (20), who did not observe a decrease in the 
enzymatic activity of U81 snoRNA (methylation of 
A391 in the 28S rRNA molecule), even though the levels 
of this RNA were diminished by 60%. In this regard it 
is important to mention that pre-rRNA processing did 
not appear to be affected in CHH patient-derived cells
(21). To study the nucleolar function of human RNase 
MRP, its levels might have to be lower than what can 
be achieved with siRNA-mediated knockdown. Ideue 
and collegues observed 90% knockdown of different 
snoRNAs which were targeted with phosphorothioate- 
modified chimeric antisense oligonucleotides (ASOs), 
already at 6 hours after their introduction in the nu­
cleus (22). Future studies have to reveal whether this 
approach will be equally successful for RNase MRP or 
RNase P However, it is possible that these ASOs also 
lead to off-target effects and therefore the effects of 
different ASOs should be compared with each other.
siRNA-mediated knockdown is a popular method to 
downregulate mRNAs in mammalian cells. However, 
several studies are published on off-target effects of 
siRNA and it becomes increasingly clear that siRNAs 
are not the specific tools once thought they were. Not 
only can the interferon response be induced by siRNAs, 
but the expression of other (non-target) genes can be 
downregulated as well. As a result of indirect effects, 
either due to downregulation of the target or of 'off­
targets', the expression of other genes may be up- or 
downregulated, and therefore functional consequences 
have to be interpreted with care. Stable expression of 
shRNAs in mammalian cells has been reported to re­
duce the chance of off-target effects due to the lower 
dsRNA concentrations, although the corresponding 
shRNA vectors might induce an interferon response 
(23). The most widely applied siRNA for EGFP (5'- 
(G)CAAGCUGACCCUGAAGUUC(dTdT)-3' from Ambion, 
Qiagen and Dharmacon has been used in a microarray 
study to globally analyze off-target effects. The expres­
sion levels of 397 genes were significantly altered upon 
transfection of this siEGFP (24). Recently, microarrays 
were performed to monitor the off-target effects of 13 
frequently used control siRNAs in three, two human 
and one mouse, cell lines (25). The cumulative off-tar­
get effects for these siRNAs varied between 4 and 471. 
Taken together, these results indicate that side effects 
are common in siRNA-mediated knockdown experiments 
and that these should be taken into account during the
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interpretation of the data. The use of a number of dis­
tinct siRNAs for the gene of interest to study its bioche­
mical function in intact cells is highly recommended.
Materials and Methods
Cell culture and reagents
HeLa cells were cultured in DMEM + Glutamax supple­
mented with 10% heat-inactivated fetal calf serum 
(FCS) in a humidified 37° C, 5 %  CO2 incubator.
Antibodies
Monoclonal antibodies used: anti-Rpp20 (1 F11, Modi- 
Quest) and anti-y-tubulin (GTU-88, Abcam). Polyclonal 
rabbit sera against hPop1, Rpp25, Rpp38 and Rpp40 
were a kind gift of Sidney Altman.
Immunoblotting
For immunoblot analysis, proteins were separated by 
SDS-PAGE and transferred to nitrocellulose membranes 
by electroblotting. As secondary antibodies, the IRDye 
800CW Goat Anti-Mouse Secondary Antibody (LiCOR 
Biosciences) and IRDye 800CW Goat Anti-Rabbit Se­
condary Antibody (LiCOR Biosciences) were used. Signals 
were visualized by the Odyssey imaging system (LiCOR 
Biosciences).
RNA interference
The siRNAs against Rpp38 was published previously 
(26). The following siRNA duplexes were purchased 
from Eurogentec:
sihPop1 (5'-GAAUUUAACCGUAGACAAAdTdT-3'); 
siRpp20 (1) (5'- CCAUCAACCGCGCCAUCAAdTdT-3'), 
siRpp20 (2) (5'- GGAAUACACCCUUAGGAAAdTdT-3'), 
siRpp20 (3) (5'- GCUCUGAGAUCUACAUUCAdTdT-3'), 
si Rpp2 5 (1) (5'-GUGCGCCGAGAUCCUCAAGdTdT-3'), 
siRpp25 (2) (5'-GCACAUGCGGGUCAAGGAAdTdT-3'), 
siRpp25 (3) (5'- GUCUCAGCGUACUUAAGAAdTdT-3'), 
siRpp40 (5'-CCUUAAACUUGGAUUCUAAdTdT-3'), 
siEGFP (5'-CGAGAAGCGCGAUCACAUGdTdT-3') siLuc 
(5'-CGUACGCGGAAUACUUCGAdTdT-3').
For a typical siRNA experiment in 12-well plates, 5 x 104
HeLa cells were transfected with 10 pmol of siRNA 
using Oligofectamine reagent (Invitrogen) according to 
the manufacturer's instructions with the exception that 
the medium contained 10% FCS during transfection.
Metabolic labeling
HeLa cells were treated with siRNAs in 12-well plates 
as described above. Forty-eight hours post-transfection 
the medium was replaced with 800 pl of phosphate­
free medium containing 10% dialyzed FCS. After incu­
bation at 37 ° C for one hour, 200 pl phosphate-free 
medium containing 10% dialyzed FCS and 20 pCi 32P- 
labeled inorganic phosphate was added and the cells 
were incubated at 37 ° C for one hour. Subsequently, 
the cells were washed with 2 ml regular culture me­
dium containing 10% FCS. After an additional incuba­
tion of 90 minutes at 37 ° C, the cells were washed 
twice with 2 ml regular culture medium. Trizol (Invitro­
gen) was then added and total RNA isolated according 
to manufacturer's instructions.
Isolation of nuclear RNA
HeLa cells were incubated for ten minutes at room tem­
perature in lysis buffer containing digitonin (25 mM 
Tris-HCl, pH 8.0, 150 mM KCl, 1 mM EDTA, 0.5 mM 
PMSF, 1 mM DTT and 0.025% digitonin). Nuclei were 
isolated by centrifugation for eight minutes at 800 g. 
Trizol (Invitrogen) was added to the nuclei and RNA 
was isolated according to manufacturer's instructions.
Northern blot hybridization
For analysis of low molecular weight molecules, 1 pg of 
total nuclear RNA or approximately 2 pg of total 32P- 
labeled RNA was separated on a denaturing 6 %  poly­
acrylamide gel. Electroblotting and crosslinking to a 
Hybond-N membrane were then performed as descri­
bed previously (19).
For analysis of high molecular weight molecules, 1 pg 
of total nuclear RNA or approximately 2 pg of total 
32P-labeled RNA was separated on a 0.8% agarose-for- 
maldehyde gel. The RNA was then transferred and cross­
linked to a Hybond-N membrane.
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The following DNA oligonucleotides were 5'-end labe­
led using T4 polynucleotide kinase in the presence of 
[y-32P]-ATP:
1788-ETS1, 5'-ACCGGTCACGACTCGGCA -3';
18S, 5'- TTTACTTCCTCTAGATAGTCAAGTTCGACC-3'; 
5'-ITS1, 5'-CCT CGCCCT CCGGGCT CCGTTAATT GATC-3'; 
3'-ITS1, 5'- TACGAGGTCGATTTGGCGA-3';
5.8S, 5'-ATCGACGCACGAGCCGAGTGATCCAC-3'; 
5'-ITS2, 5'-CCGGGGCGATTGATCGGCAAGC-3';
28S, 5'-CCCGTTCCCTTGGCTGTGGTTTCGCTAGATA-3'. 
To monitor the levels of U3 snoRNA, U1 snRNA, U8 
snoRNA, RNase MRP RNA and RNase P RNA, antisense 
probes were generated by in vitro transcription in the 
presence of [a-32P]-UTP as described elsewhere (27).
Actinomycin D treatment
HeLa cells were treated with siRNAs in 12-well plates 
as described above. Forty-eight hours post-transfection 
the medium was replaced with 1 ml of medium con­
taining 10% FCS and 40 ng/pl Actinomycin D. After 
incubation at 3 7 °C  for one hour, cells were harvested 
and protein and nuclear RNA analyzed by western and 
northern blotting as described above.
ACKNOWLEDGEMENTS
We thank Sidney Altman (Yale University, New Haven, 
U.S.A.) for providing us with anti-RNase MRP protein 
antibodies and J. van Beers for helpful discussions. This 
work was supported in part by the Netherlands Orga­
nization for Scientific Research (NWO-CW).
References
1. Hadjiolova, K.V., Nicoloso, M., Mazan, S., Hadjiolov, A.A. and 
Bachellerie, J.P. (1993), Alternative pre-rRNA processing pathways 
in human cells and their alteration by cycloheximide inhibition 
of protein synthesis. Eur. J. Biochem.; 212, 211-215.
2. Rouquette, J., Choesmel, V. and Gleizes, PE. (2005), Nuclear ex­
port and cytoplasmic processing of precursors to the 40S ribos- 
omal subunits in mammalian cells. EMBOJ.; 24, 2862-2872.
3. Ridanpaa, M., van Eenennaam, H., Pelin, K., Chadwick, R., 
Johnson, C., Yuan, B., van Venrooij, W., Pruijn, G., Salmela, R., Roc-
kas, S. et al (2001), Mutations in the RNA component of RNase 
MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. 
Cell.; 104, 195-203.
4. Mattijssen, S., Welting, T. and Pruijn, G. (2010), RNase MRP 
and disease. Wiley Interdisciplinary Reviews-RNA; 1, 102-116.
5. Chang, D.D. and Clayton, DA. (1987), A  novel endoribonuclease
cleaves at a priming site of mouse mitochondrial DNA replication. 
EMBO J.; 6, 409-417
6. Chang, D.D. and Clayton, D.A. (1987), A  mammalian mito­
chondrial RNA processing activity contains nucleus-encoded RNA. 
Science.; 235, 1178-1184.
7. Lygerou, Z., Allmang, C., Tollervey, D. and Seraphin, B. (1996), 
Accurate processing of a eukaryotic precursor ribosomal RNA by 
ribonuclease MRP in vitro. Science.; 272, 268-270.
8. Robertson, H.D., Altman, S. and Smith, J.D. (1972), Purification 
and properties of a specific Escherichia coli ribonuclease which 
cleaves a tyrosine transfer ribonucleic acid presursor. J. Biol. Chem.; 
247, 5243-5251.
9. Reiner, R., Krasnov-Yoeli, N., Dehtiar, Y. and Jarrous, N. (2008), 
Function and assembly of a chromatin-associated RNase P that is 
required for efficient transcription by RNA polymerase I. PLoS. 
ONE.; 3, e4072.
10. Reiner, R., Ben-Asouli, Y., Krilovetzky, I. and Jarrous, N. (2006),
A  role for the catalytic ribonucleoprotein RNase P in RNA poly­
merase III transcription. Genes Dev.; 20, 1621-1635.
11. Chamberlain, J.R., Pagan, R., Kindelberger, D.W. and Engelke, 
D.R. (1996), An RNase P RNA subunit mutation affects ribosomal 
RNA processing. Nucleic Acids Res.; 24, 3158-3166.
12. Lindahl, L., Bommankanti, A., Li, X., Hayden, L., Jones, A., 
Khan, M., Oni, T. and Zengel, J.M. (2009), RNase MRP is required 
for entry of 35S precursor rRNA into the canonical processing 
pathway. RNA.; 15, 1407-1416.
13. Schilders, G., van Dijk, E. and Pruijn, G.J. (2007), C1D and
hMtr4p associate with the human exosome subunit PM/Scl-100 
and are involved in pre-rRNA processing. Nucleic Acids Res.; 35, 
2564-2572.
14. Granneman, S., Vogelzangs, J., Luhrmann, R., van Venrooij, 
W.J., Pruijn, G.J. and Watkins, N.J. (2004), Role of pre-rRNA base 
pairing and 80S complex formation in subnucleolar localization 
of the U3 snoRNP Mol. Cell Biol.; 24, 8600-8610.
15. Peculis, B.A. and Steitz, J.A. (1993), Disruption of U8 nucleolar 
snRNA inhibits 5.8S and 28S rRNA processing in the Xenopus
91
From a small RNA to a small man
oocyte. Cell.; 73, 1233-1245.
16. Lygerou, Z., Mitchell, P., Petfalski, E., Seraphin, B. and Tollervey, 
D. (1994), The POP1 gene encodes a protein component common 
to the RNase MRP and RNase P ribonucleoproteins. Genes Dev.;
8, 1423-1433.
17. Hua, Y. and Zhou, J. (2004), Rpp20 interacts with SMN and is 
re-distributed into SMN granules in response to stress. Biochem. 
Biophys. Res. Commun.; 314, 268-276.
18. Jiang, T. and Altman, S. (2001) Protein-protein interactions 
with subunits of human nuclear RNase P Proc. Natl. Acad. Sci. 
U.S.A.; 98, 920-925.
19. Welting, T.J., Kikkert, B.J., van Venrooij, W.J. and Pruijn, G.J.
(2006), Differential association of protein subunits with the human 
RNase MRP and RNase P complexes. RNA.; 12, 1373-1382.
20. Ploner, A., Ploner, C., Lukasser, M., Niederegger, H. and Hutten­
hofer, A. (2009), Methodological obstacles in knocking down 
small noncoding RNAs. R N A 15, 1797-1804.
21. Hermanns,P (2005), Cartilage-hair hypoplasia and the RMRP 
gene. PhD Thesis, p.p. 75.
22. Ideue, T., Hino, K., Kitao, S., Yokoi, T. and Hirose, T. (2009),
Efficient oligonucleotide-mediated degradation of nuclear non­
coding RNAs in mammalian cultured cells. RNA.; 15, 1578-1587
23. Bridge, A.J., Pebernard, S., Ducraux, A., Nicoulaz, A.L. and Iggo, 
R. (2003), Induction of an interferon response by RNAi vectors in 
mammalian cells. Nat. Genet; 34, 263-264.
24. Tschuch, C., Schulz, A., Pscherer, A., Werft, W., Benner, A., Hotz- 
Wagenblatt, A., Barrionuevo, L.S., Lichter, P and Mertens, D. (2008), 
Off-target effects of siRNA specific for GFP BMC. Mol. Biol.; 9:60., 
60.
25. Baum, P, Fundel-Clemens, K., Kreuz, S., Kontermann, R.E., 
Weith, A., Mennerich, D. and Rippmann, J.F. (2010), Off-target 
analysis of control siRNA molecules reveals important differences 
in the cytokine profile and inflammation response of human fi­
broblasts. Oligonucleotides.; 20, 17-26.
26. Cohen, A., Reiner, R. and Jarrous, N. (2003), Alterations in the 
intracellular level of a protein subunit of human RNase P affect pro­
cessing of tRNA precursors. Nucleic Acids Res.; 31, 4836-4846.
27. Welting, T.J., van Venrooij, W.J. and Pruijn, G.J. (2004), Mutual 
interactions between subunits of the human RNase MRP ribonu- 
cleoprotein complex. Nucleic Acids Res.; %19;32, 2138-2146.
28. Gerus, M., Bonnart, C., Caizergues-Ferrer, M., Henry, Y. and 
Henras, A.K. (2010), Evolutionarily conserved function of RRP36 
in early cleavages of the pre-rRNA and production of the 40S ri- 
bosomal subunit. Mol. Cell Biol.; 30, 1130-1144.
92
Chapter 6
RNase MRP 
is regulated during 
skeletal development
TIM J.M. WELTING* • SANDY MATTIJSSEN** • MARJOLEIN M.J. CARON* •
DON A.M. SURTEL* • GER J.M. PRUIJN** • LODEWIJK W. VAN RHIJN*
* Department of Orthopaedic Surgery, Maastricht University Medical Center,
P.O. Box 5800, NL-6202 AZ, Maastricht, the Netherlands 
** Department of Biomolecular Chemistry, Nijmegen Center for Molecular Life Sciences.lnstitute for Molecules and Materials, 
Radboud University Nijmegen, PO. Box 9101, NL-6500 HB Nijmegen, the Netherlands

RNase MRP is regulated during skeletal development
TO BE ADDED LATER
95
From a small RNA to a small man
96
RNase MRP is regulated during skeletal development
97
From a small RNA to a small man
98
RNase MRP is regulated during skeletal development
99
From a small RNA to a small man
100
RNase MRP is regulated during skeletal development
101
From a small RNA to a small man
102
RNase MRP is regulated during skeletal development
103
From a small RNA to a small man
104
RNase MRP is regulated during skeletal development
105
From a small RNA to a small man
106
Chapter 7
General discussion

General discussion
The first examples of disease-associated mutations in noncoding RNA (ncRNA) concerned mi­
tochondrial tRNA (mt-tRNA) genes. These mutations have an effect on mitochondrial transla­
tion and as a consequence the expression of multiple subunits of the oxidative phosphorylation 
(OXPHOS) system is affected, which leads to combined OXPHOS system deficiencies. In Chapter 
2, we have identified two new pathogenic mt-tRNA mutations causing combined Complex I, III 
and IV deficiencies. So far, mutations in two nuclear encoded ncRNAs have been reported to 
be associated with inherited diseases. Mutations in the TERC gene, which encodes for the struc­
tural RNA component of telomerase, are the cause of the disease dyskeratosis congenita (DC). 
RMRP gene mutations result in the autosomal recessive inherited disease cartilage-hair hyp­
oplasia (CHH). RMRP encodes for the RNA component of the human RNase MRP complex, an 
endoribonuclease that in addition to the structural RNA component, consists of at least 7 pro­
teins. Some CHH-associated mutations affect the steady-state level of the RNase MRP RNA, 
other mutations might have an effect on the subcellular localization, the catalytic activity or 
the assembly of the ribonucleoprotein complex. In Chapter 3, the results of the first study aimed 
at the molecular mechanism underlying the pathogenesis of CHH are described. A number of 
CHH-associated mutations in the P3 domain of the RNase MRP RNA abrogate the binding of 
Rpp25 and the Rpp20-Rpp25 heterodimer to the RNA and thus interfere with the assembly of 
the complex. Chapters 4 through 6 describe the results of studies to elucidate the functional 
role of human RNase MRP in biochemical and developmental processes. Viperin mRNA was 
found to be a new substrate for human RNase MRP and a disturbance of viperin expression 
may be involved in the pathogenesis of CHH. In addition, RNase MRP components appeared 
to be up- regulated in hypertrophic chondrocytes in the growth plate. The results of experiments 
aimed at the elucidation of the role of RNase MRP and RNase P in pre-rRNA processing demon­
strated that the application of the siRNA-mediated knockdown technology to study the function 
of (ribonucleo)proteins in human cells is prone to off-target effects.
Enzymatic activity of RNase MRP
The first biochemical process in which RNase MRP was 
implicated, and where its name (ribonuclease for Mi­
tochondrial RNA Processing) was derived from, is the 
generation of the mitochondrial RNA primer that is re­
quired for mitochondrial DNA replication. However, the 
involvement of RNase MRP in this process is under de­
bate, because it has been shown that only about 10 
molecules of RNase MRP RNA reside in the mitochondria 
of a single mammalian cell (1 ). Similarly, the amount 
of RNase P RNA molecules in the mitochondria was es­
timated at 33 to 175 molecules per cell. More recently, 
it was shown by Rossmanith and colleagues that mito­
chondrial RNase P consists of 3 proteins without any 
structural RNA component and that these proteins show 
no homology to the nuclear RNase P or MRP proteins 
(2). In addition, they did not find any nuclear RNase P 
or RNase MRP-associated proteins in any of their mi­
tochondrial purifications. This suggests that the con­
clusion of Puranam and Attardi that a small subset of 
the "nuclear" RNase MRP and RNase P is found in the 
mitochondria might be due to a contamination of the
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purified mitochondria with material from other cellular 
compartments. A RNase MRP independent mechanism 
for mitochondrial DNA replication primer synthesis, in 
which primers are formed by sequence-specific tran­
scription, has been proposed based on in vitro experi­
ments (3, 4). More research is needed to elucidate the 
mechanism of mitochondrial DNA replication primer 
generation in vivo and the factors involved.
Because RNase MRP strongly accumulates in the nu­
cleoli, its involvement in pre-rRNA processing was ex­
pected. Yeast RNase MRP cleaves the A3 site in the 
Internal Transcribed Spacer 1 (ITS1), and more recently 
RNase MRP has been shown to be required for entry 
of the pre-rRNA molecule into the canonical ribosomal 
processing pathway (5-7). The involvement of RNase 
MRP in ITS1 cleavage in the human system is supported 
by data published by Thiel and collaborators (8, 9). In 
the studies described in Chapter 5, we have targeted 
several RNase MRP protein components by siRNA- me­
diated knockdown. However, although the siRNAs ap­
peared to be effective in diminishing the levels of the 
corresponding proteins, we did not find consistent and 
reproducible effects on pre-rRNA processing. In addi­
tion to the lack of involvement of RNase MRP and 
RNase P in pre-rRNA processing, a likely explanation for 
these observations is that the remaining amount of ac­
tive complex in the nucleoli is sufficient to support nor­
mal pre-rRNA processing. As an alternative approach 
to obtain evidence for the involvement of the human 
RNase MRP in pre-rRNA processing, we have tried ex­
tensively to set up an in vitro activity assay for human 
RNase MRP by immunoaffinity isolation of the complex 
from cell lysates and incubating this with various parts 
of in vitro transcribed human ITS1 (hITSI). With the 
most 3' half of hITSI we observed the appearance of 
RNA molecules of about 120 nucleotides, but this was 
accompanied by many non-specific reaction products 
(Figure 1). As a consequence of these background pro­
ducts, it appeared to be impossible to determine if this 
was on the 5' or the 3' end of the substrate. Mg2+ was 
essential for the reaction and could not be replaced by 
other divalent ions (Figure 1 B). Although the cleavage
B
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Figure 1: RNase MRP/P cleaves hITSI in vitro
A: HEp-2 cell extracts were subjected to immuno- 
precipitation by immobilized antibodies against the Rpp20 
protein. The resulting precipitates were incubated with 
radiolabeled hITSI fragment 604-1094 (second half of 
h ITSI). The cleavage of pre-tRNA was analyzed as a positive 
control (data not shown). The reaction products were 
analyzed by denaturing gelelectrophoresis. The numbers on 
the left indicate the size of the pre-tRNA, 110 nucleotides, 
and the hITS1 segment, 490 nucleotides. The 100% lane 
contains the radiolabeled RNA that was not incubated with 
the precipitated material.
B: Same assay as in panel A. Mg2+ in the reaction buffer 
was replaced by H2O (-), Ca2+, Mn2+, Rb2+ or Zn2+.
efficiency is low, these data do suggest that RNase MRP 
or RNase P has the capacity to cleave the human ITS1. 
It should be taken into account that the inefficient 
cleavage might at least in part be due to improper fol­
ding of the substrate molecules used in these experi­
ments. Because hITSI has a GC content of 80%, RNA- 
binding proteins are likely important for the overall sta­
bility of the pre-rRNA molecule and for the formation 
of a structural element in the pre-rRNA that is required 
for efficient cleavage by RNase MRP Smaller segments 
of hITS1 were also used as substrates in the in vitro ac­
tivity assay, and although these resulted in less back­
ground products, they were not specifically cleaved by 
RNase MRP or RNase P. Therefore, we were not able to 
map the hITSI cleavage site in more detail. Cohen and 
coworkers used nuclease protection assays with a probe 
that covers the same segment of hITSI that we used 
as a substrate (nucleotides 606-1094 of hITSI) in our 
assay (10). A fragment of approximately 130 nucleoti­
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des was protected and this might be in accordance 
with the cleavage site we identified in vitro, which is 
located either approximately 120 or approximately 370 
nucleotides from the 3' end of hITS1 (Figure 1). Obvi­
ously, more research is needed to determine if and where 
the human RNase MRP cleaves in hITS1.
Yeast RNase MRP cleaves the 5'-UTR of the CLB2 
mRNA, after which XRN1 degrades the messenger and 
the cell can exit mitosis (11). In Chapter 4 we present 
the results of a microarray study in which we knocked 
down hPop1 and Rpp40 in HEp-2 cells. The mRNA 
level of B-cyclin homologs was not upregulated in these 
datasets (Microarray data have been deposited with 
ArrayExpress under accession no. E-TABM-981). Human 
cyclin B1 was even slightly, though significantly down- 
regulated after knockdown of both hPop1 and Rpp40 
(1.6 fold and 1.2 fold, respectively), whereas cyclin B2 
was significantly downregulated 1.2 fold after hPop1 
knockdown. Published data from a transcriptome ana­
lysis of different CHH patient leukocytes showed no 
change in B-cyclin expression (12). Also the analysis of 
fibroblast cell lines derived from CHH patients did not 
show a higher level of human B-cyclin homologs when 
compared to control fibroblasts, some of which were 
derived from their parents (data not shown). Thiel and 
coworkers showed that transient expression of the 
70A>G mutant of RNase MRP RNA in human fibro­
blasts significantly influenced the expression of cyclin 
B2 mRNA (9). Similar experiments with other RNase 
MRP RNA mutants did not affect cyclin B2 mRNA le­
vels. In conclusion, although most of these data argue 
against a role of RNase MRP in the regulation of cyclin 
B2 mRNA levels in human cells, more experimental 
data will be required to clarify whether mRNAs of B- 
cyclin homologs are affected by RNase MRP in human 
cells and whether increased expression of these genes 
caused by an impaired RNase MRP activity is involved 
in CHH.
Our transcriptome study led to the identification of vi­
perin mRNA as a new target for RNase MRP and the 
mapping of two cleavage sites, which are located in 
the coding sequence of the viperin mRNA (Chapter 4).
This is in agreement with increased viperin expression 
in CHH-patient leukocytes. Viperin (virus inhibitory pro­
tein, endoplasmic reticulum-associated, interferon-in- 
ducible) is strongly induced after viral infection and 
has been shown to inhibit viral replication (13-16). In 
addition, viperin is required for the efficient Th2 res­
ponse and T-cell receptor mediated activation of NF- 
k B and AP-1 in mice (17). CHH patients can suffer from 
immune deficiencies, ranging from weakly affected 
cases to severe combined immune deficiency syndrome 
(SCID) (18, 19). Most patients display a defect in cellular 
immunity, but in 35%  of CHH patients humoral immu­
nity is also compromised (20). The deregulated viperin 
expression in CHH patients might be involved in these 
immune deficiencies. Rat viperin is expressed during 
osteoblast differentiation, suggesting a role for viperin 
in the differentiation or proliferation of these bone-for­
ming cells (21). However, such a role does not seem to 
be critical, since viperin knockout mice do not show a 
skeletal phenotype. Currently, it is unknown if altered 
viperin expression in CHH patients is involved in the 
dwarfism phenotype.
Where in the cell does RNase MRP exert its endoribo- 
nucleolytic activity on mRNAs? It is not likely that this 
occurs in the nucleolus, the subcellular compartment 
with the highest concentrations of RNase MRP. RNase 
MRP/P protein components, and possibly their RNA 
components as well, are not very tightly associated 
with nucleolar constituents. Upon actinomycin D tre­
atment or adenovirus infection of HeLa cells, hPop1 
has been reported to translocate from the nucleolus to 
the nucleoplasm (22, 23). In addition, when HEK293 
cells were infected with Influenza A virus (strain A/ 
Udorn/72), several protein components (hPop1, 
hPop5, Rpp14, Rpp20 and Rpp30) leave the nucleolus 
and accumulate in the nucleoplasm (24). These obser­
vations are also interesting in view of the cleavage of 
viperin mRNA. Infection of mammalian cell lines by vi­
ruses generally leads to elevated levels of viperin 
mRNA and protein expression. The translocation of 
RNase MRP to the nucleoplasm and/or cytoplasm
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might subsequently be important to restore normal vi­
perin mRNA and possibly other mRNA levels.
Towards the molecular mechanism 
of CHH development
In Chapter 3, we showed that for a subset of CHH-as- 
sociated mutations in the P3 domain, the binding of 
the Rpp20-Rpp25 heterodimer is diminished or even 
completely abrogated. In addition, for the 40G>A mu­
tation, we have shown by NMR analysis that the se­
condary structure of the P3 apical stem-loop is altered. 
This is likely the cause of the reduced Rpp20-Rpp25 
binding. Upon substitution of 47U by a C, the confor­
mation of the stem-loop was not detectably changed, 
but protein binding was abrogated, which might be ex­
plained by the direct involvement of 47U in protein 
binding. These studies provided the first experimental 
evidence for the consequences of CH H-associated mu­
tations on the integrity of RNase MRP, which are most 
likely directly affecting the enzymatic activity of this 
enzyme. It would be interesting to investigate the ef­
fects of other CHH-associated mutations on protein 
binding. We performed GST pulldown experiments to 
test if CHH-associated mutations in the P12 domain 
disturbed the binding of Rpp38. For the mutations that 
we have tested (146G>C, 146G>A, 152A>G, 154G>U 
and 168G>A) no decrease in in vitro binding affinity 
of Rpp38 was observed (unpublished results).
To study the effect of CHH-associated mutations on 
the catalytic activity, an in vitro activity assay with re­
constituted RNase MRP would be an attractive appro­
ach, because the mutations could be easily introduced 
in the in vitro transcribed RNA subunit used for recon­
stitution of the complex. To reconstitute the complete 
human RNase MRP complex, with an RNA component 
and at least 7 proteins is a challenging task. It would 
be easier to determine the minimal subunit require­
ments for its catalytic activity and reconstitute a 'mini- 
MRP'. For the human RNase P complex, the minimal 
subunit requirements for catalytic activity were deter­
mined by Mann and coworkers (25). They were able to
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Figure 2: Secondary structure of the RNA component 
of human RNase MRP
The various helices are indicated as P1, P2, P3a, P3b, P4,
P8, P9, P10/11, P12 and P19 in accordance with the corres­
ponding domains in related RNAs. The long distance inter­
action that is known as the P4 helix is marked by the line. 
Adapted from Welting et al (41).
reconstitute pre-tRNA cleavage activity by incubating 
the RNA component, Rpp21 and Rpp29 (hPop4). When 
the reconstitution of mini-MRP would be successful, the 
question arises as to what to use as a substrate to 
study its activity. Viperin mRNA is until now the only 
substrate that can be cleaved efficiently in vitro by 
RNase MRP. In view of the heterogeneity of CHH, some 
mutations might affect the cleavage of viperin mRNA, 
whereas the cleavage of other substrates, e.g. the pre- 
rRNA substrate, might be more sensitive to other mu­
tations. It has already been suggested by Thiel and 
coworkers that mutations in the P3 and P4 domains of 
the RNA component affect cyclin B2 mRNA decay and 
in the domains P1, P2, P8, P9, P12 and P19 pre-rRNA 
processing (Figure 2) (9).
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Telomerase consists of two copies each of telomerase- 
associated reverse transcriptase (TERT), dyskerin and a 
structural RNA component, TERC. This ribonucleopro- 
tein complex is responsible for adding telomere repeats 
to the ends of chromosomes. Maida and coworkers 
showed that RNase MRP RNA forms a complex with 
TERT, which is named the TERT-RMRP complex (26). 
TERT-RMRP displays RNA-dependent RNA polymerase 
(RdRP) activity. It produces double-stranded RNAs that 
are processed by Dicer into siRNAs directed against the 
RNase MRP RNA. This process may represent a feed­
back mechanism to control RNase MRP RNA levels. The 
identification of the TERT-RMRP complex raises the 
question whether CHH-associated RMRP mutations so­
mehow interfere with the regulation of RNase MRP le­
vels suggested by Maida and collaborators (26). For 
some CHH-associated mutations RNase MRP RNA le­
vels appeared to be lower than in healthy controls 
(12,27,28). Promoter mutations generally cause silen­
cing of the allele, whereas mutations in the transcribed 
part might cause transcript instability. A reduction of 
RNase MRP RNA levels would lead to lower levels of 
the TERT-RMRP complex. Currently, no data are avai­
lable on the effects of different CHH mutations on the 
in vitro RdRP activity of the TERT-RMRP complex.
Protein components of RNase MRP
Although most of the protein components of RNase 
MRP and RNase P are well characterized, the possibility 
that each of these ribonucleoprotein complexes con­
tains proteins that are exclusively associated with only 
one of them still exists. To identify additional and pos­
sibly unique proteins of either RNase MRP or RNase P 
we have tried to purify these complexes via the ”RNA 
affinity in tandem" purification method developed by 
Hogg and Collins (29). Tagged versions of RNase MRP 
(mutant) and RNase P RNA were generated and ex­
pressed in HEp-2 cells. Unfortunately, the expression 
levels were so low that we were not able to purify the 
tagged RNA with the required yields and levels of pu­
rity. The low expression level might result from the ne­
gative feedback mechanism proposed by Maida and
Figure 3: siRNA targeting of RNase MRP RNA and 
RNase P RNA is not effective
Northern blotting analysis of RNase MRP RNA (MRP),
RNase P RNA (P) and U1 RNA (U1) 48 hours after 
treatment of HEp-2 cells with siRNAs targeting RNase MRP 
RNA or RNase P RNA. Material from mock transfected cells 
and cells transfected with a EGFP siRNA was analysed in 
parallel. The U1 snRNA served as a loading control. The 
siRNAs were ordered from Eurogentec and had the follo­
wing sequences:
siMRP 1 (5'-CGU CAGCU CCCUCUAG U UAdT dT-3'), 
siMRP 2 (5'-GGCUACACACUGAGGACUCdTdT-3'), 
siP 1 (5'-AAGUGAGUUCAAUGGCUGAdTdT-3') and 
siP 2 (5'-GGCCACGAGCTGAGTGCGTdTdT-3').
colleagues (26). However, we were not able to express 
tagged versions of RNase P RNA either. As an alterna­
tive approach, attempts have been initiated to express 
Sl-tagged versions of RNase MRP RNA and RNase P 
RNA in HEK-293 cells. By using these cell lines in sta­
ble isotope labeling by amino acids in cell culture 
(SILAC) mass spectrometry (MS) it may be possible to 
identify proteins that are associated with RNase MRP 
and/or RNase P RNA, even when their expression levels 
are relatively low. The SILAC-MS method has recently 
been applied successfully in vitro by coupling S1 -tagged 
RNA to streptavadin beads and fishing for protein bin­
ding partners in labeled cell extract (30). Human RNase 
MRP and RNase P would be the ideal candidates to in­
vestigate the applicability of this approach in vivo, 
since these complexes are similar in their protein com­
position. It is expected that like for yeast RNase MRP 
and RNase P, several unique protein components exist 
in the human complexes as well.
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Specific knockdown of RNase MRP
The knockdown experiments described in this thesis 
were all aimed at the mRNAs encoding protein com­
ponents of RNase MRP. Because all of these protein 
components are shared with RNase P, the effects ob­
served might be due to interference with the function 
of either of these two complexes. To downregulate 
RNase MRP more specifically, the only option that is 
currently available is to target its unique RNA compo­
nent. Maida and colleagues demonstrated that siRNA- 
mediated knockdown can be applied to diminish RNase 
MRP RNA levels (26). However, we and others (Figure 3 
and P. Hermanns pers. comm.) were unable to achieve 
specific knockdown of RNase MRP or RNase P RNA 
using different siRNAs (including the one that was suc­
cessful in the hands of Maida and colleagues). Why the 
siRNA reported by Maida does not work in the experi­
ments performed in our and other researchers' labora­
tories is unclear. However, it has been published that 
siRNAs are not suitable tools to knock down snoRNAs 
(31), which is not really surprising if we take into ac­
count that these RNAs reside in the nucleoli and not 
in the cytoplasm, where the siRNAs are believed to act. 
A more efficient strategy to downregulate snoRNAs 
was applied by Ideue and collegues (32). They used 
phosphorothioate-modified chimeric antisense oligo­
nucleotides (ASOs) to degrade several snoRNAs and 
other nuclear ncRNAs. By nucleofection, they achieved 
highly efficient downregulation of the target RNA, 
which, for some snoRNAs was more than 9 0 %  six 
hours post nucleofection. This knockdown efficiency 
was enough to affect the function of U7 snRNA and 
HBII295 boxC/D snoRNA (32). Therefore, it would be 
interesting to apply this technique to target RNase 
MRP RNA or RNase P RNA, which may allow a distinc­
tion between the effects of specifically inhibiting either 
snoRNA and therefore might provide interesting op­
portunities to elucidate their functions.
siRNA off-target effects
The use of different negative control siRNAs and alter­
native siRNAs for the same gene demonstrated that
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Figure 4: Caspase-7 mRNA is targeted by siEGFP
Western blotting analysis of caspase-7 48 hours post siRNA 
treatment of HEp-2 cells.
A: Caspase-7 levels after treatment with the siRNAs 
targeting EGFP and several RNase MRP/P subunits. 
y-tubulin was detected as a loading control. The positions 
of caspase-7 and its N-terminally truncated isoform 
(caspase-7-AN) are indicated.
B: Similar experiment as in panel A, but now with two 
additional controls, mock transfected cells and cells treated 
with an siRNA for luciferase (siLuc). y-tubulin was detected 
as a loading control.
off-target effects of siRNAs might be more frequent 
than anticipated at the start of this project. The micro­
array data presented in Chapter 4 show a 2.5-fold and 
2.1-fold increase of caspase-7 mRNA after knockdown 
of hPop1 or Rpp40, compared to a control knockdown 
(siEGFP), respectively. Upon induction of apoptosis, pro- 
caspase-7 (35 kDa) is first converted to a 32 kDa in­
termediate (caspase-7-AN), which is further processed 
into the active enzyme consisting of 20 kDa and 11 
kDa subunits (33). We confirmed the upregulation of 
pro-caspase-7 and caspase-7-AN by western blotting 
(Figure 4A). However, when we compared the effects 
of the EGFP control siRNA with those of another con­
trol siRNA (luciferase) and with mock-treated cells, it 
became clear that the siRNA for EGFP was actually 
downregulating caspase-7 as an off-target effect (Fi­
gure 4B). A microarray study that was aimed at the 
identification of the off-target effects of the most wi­
dely used siRNA against EGFP (5'-CAAGCUGACCCU
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GAAGUUCdTdT-3' from Ambion and Qiagen; the Dhar- 
macon control siRNA differs only one nucleotide, 5'- 
GCAAGCUGACCCUGAAGUUC-3'), found 397 genes 
that were differentially expressed upon treatment with 
siEGFP (34). About 50 %  of these genes were downre- 
gulated and the other genes appeared to be upregu- 
lated, which is most likely due to indirect secondary 
effects of the siRNA transfection. Caspase-7 was upre- 
gulated by this siRNA, in contrast to the downregula- 
tion we observed after transfection of our siRNA. In a 
recent microarray screen, 13 distinct, frequently used 
control siRNAs were tested for off-target effects in two 
human and one mouse cell line (35). After transfection 
with the siRNA 'siControl RISC-free siRNA #1' (Dhar- 
macon, Cat no. D-001220-01-20) only four genes were 
differentially expressed compared to untransfected 
cells. However, transfection with other control siRNAs
gave up to 252 differentially expressed genes in the 
HT1080 cell line. Taking these observations into ac­
count, it does not seem to be surprising to find an off­
target mRNA for the si EGFP (5'-CGAGAAGCGCGAU 
CACAUGdTdT-3') used in our studies.
Prior to the microarray study described in Chapter 4, 
we performed another microarray analysis using mate­
rial from HEp-2 cells treated with another siRNA for 
hPopl than the siRNA that was used in Chapter 4 (5'- 
GCACGAGCUGCUGAAAUCAdTdT-3') and material 
from mock transfected HEp-2 cells. The genes that were 
more than 3 fold up- or downregulated are shown in 
Table 1. The human papilloma virus (HPV) E1, E6 and 
E7 mRNAs were more than 3 fold downregulated upon 
hPopl knockdown. HEp-2 cells contain about 50 co­
pies of HPV-18 DNA stably integrated in their genome
Table 1A: 3-fold or more upregulated transcripts after siRNA-mediated knock-down of hPopl in HEp-2 cells 
compared to mock transfected cells.
Gene symbol Description Fold change* GO-term biological process**
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, C ipl) 8.7 regulation of cyclin-dependent protein 
kinase activity
GDF15 Growth/differentiation factor 15 8.4 transforming growth factor beta 
receptor signaling pathway
GADD45A Growth arrest and DNA-damage-inducible 
protein GADD45 alpha
6.3 regulation of cyclin-dependent protein 
kinase activity
TXNIP Thioredoxin-interacting protein 4.9 cell cycle
FAM129A Niban protein 4.6 regulation of protein amino acid 
phosphorylation /  response to stress
BLVRB biliverdin reductase B (flavin reductase (NADPH) 4.0 regulation of nitrogen utilization /
heme catabolic process
E2F7 E2F transcription factor 7 3.7 regulation of transcription, 
DNA-dependent /  cell cycle
C6orf48 Protein G8 3.5 ?
BRF2 subunit of RNA polymerase III transcription 
initiation factor, BRFl-like
3.2 transcription initiation
TSC22D3 TSC22 domain family protein 3 3.2 regulation of transcription
ECM2 Extracellular matrix protein 2 3.0 cell-matrix adhesion
* Only genes more than 3-fold up-regulated by both the hPopl and Rpp40 knock-downs are shown. 
** GO-terms listed are from the Gene Onthology Consortium (40)
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Table 1B: 3-fold or more downregulated transcripts after siRNA-mediated knock-down of hPopl in HEp-2 cells 
compared to mock transfected cells.
Gene symbol Description Fold change* GO-term biological process**
MRPL2 mitochondrial ribosomal protein L2 -5.6 translation
HPVE1 Human Papilloma Virus protein El -5.5
GLO1 glyoxalase I -4.0 carbohydrate metabolic process
BCAT1 branched chain aminotransferase 1, cytosolic -3.9 G1/S transition of mitotic cell cycle
CCNB1 Cyclin B1 -3.8 G2/M transition of mitotic cell cycle
HPVE6 Human Papilloma Virus protein E6 -3.5
PPT1 palmitoyl-protein thioesterase 1 -3.5 protein depalmitoylation /  DNA 
fragmentation involved in apoptosis
GTF3C6 general transcription factor IIIC, polypeptide 6, 
alpha 35kDa
-3.4 transcription, DNA-dependent
HNRNPR heterogeneous nuclear ribonucleoprotein R -3.3 mRNA processing
HPVE7 Human Papilloma Virus protein E7 -3.3
ACAA2 acetyl-Coenzyme A  acyltransferase 2 -3.2 lipid metabolic process
NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4, 9kDa
-3.1 mitochondrial electron transport, 
NADH to ubiquinone
PAK1IP1 PAK1 interacting protein 1 -3.1 negative regulation of signal 
transduction
RAD21 RAD21 homolog (S. pombe) -3.1 double-strand break repair
RPL7L1 ribosomal protein L7-like 1 -3.1 translation
HSPE1 heat shock 10kDa protein 1 (chaperonin 10) -3.1 activation of caspase activity
CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 -3.0 protein complex assembly
S100P S100 calcium binding protein P -3.0 endothelial cell migration
ZMPSTE24 zinc metallopeptidase (STE24 homolog, S. cerevisiae) -3.0 proteolysis
CNBP CCHC-type zinc finger, nucleic acid binding protein -3.0 regulation of transcription, 
DNA-dependent
EID1 EP300 interacting inhibitor of differentiation 1 -3.0 cell cycle
* Only genes more than 3-fold down-regulated by both the hPopl and Rpp40 knock-downs are shown.
** GO-terms listed are from the Gene Onthology Consortium (40)
and express several HPV-18 encoded proteins. The E6 
protein binds to and promotes degradation of the 
tumor-suppressor protein p53. The E7 protein in turn 
binds to the active, hypophosphorylated form of the re­
tinoblastoma tumor-suppressor protein pRB. Together, 
the E6 and E7 proteins prevent the cell from apoptosis 
and cell cycle arrest. When the E6 and E7 proteins were 
downregulated after the sihPopl transfection, the p53 
level increased dramatically and the cells were arrested 
in the G1 phase (Figure 5A and data not shown). Im­
portantly, p53 did not appear to be upregulated after 
knockdown of Rpp20, Rpp25 or Rpp38. Therefore, ano­
ther siRNA for hPopl mRNA (5'-GAAUUUAACCGUA- 
GACAAAdTdT-3') was used to further investigate this 
phenomenon. The new sihPopl was comparable to the 
old sihPopl in its ability to downregulate the hPopl 
protein, but we did not observe a detectable increase 
in the p53 protein (Figure 5B). These results left us to 
conclude that the downregulation of the HPV-18 mRNAs 
is an off-target effect of the old siRNA for hPopl.
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Figure 5: Off-target effects of one of the siRNAs 
targeting hPopI
A: Western blotting analysis of p53, 48 hours post 
treatment of HEp-2 cells with siRNAs as indicated. y-tubulin 
was detected as a loading control.
B: The effects of two distinct siRNAs for hPopl on p53 and 
hPopl expression, monitored by western blotting. y-tubulin 
was detected as a loading control.
In Chapter 5, we used three different siRNAs against 
Rpp20 and Rpp25. Treatment of cells with the first 
siRNA for each of these proteins resulted in marked ef­
fects on pre-rRNA processing. However, these effects 
were not observed with the other siRNAs, although 
they were able to downregulate their protein targets 
with similar efficiencies. These results clearly indicated 
that care should be taken when using only one siRNA 
to study the effect of protein depletion. Even when the 
effect that is observed fits with the hypothesis, addi­
tional siRNAs have to be used to confirm these obser­
vations. A study that bases its conclusions on the 
results obtained with only one siRNA for the protein of 
interest has to be read with a critical view. At least two 
siRNAs that downregulate the corresponding protein 
have to be compared to a control siRNA and mock 
transfected cells. Since the control siRNAs also have 
multiple off-target effects, these should be chosen ca­
refully (for the process studied, they should not give 
different results than the mock transfection). Another
option would be to transfect cells with a pool of siRNAs 
directed against a single mRNA, the idea behind this 
is that the concentration of each siRNA is lower, which 
will result in less off-target effects, since the cumulative 
effect of the specific downregulation of the target is 
larger than that of the off-target for each siRNA. For a 
transcriptome analysis by microarrays, a good strategy 
would be to include at least two negative controls 
(mock transfection and a (pool of) negative control 
siRNA(s)) and compare this with a pool of siRNAs di­
rected against the mRNA encoding the protein of in­
terest. A rescue experiment, in which the siRNA is 
co-transfected with a vector encoding the protein of in­
terest, containing silent mutations in the siRNA target 
sequence, seems to be a good approach to determine 
if the observed phenotype is specific for the depletion 
of that particular protein. When a complex like RNase 
MRP or RNase P is downregulated, it is advisable to per­
form knockdown of multiple subunits and compare the 
results, as is for example described in Chapter 4. If the 
same phenotype is observed, it is unlikely that it is an 
off-target effect.
Concluding remarks and future perspectives
RNase MRP is an intriguing enzyme, not only from a 
functional point of view, but also in the light of its in­
volvement in autoimmunity and cartilage-hair hypo­
plasia. The question why tolerance to RNase MRP is 
broken in certain autoimmune diseases remains unans­
wered. Also more research is needed to understand why 
this complex is targeted by the immune system in cer­
tain diseases, but not in others, and why this response 
is seen in only a subset of such patients. In case of CHH 
it seems clear that the mutations in the RMRP gene 
lead to an impaired RNase MRP function, which is the 
causative factor of the disease. One of the basic ques­
tions is how the impaired RNase MRP activity leads to 
the phenotypes observed. To understand the pathophy­
siological role of RNase MRP in CHH in more detail 
more work needs to be done. More insight in the variety 
of RNase MRP substrates and the biochemical proces­
ses it is involved in may provide new clues. Although
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impaired cell proliferation has been proposed as a ge­
neral phenomenon in CHH patients (11, 36, 37), there 
are some issues that should be considered in this res­
pect. As cell proliferation is directly or indirectly affec­
ted by mitochondrial DNA replication, pre-5.8S rRNA 
processing, the regulation of specific mRNAs and the 
function of the TERT-RMRP complex, it is difficult to 
define the relative contribution of these separate func­
tions in a specific cell type or tissue. We therefore hy­
pothesize that the effect of RNase MRP RNA mutations 
on cellular and developmental processes depends on 
two individual determinants.
1) The position of the mutation in the RMRP gene and 
transcript. This may determine in which way (expression 
level, structural integrity of the complex, subcellular lo­
calization, substrate selection, catalysis etc.) the muta­
tion interferes with a (specific) RNase MRP-dependent 
process.
2) The cell type. The requirement for distinct functional 
activities of RNase MRP and the efficiency by which 
different RNase MRP substrates need to be converted 
will differ from cell to cell and from tissue to tissue. 
Therefore, the effect of impaired RNase MRP function 
is likely to depend in part on the cellular context.
With regard to the most pronounced characteristic fea­
ture of CHH, metaphyseal chondrodysplasia, clues have 
been obtained for the involvement of endochondral ossi­
fication. In Chapter 6, we have shown that there exists 
a correlation between chondrocyte hypertrophy and 
increased expression of RNase MRP. Hermanns and col­
leagues showed that RNase MRP RNA is highly expres­
sed in the mouse growth plate (12) and one of the 
radiological features of CHH is abnormal growth plate 
development (38). Highly proliferating chondrocytes in 
the growth plate produce vast amounts of collagens 
and other extracellular matrix components (39). In the 
growth plates of CHH patients, the high demand of 
housekeeping molecules enabling the enormous trans­
lational, metabolic and proliferative activity might be
impaired by defective mitochondrion synthesis, reduced 
ribosome synthesis or suboptimal cell division. Challen­
ging this highly demanding developmental process 
would unavoidably lead to developmental defects such 
as impaired skeletogenesis. The haematological and 
spermatogenesis defects in CHH patients might origi­
nate from a similar tissue specific effect.
Many of these questions might be addressed after the 
generation of a CHH mouse model. Early attempts to 
generate an RMRP knockout mouse have failed, most 
likely because of embryonic lethality (E. Nakashima, 
personal communication; P. Hermanns personal com­
munication). This is also consistent with the absence 
of a combination of two promoter mutation alleles in 
CHH patients, which suggests that the lack of RNase 
MRP RNA expression is lethal. It is feasible that more 
subtle approaches, such as the generation of mice con­
taining the equivalent of a CHH-associated mutation 
instead of the wild-type gene or conditional knock-out 
mice might be more successful. When a ”CHH mouse" 
becomes available, growth plate development and the 
distribution of RNase MRP subunits in such tissues can 
be assessed by (immuno-)histochemistry. Mouse bone 
marrow stromal cells can be isolated from mutant and 
control mice and chondrogenesis and hypertrophic dif­
ferentiation can be monitored. In addition, cell lines 
can be generated from such mice to further explore the 
effects of the mutations on the biochemical processes 
mediated by RNase MRP
As discussed above, the specific targeting of RNase 
MRP in a cell culture system may also provide an at­
tractive strategy to investigate the different processes 
it is involved in. Finally, the biochemical purification of 
RNase MRP from different cell types, including CHH- 
derived cells, followed by the in vitro analysis of its ac­
tivities may yield valuable information about the pro­
cesses it mediates and the effects of RMRP mutations.
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From a small RNA to a small man
Summary
The human RNase MRP complex consists of a structural 
RNA and at least 7 protein components. It displays en- 
doribonucleolytic activity and is able to cleave mito­
chondrial RNAs, ribosomal RNAs and mRNAs in a 
highly specific fashion. The complex is evolutionary re­
lated to the RNase P complex, and shares all protein 
components with this endoribonuclease, which cleaves 
the 5'-leader of pre-tRNAs. Mutations in the RMRP gene 
that encodes the RNA component of RNase MRP are 
the cause of the autosomal recessive inherited disease 
cartilage-hair hypoplasia (CHH, also called McKusick- 
type metaphyseal chondrodysplasia). This was the first 
example of a disease that was caused by mutations in 
a nuclear encoded, noncoding RNA (ncRNA). CHH is 
characterized by short-limbed dwarfism, hypoplastic 
hair and defective immunity (adult height ranges from 
80 cm-149 cm). Before the identification of disease- 
associated mutations in nuclear encoded ncRNAs, mu­
tations in mitochondrial tRNA genes (mt-tRNAs) were 
identified as the cause of combined oxidative phospho­
rylation (OXPHOS) system deficiencies, resulting in se­
veral heterogeneous, primarily neuromuscular disorders. 
In CHAPTER 1, a general overview of the current know­
ledge about the relationship between mutations in 
ncRNAs and disease is given, with a strong emphasis 
on RNase MRP and CHH.
CHAPTER 2 reports on the identification of two new 
pathogenic mt-tRNA nucleotide substitutions, contri­
buting to the expanding number of disease-associated 
mt-tRNA mutations. These were discovered in two un­
related patients displaying combined complex I, III and 
IV deficiencies, and the affected genes encode tRNATrp 
(MT-TW, m.5556G>A) and tRNAAl9 (MT-TR, m.10450A>G). 
The corresponding patients both suffered from progres­
sive multisystemic diseases. We have shown that the 
mutations are pathogenic, they cause a structural al­
teration and a decrease in the steady-state levels of 
the corresponding mt-tRNAs, both in patient fibro­
blasts and in cybrid cell lines. The mitochondrial trans­
lation was defective in patient fibroblasts and the OX­
PHOS complex assembly appeared to be impaired both 
in patient fibroblasts and in cybrid cell lines.
Rpp20 and Rpp25 bind to the P3 domain of RNase 
MRP RNA and RNase P RNA. This domain is highly con­
served among these two RNAs and between species. 
Several CHH-associated mutations have been identi­
fied in the P3 domain. The effect of these and other 
nucleotide substitutions on the binding of Rpp25 and 
the Rpp20-Rpp25 heterodimer to this domain were 
studied in the experiments described in CHAPTER 3. 
The results provided the first evidence for the molecular 
mechanism by which CHH-associated mutations alter 
the function of RNase MRP. For several mutations we 
observed a decrease in binding of Rpp25 and the 
Rpp20-Rpp25 heterodimer to the P3 domain. The 
CHH-associated 40G>A substitution completely abo­
lished the binding of these proteins. To obtain infor­
mation on the consequences of this mutation on the 
secondary and tertiary structure of the apical stem loop 
of the P3 domain this region was analyzed by nuclear 
magnetic resonance (NMR). The NMR data indicated 
that the secondary structure of the P3 domain is alte­
red as a result of the 40G>A substitution. We propose 
that this structural alteration is the cause of the abro­
gated binding of Rpp25 and the Rpp20-Rpp25 hete­
rodimer to the P3 domain.
Yeast RNase MRP is able to cleave the mRNA of cyclin 
B2. For the human complex, no direct evidence existed 
that it acts on mRNA substrates. In CHAPTER 4, results 
are presented of a transcriptome analysis performed to 
identify mRNA targets of human RNase MRP or RNase 
P. Rpp40 or hPop1 was downregulated in HEp-2 cells 
by siRNA-mediated knockdown to interfere with the 
activity of RNase MRP (and RNase P). Because of the 
endoribonucleolytic activity of RNase MRP and RNase 
P, target mRNAs were expected to be upregulated upon
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reducing the activity of these enzymes. Viperin was 
amongst the most highly upregulated genes. The upre- 
gulation of viperin after knockdown of hPopl, Rpp20, 
Rpp25 and Rpp40 was confirmed, both at the mRNA 
and protein levels, by qPCR and western blotting. In 
vitro activity assays demonstrated that the viperin mRNA 
is directly cleaved by RNase MRP/RNase P at two sites 
in the coding sequence. The experimental approach did 
not allow a distinction between RNase MRP and RNase 
P, although based on CHH patient data viperin mRNA 
is predicted to be a substrate of RNase MRP 
In yeast, extensive evidence indicates that RNase MRP 
is the endoribonuclease responsible for the cleavage at 
the A3 site in the ITS1 of pre-rRNA and, as a conse­
quence, for the maturation of the short form of 5.8S 
rRNA. More importantly, yeast RNase MRP is required 
for the entry of the pre-rRNA transcript into the cano­
nical processing pathway. We set out to investigate 
whether these functions of RNase MRP are conserved 
in man. To this end, we downregulated various human 
RNase MRP and RNase P protein components and mo­
nitored the effects on rRNA processing, the results of 
which are presented in CHAPTER 5. After knockdown 
of Rpp20, 18S rRNA maturation was impaired, whereas 
downregulation of Rpp25 resulted in diminished 28S 
rRNA maturation. However, these results could not be 
confirmed by using two additional siRNAs targeting 
the mRNAs for each of these proteins. Although the al­
ternative siRNAs were effective in downregulating the 
corresponding proteins, no effects on pre-rRNA proces­
sing was observed. These results suggest that the ef­
fects on pre-rRNA processing of the first siRNAs for 
Rpp20 and Rpp25 are most likely due to off-target ef­
fects of the siRNAs. In view of the relatively mild de­
pletion of RNase MRP and RNase P by siRNA-mediated 
knockdown, other experimental approaches that lead 
to more efficient repression of RNase MRP and RNase 
P activities will be necessary to study the role of RNase 
MRP and RNase P in ribosomal RNA maturation in the 
nucleolus.
RNase MRP is likely involved in skeletal development, 
since CHH patients display a short-limbed dwarfism 
phenotype. Growth plate activity determines longitu­
dinal bone growth during development, including 
lengthening of the limbs. Our hypothesis therefore is 
that RNase MRP critically determines growth plate de­
velopment. In CHAPTER 6, we present data showing 
that RNase MRP subunit expression is regulated during 
chondrogenesis and is especially associated with hy­
pertrophic chondrocyte differentiation in the growth 
plate. For the first time, these data demonstrate the as­
sociation of RNase MRP with skeletal development and 
provide a starting point for studying the molecular me­
chanism leading to the CHH-associated skeletal phe­
notype.
In CHAPTER 7, the results presented in this thesis are 
discussed and additional preliminary data is provided. 
Furthermore, suggestions are given on how to study 
human RNase MRP and human RNase P in the future.
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Samenvatting
Het menselijke RNase MRP complex bestaat uit een 
structureel RNA en tenminste 7 eiwitcomponenten. Het 
heeft endoribonucleolytische activiteit en is in staat om 
mitochondriële RNAs, ribosomale RNAs en mRNAs te 
klieven op een zeer specifieke manier. Het complex is 
evolutionair gerelateerd aan het RNase P complex en 
deelt alle eiwitcomponenten met dit endoribonuclease 
dat het 5'-einde van pre-tRNAs eraf klieft. Mutaties in 
het RMRP gen, dat codeert voor de RNA component 
van RNase MRP zijn de oorzaak van de autosomaal re- 
cessief overervende ziekte cartilage-hair hypoplasie 
(CHH, ook wel McKusick-type metaphyseal chondro­
dysplasia genoemd). Dit was het eerste voorbeeld van 
een ziekte die veroorzaakt wordt door mutaties in een 
nucleair, niet coderend RNA (ncRNA). CHH is gekarak­
teriseerd door korte-ledematen dwerggroei, hypoplas­
tisch haar en een defecte immuniteit (volwassen lengte 
tussen de 80 cm en 149 cm). Voor de identificatie van 
ziekte-geassocieerde mutaties in nucleair gecodeerde 
ncRNAs, waren mutaties in mitochondriële tRNAs (mt- 
tRNAs) geïdentificeerd als de oorzaak van gecombi­
neerde oxidatieve fosforylering (OXPHOS) systeem 
deficiënties, resulterend in verscheidene heterogene, 
voornamelijk neuromusculaire aandoeningen. In 
HOOFDSTUK 1, is een algemeen overzicht gegeven van 
de huidige kennis over de relatie tussen mutaties in 
ncRNA en ziekte, met een sterke nadruk op RNase MRP 
en CHH.
HOOFDSTUK 2 rapporteert over de identificatie van 
twee nieuwe pathogene mt-tRNA nucleotide substitu­
ties, bijdragende aan het expanderende aantal van 
ziekte-geassocieerde mt-tRNA mutaties. Deze zijn ont­
dekt in twee ongerelateerde patiënten met gecombi­
neerde complex I, III en IV deficiëntie in de genen tRNATrp 
(MT-TW, m.5556G>A) en tRNAArg (MT-TR, m.10450A>G). 
De patiënten leden beiden aan progressieve multisys­
temische ziekten. We hebben aangetoond dat de mu­
taties pathogeen zijn, ze veroorzaken een structurele
verandering en een vermindering in het steady-state 
niveau van de corresponderende mt-tRNAs, zowel in 
patiënt fibroblasten als in cybride cellijnen. De mito­
chondriële translatie was defect in patiënt fibroblasten 
en de OXPHOS complex assemblage was verminderd 
zowel in patiënt fibroblasten als in cybride cellijnen. 
Rpp20 en Rpp25 binden aan het P3 domein van RNase 
MRP RNA en RNase P RNA. Dit domein is sterk gecon­
serveerd tussen deze twee RNAs en tussen soorten. Ver­
schillende CHH-geassocieerde mutaties zijn geïdenti­
ficeerd in het P3 domein. Het effect van deze en andere 
nucleotide substituties op de binding van Rpp25 en de 
Rpp20-Rpp25 heterodimeer aan dit domein zijn bestu­
deerd in de experimenten die zijn beschreven in HOOFD- 
STUK3. De resultaten leveren het eerste bewijs voor het 
moleculaire mechanisme waarmee CHH-geassocieerde 
mutaties de functie van RNase MRP veranderen. Voor 
verschillende mutaties zagen we een afname in de bin­
ding van Rpp25 en de Rpp20-Rpp25 heterodimeer aan 
het P3 domein. De CHH-geassocieerde 40G>A substi­
tutie verstoorde de binding van deze eiwitten compleet. 
Om informatie te verkrijgen over de consequenties van 
deze mutatie voor de secundaire en tertiaire structuur 
van de apical stem loop van het P3 domein, werd dit 
stuk geanalyseerd met nuclaire magnetische resonan­
tie (NMR). De NMR data geeft aan dat de secundaire 
structuur van het P3 domein veranderd wordt als resul­
taat van de 40G>A substitutie. Wij stellen voor dat deze 
structurele verandering de oorzaak is van de verstoorde 
binding van Rpp25 en de Rpp20-Rpp25 heterodimeer 
aan het P3 domein.
Gist RNase MRP is in staat om het mRNA van cycline 
B2 te klieven. Voor het menselijke complex, bestond er 
geen direct bewijs dat het mRNA substraten heeft. In 
HOOFSTUK 4, worden resultaten gepresenteerd van 
een transcriptome analyse die werd uitgevoerd om 
mRNA doelwitten van menselijk RNase MRP of RNase 
P te identificeren. Rpp40 of hPopl werd down geregu­
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leerd in HEp-2 cellen door middel van siRNA gemedi- 
eerde knockdown om te interfereren met de activiteit 
van RNase MRP (en RNase P). Vanwege de endoribo- 
nucleolytische activiteit van RNase MRP en RNase P, 
werd verwacht dat doelwit mRNAs upgereguleerd zou­
den zijn nadat de activiteit van deze enzymen was ver­
minderd. Viperin was een van de meest up gereguleerde 
genen. De toename van viperin na knockdown van 
hPopl, Rpp20, Rpp25 en Rpp40 werd bevestigd, zowel 
op het mRNA als op het eiwit niveau, door middel van 
qPCR en western blot. In vitro activiteit assays lieten 
zien dat het viperin mRNA direct gekliefd wordt op 
twee plekken in de coderende sequentie. Met de expe­
rimentele aanpak kon geen onderscheid gemaakt wor­
den tussen RNase MRP en RNase P, hoewel gebaseerd 
op CHH patiënten data, de voorspelling is dat viperin 
mRNA een substraat van RNase MRP is.
In gist is er omvangrijk bewijs dat aangeeft dat RNase 
MRP de endoribonuclease is die verantwoordelijk is 
voor de klieving van de A3 site in het ITS1 van pre- 
rRNA en, als consequentie, de rijping van de korte vorm 
van 5.8S rRNA. Nog belangrijker, gist RNase MRP is 
noodzakelijk voor de toegang van het pre-rRNA tran­
script tot het canonieke bewerkingspad. We zijn gaan 
onderzoeken of deze functies van RNase MRP in de 
mens geconserveerd zijn. Hiervoor hebben we verschil­
lende menselijke RNase MRP en RNase P eiwitcompo- 
nenten down gereguleerd en de effecten hiervan op 
rRNA processing bekeken, de resultaten hiervan zijn ge­
presenteerd in HOOFDSTUK 5. Na knockdown van 
Rpp20, is de 18S rRNA rijping verstoord, terwijl down- 
regulatie van Rpp25 tot een verminderde 28S rRNA rij­
ping lijdt. Echter konden deze resultaten niet bevestigd 
worden door het gebruik van twee additionele siRNAs 
met als doelwit de mRNAs van deze eiwitten. Ook al
waren de alternatieve siRNAs effectief in het downre- 
guleren van de corresponderende eiwitten, er werd 
geen effect op pre-rRNA bewerking geobserveed. Deze 
resultaten suggereren dat de effecten op pre-rRNA pro­
cessing van de eerste siRNAs voor Rpp20 en Rpp25 
waarschijnlijk te wijten zijn aan off-target effecten van 
de siRNAs. Met het oog op de relatief milde depletie 
van RNase MRP en RNase P door siRNA gemedieerde 
knockdown, zullen andere experimentele aanpakken 
nodig zijn die tot een efficiëntere repressie van de ac­
tiviteiten van RNase MRP en RNase P leiden om de rol 
van RNase MRP en RNase P in ribosomaal RNA rijping 
in de nucleolus te bestuderen.
RNase MRP is vermoedelijk betrokken bij skelet ontwik­
keling, omdat CHH patiënten een dwerggroei met 
korte ledematen fenotype hebben. Groeiplaat activiteit 
bepaald de longitudinale botgroei tijdens de ontwik­
keling, inclusief het verlengen van de ledematen. Onze 
hypothese is daarom dat RNase MRP doorslaggevend 
is voor de bepaling van de groeiplaat ontwikkeling. In 
HOOFDSTUK 6 presenteren we data die laten zien dat 
RNase MRP subunit expressie gereguleerd is tijdens 
chondrogenese en in het bijzonder is geassocieerd met 
hypertrofe chondrocyten differentiatie in de groeiplaat. 
Onze data laten voor het eerst een betrokkenheid zien 
van RNase MRP bij skelet ontwikkeling en geven een 
uitgangspunt voor het bestuderen van het moleculaire 
mechanisme dat leidt tot het CHH-geassocieerde ske- 
letaire fenotype.
In HOOFDSTUK 7, worden de resultaten uit dit proef­
schrift bediscussieerd en additionele preliminaire data 
gegeven. Tevens worden suggesties gedaan over het 
hoe te bestuderen van menselijk RNase MRP en RNase 
P in de toekomst.
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stand komen van dit proefschrift hebben veel mensen 
meegewerkt. Een aantal wil ik in het bijzonder be­
danken.
Als eerste wil ik mijn promotor, Prof. Ger Pruijn noemen. 
Ik heb ontzettend veel van jou geleerd! Zonder jou was 
het niet mogelijk geweest dat ik nu naar de NIH vertrek 
in de VS. Wat heb jij ongelofelijk veel uren gestopt in 
het nakijken van mijn hersenspinsels en het polijsten 
van mijn (soms) kromme zinnen. Zelfs tijdens je welver­
diende vakantie kreeg ik op mijn verjaardag onder het 
mom van 'verjaardagscadeautje' een nagekeken hoofd­
stuk doorgemaild. En dan is mijn promotie ook nog 
eens op jouw verjaardag! Van harte gefeliciteerd en ik 
hoop dat je met een goed gevoel kunt terugkijken op 
mijn verdediging.
Tim, ontzettend bedankt voor je enthousiaste begelei­
ding in mijn eerste maanden als AiO. Hierdoor werd ik 
ook meteen gek op MRP, al zou die liefde soms op de 
proef gesteld worden in de daaropvolgende jaren. In 
het begin hadden we ook nog een echt MRP-U-tje, waar­
in we samen het 'apply suction!'-experiment deden. 
Nadat je vertrok om aan botten te werken, hebben we 
contact gehouden. Samen zijn we naar Freiburg ver­
trokken ('Oh, not the curtains!'), om te gaan samen­
werken met Pia, Kerstin en Bernhard. Ik hoop dat er 
snel een klein, kaal muisje zal komen waarmee je proef­
jes kunt doen. Nu ga ik het MRP-veld verlaten, maar 
wie weet ga ik (net als jij) via een zijweg weer onder­
zoek doen aan CHH!
Lieve Joyce, U-wie en paranimf. Weet je nog dat we ons 
afvroegen in het begin of we ooit ook zoveel zouden 
weten als de oudere AiOs. Maar kijk nu, mijn proef­
schrift is af en dat van jou zal snel volgen, en iedereen 
komt nu naar ons voor advies! Het is ons mooi gelukt... 
haha. Het laatste stuk van onze promotie hebben we 
samen in de U doorgebracht, veel gelachen, geklapt,
128
From a small RNA to a small man
gepipetteerd en andere labbewoners geïrriteerd met 
ons valse gezang. Ik zal je echt gaan missen in de VS! 
Carla O., de 'moeder' van alle AiOs van BMC. Ontzet­
tend bedankt voor je troostende woorden als de resul­
taten van proefjes weer eens tegenvielen. Je had vol­
komen gelijk: het komt uiteindelijk allemaal goed!
Dan natuurlijk de baas van BMC: onze Els. Fijn dat ik 
altijd bij jou terecht kon en dat je begripvol was als ik 
in een dip zat als het weer eens allemaal tegenzat. Uit­
eindelijk komt het toch allemaal op zijn pootjes te­
recht!
Geurt (a.k.a. Paul of Peter), ik heb veel van jou geleerd. 
Wat ik helaas niet van jou heb kunnen leren en waar 
ik ontzettend jaloers op ben is dat jij altijd relaxed bent, 
zonder een spoortje stress. Hoe doe je dat? Ook hebben 
we natuurlijk twee keer flink feest gevierd op Lowlands 
en daar komen we volgend jaar weer speciaal voor 
terug. Heel veel succes toegewenst met je nieuwe baan 
en natuurlijk veel geluk met Marieke en Cas. Tot LLow! 
Sander (sènder), bedankt voor je interesse en het mee­
denken plus alle gezelligheid in, maar ook buiten het- 
lab.
Ook de studenten die mij hebben meegeholpen met 
het MRP-onderzoek wil ik bedanken: Lonneke, wat een 
PCR-werk heb jij verricht. Helaas kon Rpp38 nog steeds 
aan de gemuteerde domeinen binden, dit resultaat 
staat beschreven in hoofdstuk 7. Daarna kwam de en­
thousiaste Rob Ramakers. Jij hebt echt ontzettend hard 
gewerkt en veel verschillende technieken toegepast. Ik 
hoop dat je in de wetenschap blijft, je zal een hele 
goede AiO worden. Loes, jij hebt maar drie maanden 
stage bij mij gelopen. Je bent nu naar Zweden vertrok­
ken voor je master stage. Ik weet zeker dat je het daar 
heel goed gaat doen.
Ai! Raymond en Remon, ofwel Rembo & Rembo, ofte­
wel 'you guys, buddies and friends'. Ik heb echt ontzet­
tend veel gelachen om en met jullie, met als hoogte­
punten onder meer de boobytraps, de ponceau met 
10% afwasborstel, de proeven met droogijs en het 
draaien van goede muziek op vrijdag ('shut up woman, 
get on my horse', 'gayfish' en 'minorities'). Raymond, 
ook nog 'bedankt' voor: de speciale editie van 'Nature'
over RNase MRP en een mail sturen via 'my ncbi' dat 
ik gescoopt was. Ik kan me bijna niet voorstellen dat 
het ook zo gezellig is op welk ander lab dan ook en zal 
hier altijd met een glimlach aan terug blijven denken. 
Bye, you guys, kijk uit voor de Bok-groepen and let's 
get some Kraft Dinner when I'm back.
Siebe en Tejo, de sequentie-gel-giet-masters! Ik kan jul­
lie natuurlijk niet vergeten. In het begin vond ik jullie 
een beetje nors, maar naar verloop van tijd bleek dit 
een zelfbeschermingmechanisme tegen studenten. Ik 
vind eigenlijk dat jullie een boek uit moet brengen met 
alle trucjes die jullie in jullie carrière hebben ontwikkeld. 
De meest geordende wetenschapper die ik ken ben jij, 
Helma. Ik hoop dat je snel een vaste aanstelling krijgt, 
want als het jou niet lukt, met al jouw goede postdoc 
skills, dan kan de rest van ons er nu al wel mee stop­
pen!
Ja, Chantal! Ook bedankt voor de gezelligheid op lab 
2.55. Jij gaat echt ook promoveren, hoor.
Dan wil ik ook de 'heat shock people' Lonneke en 
Sanne bedanken voor de gezelligheid. Nog veel succes 
met de laatste loodjes, het gaat echt lukken. Lettie, jij 
hoort natuurlijk ook bij de 'heat shock club'. Ik vraag 
me nog steeds af hoe het mogelijk is dat één iemand 
zoveel over verschillende dingen kan weten. Bedankt 
voor alle input tijdens de werkbesprekingen.
Of course I cannot forget the other RNA-loving person 
Elina! Thanks for your input during the RNA meetings 
and for your support at RNA 2009, when I was so ner­
vous for my talk. Congrats with yet another perfect re­
sult of an experiment (Topi) and good luck in Finland 
with finishing your PhD.
Dear Pete and Ella, the viperin experts, thank you for 
helping out with your expertise on this protein that has 
a very cool name. It resulted in a chapter 4 of this the­
sis and will be published soon in CMLS. Dear Pia, thank 
you for sharing your microarray data with me, before 
it was published. Thanks to these data, we knew we 
had to look for viperin. Also thanks for the very nice 
city tour of Freiburg and your hospitality. Good luck 
with your future research. I would also like to thank 
Prof. Bernhard Zabel, Kerstin and Ekki for inviting Ger
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and myself last year to a very good meeting. I hope 
that together with Tim in Maastricht, the three labs will 
be successful in learning more about CHH. And maybe 
I can help out in the future ;-).
Paulien en Bert, ik vond het leuk dat ik mee kon werken 
aan jullie artikel (hoofdstuk 2 van dit proefschrift). 
Hierdoor heb ik veel geleerd over de wondere wereld 
van de mitochondrieën.
Dear Rich, thank you for the opportunity to do research 
in your lab. Thanks to you, this thesis was finished in 
an incredible short time and I can start with my next 
job. I am looking forward to seeing you December 1 st 
and starting on a new RNA subject.
Ook alle andere collega's van BMC hebben er voor ge­
zorgd dat mijn promotietijd onvergetelijk is geworden: 
Han, Reinout, Wilma, Wilbert, Carla S., Marina, Tamara, 
Judith, Annemarie, Angélique, Jeroen, Ron, Kalok, Léon 
en Erwin.
Geert, bedankt voor de vormgeving van dit proefschrift. 
Het is echt supermooi geworden, dit was mij nooit zo 
mooi gelukt. En Eveline, bedankt voor de gezelligheid 
na de layout-'vergaderingen'!
Voor het stimuleren van mij om te beginnen aan het 
promotietraject wil ik Marion Blomenröhr bedanken. Jij 
staat aan de basis van dit proefschrift, heel erg be­
dankt, je had volkomen gelijk. De promotietijd is één 
van de leukste tijden uit mijn leven geweest!
De afgelopen vijf jaar heb ik natuurlijk niet alleen maar 
op het lab doorgebracht. Mijn goede vrienden Caroline, 
Bas, Pepijn, Marije, Alex en Pauline wil ik bedanken 
voor alle lol die we de afgelopen jaren hebben ge­
maakt. Ondanks al die feestjes ligt hier toch een boekje, 
haha! Dank jullie voor alle steun en het vertrouwen in 
mij. Dit heeft mij erg veel geholpen als ik weer eens zat 
te stressen en bang was dat het allemaal niet op tijd 
af zou komen. Lieve Caroline (paranimf) en Bas, de va­
kantie vorig jaar was echt top. Nu gaan we twee jaar 
weg, maar komen terug voor Lowlands samen met jul­
lie! Veel geluk met jullie kleine Chloë, jullie zijn een lief 
gezinnetje.
Schone zuster Lies en zwagert Arne: jullie natuurlijk ook 
bedankt voor het de ondersteuning tijdens mijn pro-
motietijd en voor de vele gezellige avondjes.
Lieve Emy, bedankt voor je interesse en het meeleven 
al tijdens mijn studie, samen met Cor, die we allemaal 
ontzettend missen.
Mijn broertje en zusje, Dennis en Rianne, bedankt voor 
jullie interesse en morele steun tijdens mijn studie en 
promotie.
Lieve mama, ontzettend bedankt voor alles. De ko­
mende twee jaar zal ik je ontzettend gaan missen. Ik 
hoop dat je snel langs komt bij ons in Washington. Dan 
gaan we daar lekker de stad in en misschien kunnen 
we daar ook wel fietsen!
Pap, bedankt voor al je steun tijdens en na mijn studie. 
Jij vond het heel belangrijk dat ik mijn studie goed zou 
doen en me daar volledig op kon richten. Mede hier­
door ligt dit boekje nu voor je. Bedankt papa.
En dan ten slotte Rens. Door jouw steun heb ik mijn 
promotie goed doorlopen, altijd wist je mij weer op te 
beuren na mislukte proefjes. Nu zijn we getrouwd en 
gaan we twee jaar naar de VS. Ik vind het ontzettend 
spannend en leuk om dit avontuur met jou aan te 
gaan! Ik hou van je.
Wees blij dat 't regent, 
want als je niet blij bent, 
regent het toch!
Motto Cor Böhmer
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